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Abstract 
Rationale 
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition 
with extrapulmonary manifestations- cardiovascular diseases (CVD), impaired 
physical function, activity and increased frailty.  Integrating measures of 
function into community assessments is hindered by the space and time 
required.  The association of function, activity and CVD has not been 
extensively investigated in COPD. 
Objectives 
x Explore the potential utility of Time Up and Go (TUG) as a measure of 
physical function in COPD 
x Assess association of non-invasive measures of haemodynamics to 
physical function and self-reported activity 
x Explore ambulatory haemodynamics in COPD and controls 
Methods 
Subjects with COPD (n=119) and controls (n=58) were recruited.  Ethical and 
governance approvals were obtained.  A medical history including falls, 
spirometry, peripheral and central haemodynamics, self-reported physical 
activity questionnaires and functional assessments (TUG and six-minute walk 
distance (6MWD)) were obtained from all subjects.  Ambulatory 24-hour 
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haemodynamics including aortic pulse wave velocity (aPWV) and blood 
pressure were measured in patients (n=20) and controls (n=19). 
Results 
TUG mean(SD) was increased in patients 11.9(3.7)s compared to controls 
9.5(1.8)s, p<0.001.  In patients, fallers had longer TUG than non-fallers 
(p=0.02) and a cut-off time of 12s had the highest sensitivity and specificity to 
detect fallers and non-fallers.  Aortic stiffness was not associated to physical 
function or physical activity, p>0.05.  In the pilot study, significant nocturnal 
dip in aPWV was seen in controls, p<0.01, but not in patients, p=0.07. 
Conclusion 
TUG could be a useful measure of function and possibly be incorporated into 
COPD assessment, particularly where time and space are limited.  Finally, 
ambulatory haemodynamic machine, the Mobil-O-Graph, is feasible and 
offers opportunity to assess 24-hour haemodynamics profile including aPWV 
as opposed to a one-off measurement. 
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Introduction 
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1.1 Definition 
Chronic Obstructive Pulmonary Disease (COPD) is a descriptive term that 
encompasses both chronic bronchitis and emphysema.  As the name of the 
condition implies, there is chronic obstruction and narrowing of the airways in 
the lungs: chronic bronchitis, and elasticity loss and alveolar wall destruction: 
emphysema.  Chronic bronchitis is defined clinically as a productive cough for 
more than three months for two consecutive years; whereas emphysema is 
defined pathologically as permanent enlargement of the air space and 
alveolar wall destruction distal to terminal bronchioles (ATS-ERS, 2004).  Such 
changes progress over time and cannot be completely reversed once the 
remodelling occurs (WHO, 2012).  The American Thoracic Society (ATS) and 
the European Respiratory Society (ERS) state that these chronic airway 
ůŝŵŝƚĂƚŝŽŶƐ ĂƌĞ  “ƵƐƵĂůůǇ ƉƌŽŐƌĞƐƐŝǀĞ ĂŶĚare associated with an abnormal 
inflammatory response of the lungs to noxious particles or gases, primarily 
caused by cigarette smoking ? (ATS-ERS, 2004). 
1.2 Prevalence 
The prevalence of COPD is increasing and it is considered a leading cause of 
mortality and morbidity worldwide (Murray and Lopez, 1997, CDC, 1997).  A 
recently published study looking at the global burden of diseases showed that 
COPD became the third leading cause of death after ischemic heart disease 
(IHD) and stroke in the year of 2010 (Lozano et al., 2012).  Still, population-
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based studies show that the true prevalence of COPD is underestimated and 
underdiagnosed (Lindberg et al., 2006, Tinkelman et al., 2007). 
Mannino et al., investigated the prevalence of obstructive lung disease in over 
16,000 individuals (ageĚ A?  ? ? ǇĞĂƌƐ ŽůĚ ? ƵƐŝŶŐ ĚĂƚĂ ĨƌŽŵ ƚŚĞ dŚŝƌĚ EĂƚŝŽŶĂů
Health and Nutrition Examination Survey (Mannino et al, 2000).  Subjects in 
the study were considered having obstructive lung disease if they report 
current diagnoses of either asthma or bronchitis, or had ever been diagnosed 
with emphysema.  Airflow limitation was defined by forced expiratory volume 
in 1 second (FEV1)/forced vital capacity (FVC) ratio of <0.7 and FEV1 of <80% 
predicted.  The study showed that the majority of subjects (63%) had 
undiagnosed obstructive lung disease (Mannino et al, 2000).  Although the 
true prevalence of COPD remains underestimated around the world, 
reportedly its death rate in the year of 2000 was 2.7 million people (Lopez A., 
2006, Mannino et al, 2000).  In the UK alone, three million people have been 
estimated to have COPD, from whom two million remain undiagnosed (NICE, 
2011a).  
1.3 Risk factors 
COPD has many risk factors where smoking is considered the primary risk 
factor for developing such disease especially in developed countries (NCQA, 
2009).  Other risk factors such as gender, genetic, socioeconomic, and 
environmental exposure should not be ignored as COPD can be found in those 
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who never smoked.  The risk factors for COPD can be classified as modifiable 
and non-modifiable factors. 
1.3.1 Modifiable risk factors 
- Smoking 
Smoking  W direct tobacco usage or second-hand smokers - is the leading cause 
of COPD (WHO, 2008).  All types of smoking including cigarettes, cheroots, 
cigars and pipe are associated with COPD in different intensity (Godtfredsen 
et al., 2002).  In a population-based study comparing smokers to never-
smoked elderly in Sweden, cigarette smoking was a major and independent 
cause of COPD (Lindberg et al., 2006).  They showed that all men with severe 
COPD were smokers or ex-smokers and 90% with mild COPD were smokers or 
ex-smokers.  For smokers, the smoke, nicotine and other irritants in the 
cigarette all contribute to developing chronic airway obstruction (Bohadana 
et al., 2004).  Therefore, the World Health Organization (WHO) identifies 
smoking cessation as the most effective approach to reduce the development 
of COPD and slow its progression (WHO, 2015).  Furthermore, the latest BTS 
guideline on pulmonary rehabilitation in adults emphasises the need to 
identify smoking history in referrals and to provide opportunity to smoking 
cessations (Bolton et al., 2013). 
- Socioeconomic status 
Socioeconomic status as defined by the American Psychological Association is 
 “ƚŚĞƐŽĐŝĂůƐƚĂŶĚŝŶŐĐůĂƐƐŽĨĂŶŝŶĚŝǀŝĚƵĂůŽƌŐƌŽƵƉ ?/ƚŝƐŽĨƚĞŶŵĞĂƐƵƌĞĚĂƐĂ
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combination of education, income and occupation ? (APA, 2014).  The 
socioeconomic status was found to be directly associated with COPD 
independent of smoking history (Prescott et al., 1999).  People with lower 
socioeconomic status and those with lower level of education tend to have 
more smoking habits (Hart et al., 2010).  Even after adjusting for confounders, 
for example, smoking, body mass index (BMI) and physical activity, 
socioeconomic position is inversely associated with lung functions (Ramsay et 
al., 2011).  Further, both social class and environmental factors are associated 
with lung function.  People with lower social class are more likely to live in 
more polluted areas than those with higher social class (Wheeler and Ben-
Shlomo, 2005).  
- Environmental exposure 
Environmental factors such as long-term exposures to air-pollution (nitrogen 
dioxide, particular matters, sulphur dioxide and benzene) and living nearby 
busy roads have direct effect on lung functions and might increase the risk of 
developing COPD (Schikowski et al, 2005, Wheeler and Ben-Shlomo, 2005).  
Further, COPD is associated with the nature of work and/or the environment 
of the workplace especially in industries associated with prolonged exposure 
to chemicals, for example, rubber, plastics, and leather manufacturing, food 
products manufacturing, agriculture, construction and transportation (Hnizdo 
et al., 2002). 
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1.3.2 Non-modifiable risk factors 
- Gender 
COPD has been associated with the male gender because males were 
notoriously known for smoking, until recently in the past four decades where 
the number of female smokers has dramatically increased, COPD is no longer 
predominantly recognised as a male disease (Tinkelman and Corsello, 2003, 
Mannino et al., 2002).  Recent studies showed that females who were 
diagnosed with COPD had higher mortality rate and more susceptibility to the 
adverse effects of smoking than males with the same diagnosis (Maria-
Christina L. Machado, 2006, Gold et al., 1996).  This could be due to 
physiological and non-physiological differences. 
Recent literature shows that COPD has autoimmune components which might 
play part in the onset and/or development of the disease (van der Strate et 
al., 2006).  This might give rise to the prevalence of the disease in females as 
they are  “physiologically ? ŵŽƌĞ ƐƵƐĐĞƉƚŝďůĞto develop autoimmune disease 
(DeLisa Fairweather, 2008).  In addition, females have relatively smaller lung 
size, hence smaller capacity, than males (Camp et al., 2009); therefore, they 
are more prone to shortness of breath (The Lung Association, 2006). 
Non-physiological differences may include physician and public awareness of 
COPD amongst females, which may lead to delayed or misdiagnosis of COPD. 
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- Genetic  
Genetic susceptibility in COPD is an important area.  One of the most common 
heredity disorders is a deficiency of Alpha- ? ĂŶƚŝƚƌǇƉƐŝŶ  ?ɲ ?d ? ƉƌŽƚĞŝŶ ?
encoded by SERPINA1, leading to early onset of emphysema (Mark Wewers, 
1989).  This protease inhibitor  has a protective role over lung parenchyma 
ĨƌŽŵƉƌŽƚĞĂƐĞƐ  ?ŶĞƵƚƌŽƉŚŝůĞůĂƐƚĂƐĞ ? ?ƚŚƵƐ ?ĂĚĞĨŝĐŝĞŶǇ ŝ  ƚŚĞɲ ?d ůĞĂĚƐƚŽ
protease-antiprotease imbalance and destruction of the lung parenchyma, 
therefore, causing emphysematous lung (Hersh et al., 2004).  Only 1-2% of all 
COPD cases have been related to a severe form of ɲ ?dĚĞĨŝĐŝĞŶĐǇƐƵŐŐĞƐƚŝŶŐ
other genetic factors are involved in the predisposition of COPD (Hall and 
Lomas, 2010).  Other genetic factors that have been linked to COPD include, 
but are not limited to, matrix metalloproteinase (MMP)-9 and 12 (Demedts et 
al., 2006, Lee et al., 2010). 
1.4 ŚƌŽŶŝĐŽďƐƚƌƵĐƚŝǀĞƉƵůŵŽŶĂƌǇĚŝƐĞĂƐĞĂŶĚƉĂƚŝĞŶƚƐ ?
characteristics 
COPD is a slow progressive disease that develops over long period of time.  An 
international survey in North America and Europe of over 3000 individuals 
investigating the impact of COPD has stated that people with COPD 
experience limitations in their physical and social activity, and also have 
increased hospital admissions (Rennard et al., 2002).  Although the disease 
progresses over many years and, hence, mainly affect the older adults, 
working age people with COPD also suffer from this condition.  The same 
8 
 
survey found that 45% of patients under the age of 65 years lost their jobs in 
the past year due to COPD. 
Classical symptoms of COPD include, but are not limited to, breathlessness 
and exercise limitation.  Therefore, physical activity and social participation 
are limited in patients with COPD, in part, due to their breathing discomfort 
(ATS, 1999).  This can be partially explained by the dyspnoea-function model 
which summarises the association between dyspnoea and functional 
limitation in people with airway obstruction (Sassi-Dambron et al., 1995).  
Briefly, this model states that people with dyspnoea, gradually, tend to limit 
their activities due to the discomfort and frustration caused by their shortness 
of breath which, with time, leads to physical deconditioning which is, again, 
responsible for increasing dyspnoea.  In patients with COPD, inactivity is 
associated with faster disease progression, increased health care utilization, 
and higher mortality rate (ZuWallack and Hedges, 2008).  More recent studies 
highlighted the importance of establishing personal level of physical activity 
at an early stage of COPD and work to maintain it at that level as the decline 
in physical activity is highly associated with mortality (Vaes et al., 2014). 
Unlike healthy individuals, small changes in the physical function of patients 
with COPD significantly affect their activity of daily life and, hence, quality of 
life (Steele et al., 2000).  Therefore, it is important to have a valid functional 
test in the assessment of COPD (Introduction, p 21).  Other symptoms often 
described by patients with COPD include sputum production, wheeze and 
increased risk of exacerbations. 
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1.5 Systemic effect of chronic obstructive pulmonary 
disease 
COPD is traditionally defined as a lung condition; however the latest definition 
also includes comorbidities (NICE, 2010).  COPD is associated with systemic 
complications including, but not limited to, loss of weight and muscle, loss of 
bone mineral density (BMD) leading to osteoporosis, as well as increased 
cardiovascular (CV) diseases and psychological consequences including 
anxiety and depression (Pauwels et al., 2001, Bolton et al., 2004).    It is 
important to mention that COPD and other co-morbid diseases share 
common risk factors such as cigarette smoking, increased age, and inactivity 
(Agusti et al., 2003, Wasswa-Kintu et al., 2005).  Although the latter was 
highlighted by the ATS and the ERS COPD guidelines (ATS-ERS, 2004), still, a 
method for a routine assessments for such co-morbidities is not yet 
established. 
Alterations in body composition are important with focus previously on 
weight and muscle loss (Landbo et al., 1999, Schols et al., 1998, Schols et al., 
2005).  Indeed, being underweight is related to having an increased risk of 
mortality (Landbo et al., 1999, Schols et al., 1998).  Such studies have included 
relatively few obese patients but suggested a relatively protective mechanism 
of obesity in COPD.  With a number of factors likely to account for weight and 
muscle loss including increased energy expenditure, reduced energy intake, 
physical inactivity and the interplay of systemic inflammation and hormonal 
influences.  Patients with COPD experience nutritional depletion as a result of 
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imbalance between energy intake and energy expenditure; where the former 
is associated with loss of appetite, fatigue and postprandial dyspnoea (Cheol 
Kim et al., 2008) and the latter is believed to be cause by hypermetabolism 
(Ezzell and Jensen, 2000).   
1.6 Cardiovascular risk in patients with chronic obstructive 
pulmonary disease 
Patients with COPD are at a greater risk of developing CV diseases and 
literature shows that the mortality rate of patients with COPD is in a large 
proportion due to CV diseases (McGarvey et al., 2007, Camilli, 1991, 
Curkendall et al., 2006).  This greater risk of CV diseases in patients with COPD 
has been highlighted in literature to be over and above the effects of smoking 
(Sin and Man, 2003).  Therefore, the awareness of the association between 
CV risks and COPD as well as the recommendation to treat COPD as an 
independent risk factor for CV diseases has recently been highlighted 
(Hunninghake, 2005).  Also to note that the association between COPD and 
CV risks is not well understood; however, it might be a contribution of several 
factors including smoking, age, systemic inflammation (Sin and Man, 2003) 
and lung function. 
Arterial stiffness is a non-invasive measure and has been associated with 
future CV risks and deaths (discussed in Introduction, p 11). 
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1.6.1 Association of Lung function to cardiovascular risk 
Lung function is an independent predictor of CV risks and mortality.  This was 
shown in previous literature including a population-based study of 1,861 
participants recruited from the first National Health and Nutrition 
Examination Survey (Sin et al., 2005).  After adjusting for age, gender and 
smoking history, the study results showed that subjects in the lowest FEV1 
quantile had the highest relative risk (RR) of CV mortality, 3.36 (95% CI: 1.54-
7.34).  Another population-based study of 402 men born in 1914 found an 
inverse association between FEV1% predicted and CV mortality rate even after 
adjusting for confounders such as cigarette smoking, angina pectoris, physical 
activity, alcohol consumption, and diabetes (Engström et al., 2001).  The 
prevalence and outcome of diabetes, hypertension and CV diseases were 
investigated in over 20,200 ƉĂƌƚŝĐŝƉĂŶƚƐ  ?A? ? ? ǇĞĂƌƐ ŽůĚ ? ƌĞĐƌƵŝƚĞĚ ĨƌŽŵ
Atherosclerosis Risk in Communities and the Cardiovascular Health Study.  An 
inverse association was found between airways obstruction and CV diseases 
with high prevalence of CV diseases in patients with COPD (OR 2.4 95% CI 1.3-
1.9) (Mannino et al., 2008).  These findings, collectively, emphasise the 
association between airflow limitation and CV events, however, the 
mechanisms explaining how COPD increases the CV risks is still unclear. 
1.6.2 Association of arterial stiffness to cardiovascular risk 
Generally, aging is associated with physiologic and functional changes in the 
characteristics of blood vessels including their distensibility, compliance and 
12 
 
stiffness.  These changes, in turn, make older people more susceptible to 
developing CV events (Rodney A. Rhoades, 2012, Kelly et al., 1989).  The more 
distal (peripheral) the vasculature from the heart, the more musculature and 
stiffer (less elastic) they become; partly, due to the increased rigidity of the 
arterial walls as vessels reach the distal end of the arterial tree (Blacher, 
2005).  Arterial stiffness leads to an in increase in systolic blood pressure (SBP) 
and little or no change in diastolic blood pressure (DBP) which, eventually, 
leads to increase in pulse pressure (PP)  W the difference between SBP and DBP 
(Mackenzie et al., 2002).  There is a continuous rise in the DPB until middle-
age which is related to increasing resistance of the peripheral arteries; 
whereas, SBP is affected by arterial stiffness and continue to increase as 
arterial stiffness increases with aging (Franklin et al., 1997).  An increase in PP 
may lead to adverse cardiac events, for example, ventricular hypertrophy 
which is caused by increase in the left ventricular afterload and the 
myocardial oxygen demand (Nichols, 2005).  Furthermore, another study 
found that aortic stiffness as opposed to peripheral arterial stiffness was 
related to aging (>50 years) in healthy subjects with minimal burden of CV 
diseases (Mitchell et al., 2004).  
The pulse wave velocity (PWV) - a measure of the speed of the pulse wave as 
it travels between two regions within the arterial tree - is a non-invasive 
reproducible method to measure arterial stiffness (Laurent et al., 2006).  
Whereas, augmentation index (AIx), a measure of arterial stiffness and wave 
reflection, and pulse pressure are surrogate methods (Nichols, 2005, Laurent 
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et al., 2006).  The gold standard measure of aortic stiffness is the aortic PWV 
(aPWV) (Laurent et al., 2006).  Aortic PWV is an independent predictor of CV 
events and may help in identifying high-risk population (Ben-Shlomo et al., 
2014). 
The relationship between arterial stiffness (measured by PWV) and CV events, 
CV mortality and all-cause mortality was highlighted in a systematic review 
and meta-analysis of 17 longitudinal studies following 15,877 subjects for an 
average of 7.7 years (Vlachopoulos et al., 2010).  The results show that an 
increase of 1 m/s in aPWV is associated with an increased RR of 1.14 (95%CI: 
1.09-1.20), which equates to a 14% increase in total CV events.  Both CV 
mortality and all-cause mortality increased by 15% with a 1m/s increase in 
PWV, with the same RR of 1.15 (95%CI: 1.09-1.21) for both. 
In a population-based study, The Rotterdam Study, (n= 2835 healthy subjects, 
mean (SD) age of 72 (7)years) explored the association between arterial 
stiffness (measured by aPWV) and coronary heart disease and stroke 
(Mattace-Raso et al., 2006).  The study results showed positive associations of 
arterial stiffness to coronary heart disease (mean follow-up period 4years), 
and stroke (mean follow-up period 3years), which were attenuated slightly 
after adjusting for CV risk factors.  Increased aPWV was associated with 
approximately 1.7 to 2.5 increased risks of developing coronary heart disease 
and approximately 1.2 to 2.3 risks of developing stroke.  Increased arterial 
stiffness has been found to be associated with greater CV risks in a number of 
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conditions including renal disease (Blacher et al., 1999), and diabetes 
(Cruickshank et al., 2002, Salomaa et al., 1995).  
In a community-based study following over 2000 older subjects for a median 
of 7.8 (range, 0.2 to 8.9)years, aPWV was the only measure found to be 
associated with increased major CV risks when compared to other 
haemodynamic measures including central blood pressure, AIx, carotid-
brachial pressure and carotid-radial PWV (Mitchell et al., 2010).  Association 
between aPWV and CV event remained significant even after adjusting for 
brachial or central pulse pressure or carotid-brachial pulse pressure 
amplification. 
1.6.2.1 Association of arterial stiffness to cardiovascular risk in patients 
with COPD 
In COPD studies, there is a growing interest of investigating the association of 
arterial stiffness to COPD.  Sabit et al., explored the association in clinically 
stable patients with COPD (n=75) and age- and sex-matched controls with 
smoking history (n=42) (Sabit et al., 2007).  Both groups were similar in BP 
measurements and CV risks and results showed that arterial stiffness was 
increased in patients compared to controls and  W in patients  W it was related 
to severity of airflow obstruction.  In a small study of male subjects (18 
patients with COPD and 17 healthy subjects matched for age and smoking 
history), Maclay et al., found that the association of COPD to increased 
arterial stiffness was independent of smoking, characterised by elevated 
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augmentation index and reduced time to wave reflection (Maclay et al., 
2009).  McAllister et al., investigated the association of arterial stiffness to the 
severity of emphysema using brachial PWV (less prognostic measure of 
arterial stiffness) in 157 patients with COPD (McAllister et al., 2007).  After 
adjusting for age, smoking history, sex, lung function, and other potential 
confounders, the study concluded that brachial arterial stiffness is 
independently associated with the severity of emphysema on HRCT scanning 
of the chest (r= 0.47, P<0.001). 
Patients with COPD have increased markers of systemic inflammation (Sin and 
Man, 2003), which was discussed in later studies to be a potential reason for 
increased arterial stiffness in this population (Sabit et al., 2007, Mills et al., 
2008).  Other studies raised the possibility that the contribution of increased 
arterial stiffness in patients with COPD was linked to aortic calcification 
(Bolton et al., 2011) and microvascular damage (John et al., 2013). 
1.7 Lung function, arterial stiffness, and physical functional 
limitation 
Lung function, arterial stiffness, and physical limitation are all altered by the 
aging process independent of co-morbidity (Janssens et al., 1999, Mitchell et 
al., 2004, Freedman and Martin, 1998).  However, Bolton et al., found that 
lung function in is an independent predictor of arterial stiffness over and 
above age in adult males (Bolton et al., 2009).  They found that mid-life lung 
function was a stronger predictor of arterial stiffness than later-life where a 
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reduced volume of 500ml in FEV1 and FVC was associated with an increase of 
PWV of 0.52m/s and 0.42m/s; respectively.  Recently, there has been an 
interest in literature in exploring the association between arterial stiffness 
and functional limitation in the general population and in patients with 
chronic conditions including COPD. 
In a population-based study, the Whitehall II, the association of arterial 
stiffness to physical function, functional limitation, and lung function was 
investigated using 5,392 relatively-healthy older subjects (Brunner et al., 
2011).  Gait speed was used to assess physical function over 8-ft track.  The 
results of this study (adjusted for confounders such as age, gender and 
ethnicity) showed that arterial stiffness, using applanation tonometry 
(SphygmoCor), was inversely related to physical function (-0.96, 95% CI: -1.29 
- -0.64 m/s) and to spirometry lung function (-1.23, 95% CI: -1.53 - -0.92 L).  
Similarly, inverse association between arterial stiffness, using doppler-
recorded carotid and femoral pulse waveforms, and 20m gait speed in 
patients with peripheral arterial disease (PAD) but not in subjects without 
PAD (Watson et al., 2011).  The authors summarised that therapeutic 
intervention in patients with PAD could be directed to arterial stiffness in 
order to improve peripheral perfusion and, hence, walking performance. 
A previous study by Castagna et al., looked at PAD, primarily PAD contribution 
to arterial stiffness, and exercise capacity in patients with COPD (Castagna et 
al., 2008).  The authors found that exercise capacity was inversely related to 
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arterial stiffness  W measured by the carotid-femoral PWV (Comlior, France) - 
and, therefore, screening for CV risk in patients with COPD is important. 
Given that patients with COPD are more susceptible to developing physical 
disability than healthy adults, the addition of physical functional assessment 
to spirometric measurements in the management of COPD may add valuable 
information that may guide therapeutic intervention (Celli et al., 2004, Geijer 
et al., 2007). 
1.8 Determinants and potential benefits of aortic pulse 
wave velocity measurements in the assessment of 
COPD 
 Determinants of increased aortic stiffness differ from determinants of other 
conventional predictors of CV risk, for example hypertension.  It was shown in 
previous studies that aortic stiffness predicts future incidents of hypertension; 
hence, aortic stiffness is not caused by hypertension (Kaess et al., 2012).  It is 
important to mention that smoking (Mahmud and Freely., 2003) as well as 
some medical conditions like hypertension, diabetes mellitus and 
hypercholesterolemia are associated with increased aortic stiffness (Laurent 
et al., 2006).  Early life determinants of increased arterial stiffness in 
adulthood have been highlighted in literature.  Examples of these 
determinants are increased blood pressure and central fatness which are 
associated with poorer levels of blood lipids, cardiorespiratory fitness and 
heart rate (Ferreira et al., 2012). 
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As we age there is a linear increase of central haemodynamic measures, for 
example pulse pressure, but not aPWV which follows different pattern with a 
remarkable increase after the age of 50 years (McEniery et al., 2005).  This 
suggests that using aPWV for people after the age of 50 years would give 
better prediction of future CV events.  Comparison of age-matched groups of 
males and females showed different characteristics of increased aortic 
stiffness that appeared to be mainly affected by post-menopausal period 
(Nethononda et al., 2015).  For example, females during pre-menopause have 
lower aortic stiffness than males and it is increased remarkably post-
menopause, which was suggested to be a result of hormonal changes and/or 
fat distribution patters in females following menopause (Nethononda et al., 
2015). 
Drug therapy also has an effect on lowering arterial stiffness but in a different 
manner from drugs affecting peripheral or central haemodynamic 
measurements.  Mackenzie et al. 2009 investigated the effect of four 
antihypertensive drugs (perindopril, atenolol, lercanidipine or bendrofluazide) 
on 59 patients with untreated isolated systolic hypertension (Mackenzie et al., 
2009).  They showed that each of these drugs has different effect on 
peripheral and central blood pressures, but no effect was found on aPWV.  A 
double-blinded randomised study comparing the effects of combined drugs 
(perindopril and indapamide) and atenolol in hypertensive subjects over 12 
months showed greater reductions of PWV in subjects treated with the 
combined drugs than those treated with the atenolol only (de Luca et al., 
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2004).  These findings suggest that assessment of aortic stiffness would 
provide better guidance to drug therapy.  
In summary, it is apparent that measurements of peripheral BP, central BP 
and aPWV are not exchangeable and that assessment of aPWV provides 
additional information, which may lead to the advancement of clinical 
practice.  Since CV events are common in patients with COPD, aPWV 
measurements could be used as a target for treatment as well as to detect 
improvement post drug and/or rehabilitation intervention to prevent or 
reduce the risks of CV events.  Previous studies showed that patients with 
COPD have increased aortic stiffness (Sabit et al., 2007, Maclay et al., 2009) 
and it can be improved with rehabilitation through the improvement of BP 
(Gale et al., 2011, Vivodtzev et al., 2010).  A direct measurement of the 
association of aortic stiffness to physical performance tests and self-reported 
physical activity is yet to be explored.  The current research was to explore 
these associations in a wide range of patients with COPD and compared 
results to age- and gender-matched controls.   
1.9 Assessment of physical performance  
The concept of physical function has been used in literature to account for a 
wide range of assessment including, but not limited to, physical performance 
and psychological aspects (Podsiadlo and Richardson, 1991, Beauchamp et al., 
2009, Schieman and Plickert, 2007).  The current research focuses on the TUG 
test as a determinant of the physical limitation by based on performance 
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between patients and controls.  Therefore, in this thesis the term physical 
performance is used when referring to the physical assessment tests. 
There are two distinct methods used for the measurements of the physical 
performance: subjective and objective assessments.  This thesis focuses on 
objective methods relevant to COPD. 
1.9.1 Types of physical performance assessment 
1.9.1.1 Subjective method 
This approach includes self-reports and can be obtained by either 
questionnaire or telephone interview.  Some of the advantages of this 
method are: relatively inexpensive and can be directed to address a specific 
area of problem (Reuben et al., 2004), and it is patient friendly (patients do 
not need to perform an activity in order to be assessed).  Nevertheless, 
results obtained using these methods are more likely to be over or 
ƵŶĚĞƌĞƐƚŝŵĂƚĞĚ ĚĞƉĞŶĚĞŶƚ ŽŶ ƚŚĞ ƉĞƌƐŽŶ ?Ɛ ũƵĚŐŵĞŶƚ ĂŶĚ ĂďŝůŝƚǇ ƚŽ
accurately recall information.  Moreover, the longer the recall, the less 
accurate and reliable the information becomes (Sallis, 1993). 
1.9.1.2 Objective method 
Objective measures are performance-based tests.  Objective methods may 
have less confounding variables in comparison to subjective methods (Ostir et 
al., 2002, Linn et al., 1980).  
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1.9.2  Physical performance tests 
Assessment of physical performance in the general population is very 
important owing to its ability to provide a dimensional summary of the 
ŝŶĚŝǀŝĚƵĂů ?Ɛ ƉŚǇƐŝĐĂů ĞŶǀŝƌŽŶŵĞŶƚ ? ƐŽĐŝĂů ƉĂrticipation and his/her daily life 
activity.  Additionally, studies have proven repeatedly the ability of exercise 
tests to predict mortality, nursing home admissions, hospitalization, future 
incidence of disability (even for healthy individuals) (Chang et al, 2004, Eisner 
et al., 2007, Guralnik et al., 1994, Landi, 2007, Ostir et al., 2002, Rantanen et 
al., 1999, Studenski et al., 2003). Similarly, there is increasing interest in the 
use of exercise tests in patients with COPD because of its objectivity in 
evaluating exercise capacity and detecting changes pre/post intervention 
(Palange et al., 2007) 
This section of the literature review critically discusses some of the up-to-date 
performance tests, which may be applicable to subjects with COPD.  These 
tests include: the Six-Minute-Walk Test (6MWT), the Incremental Shuttle 
Walk Test (ISWT), the Short Physical Performance Battery (SPPB) and the Time 
Up and Go (TUG) test.  The literature review addresses the advantages and 
disadvantages, nature of the test, validity, reliability and the sensitivity to 
change of each of these tests. 
1.9.2.1 Six-Minute-Walk Test (6MWT) 
Six minute walk test is a commonly used test in the assessment and 
evaluation of physical performance in pulmonary rehabilitation assessments 
22 
 
(Bromboszcz J, 2010).  Over the past years, the measurements of physical 
performance using self-paced timed walking tests have become the scope of 
interest for many researchers.  Self-paced walking tests were not restricted to 
six minutes only; investigators were interested in examining the different 
variations of timed-walk tests such as 12, 4, and 2-minute walking tests.  
However, the 6MWT, amongst all tests, was most favourable and thought of 
as a compromise between the 2 and the 12 minutes walking tests (Butland RJ, 
1982). 
1.9.2.1.1 Nature of the 6MWT 
Six-minute walk is a timed submaximal test where individuals are instructed 
to walk as far as they can at their regular speed for 6 minutes.  By the end of 
the 6min, the walked distance (6MWD) is recorded and used in the analysis as 
the primary outcome measure.  It is a self-paced test that is performed on a 
marked walkway with two chairs  W one at each end of the walkway - allowing 
the individuals to rest if needed.  The ATS has published general guidelines 
with recommendations to follow for the 6MWT (ATS, 2002).  The guidelines 
recommend that the test should be performed indoors on a straight, flat, and 
hard surface (30 metres) long. 
Dyspnoea is an important part of the 6MWT and it can be measured 
subjectively using the Borg Scale (Galiè et al., 2004).  The familiarity and 
simplicity of the test are plausible since walking is a simple activity of daily life 
and subjects are allowed to stop and rest if needed, within the allotted time.  
In addition, the 6MWT is an economic tool and only requires a stopwatch, a 
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pair of cones, a pair of chairs to be placed at each end of the walkway, and an 
oximeter device to measure the heart rate and oxygen saturation. 
Furthermore, the 6MWT can detect certain walking behaviours such as the 
pace of the walk and the frequency of stops during the walk (Pitta et al., 
2005a). 
1.9.2.1.2 Validity  
Examining the validity of a particular machine or questionnaire means 
investigating whether the machine or the questionnaire is actually measuring 
what it is supposed to measure.  Harada et al., investigated the 6MWT on 
individuals from retirement homes and community centres and found a 
constructive validity of the 6MWT with five other physical performance tests 
(Harada et al., 1999).  The correlation of the 6MWT was found in the chair 
stands (r= 0.70), tandem balance (r= 0.59), 8 feet walk (r= 0.68), but to a less 
extent to self-assessment measures.  The associations between the 6MWT 
and other performance-based measurements were well established and 
similar results were found in other studies (Bean et al., 2002, Flansbjer et al., 
2005). 
1.9.2.1.3 Reliability and reproducibility 
Reliability can be defined as the ability of a measure  W e.g. a questionnaire or 
a device  W to produce same results over different time.  The test-retest 
reliability and reproducibility of the 6MWT have been shown in literature to 
be of a high standard, regardless of the different methodologies used in 
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different studies.  For example, an observational study investigating the 
mobility-related function in healthy individuals (n=86) recruited from 
retirement homes and community centres (Harada et al., 1999).  The authors 
reported that the 6MWT had a very high (r= 0.95) one week test-retest 
reliability.  Other studies showed high one day test re-test reliability in elderly 
adults (61-89 years) and in patients with advanced heart failure (HF), 
interclass correlation coefficient (ICC)= 0.95 and ICC= 0.96; respectively 
(Cahalin et al., 1996, Steffen et al., 2002).  Other studies presented similar 
findings in cardiac patients (K ?<ĞĞĨĨĞĞƚĂů ? ? ? ? ? ?). 
In COPD, Poulain et al., investigated the ability of the 6MWT to detect oxygen 
desaturation in 80 patients with COPD: FEV1= 62.4 ± 2% predicted by 
comparing it to the cardiopulmonary exercise test (Poulain et al., 2003).  The 
results obtained from the 6MWD (mean (SD) 495 (4)m) were similar to the 
results from the reference 6MWD (499 (18)m) confirmed by the low variation 
coefficient (5.4 ± 2%).  The authors recommended the 6MWT to be used not 
only as a measurement tool of functional status and effectiveness of 
therapeutic intervention, but also as a diagnostic tool, for example, 
investigate the exercise-induce desaturation (Poulain et al., 2003).  High 
reproducibility (ICC=0.93) was also found between the first and second 
6MWD in a large retrospective observational study of 1,514 COPD patients 
with COPD (Hernandes et al., 2011).  
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1.9.2.1.4 Minimal Clinical Important Difference 
The main outcome of the 6MWT is the distance covered by the end of the 
test.  Therefore, clinicians need to determine the minimal clinical important 
difference of the distance covered, from which clinicians can determine the 
ŝŶĚŝǀŝĚƵĂůƐ ?ŝŵƉƌŽǀĞŵĞŶƚƐ of physical performance.  With an intervention, the 
minimal clinical difference for patients with COPD was demonstrated in a 
study of 112 patients with COPD (mean age 67 years) who were already 
participating in a rehabilitation program strictly for their COPD conditions 
(Redelmeier et al., 1997).  Patients were asked to perform 3 6MWTs on 
separate days and the third test was used in the analysis.  To calculate the 
minimal clinical important difference, the authors compared the subjective 
 ?ƉĂƚŝĞŶƚƐ ?ƌĂƚŝng: about the same/ a little bit better/ a little bit worse) and the 
objective (the 3rd 6MWT) methods after the rehabilitation.  In the subjective 
method, patients were asked to rate performance against their peers.  The 
results of the study showed that patients would recognise a difference in their 
physical performance when there is a 54 m difference in the distance they 
covered during the 6MWT.  This cut-off value of 54m for the MCID has 
accepted and used in clinical practice.  The method used in the study, where 
participants were asked to evaluate performance in comparison with each 
other, might be a useful to eliminate recall bias; however, this method might 
create an environmental bias where decisions on improvements might 
depend on the social interactions between subjects (S
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Two more recent studies, Puhan et al., and Holland et al., have re-evaluated 
the minimal important difference (35m and 25m, respectively) in people with 
COPD (Puhan et al., 2008, Holland et al., 2010).  The main difference between 
these two studies and the Redelmeier et al., study was the methodological 
ĂƉƉƌŽĂĐŚƵƐĞĚĨŽƌƚŚĞƉĂƚŝĞŶƚƐ ?ĂƐƐĞƐƐŵĞŶƚƐŽĨƚŚĞŝƌŝŵƉƌŽǀĞŵĞŶƚƐ ?dŚĞƚǁŽ
studies used anchor-based and distribution-based methodologies and 
patients were asked to evaluate their improvement overtime.  The small MID 
difference might be due to the self-report strategy used in each study.  For 
example, Holland et al., ĂƐŬĞĚ ƉĂƚŝĞŶƚƐ ƚŽ ƌĂƚĞ ƚŚĞŵƐĞůǀĞƐ ƵƐŝŶŐ Ă  “ƉĂƚŝĞŶƚ
ĂŶĐŚŽƌ ƐƉĞĐŝĨŝĐ ƚŽ ĨƵŶĐƚŝŽŶĂů ǁĂůŬŝŶŐ ĐĂƉĂĐŝƚǇ ? ŝŶƐƚĞĂĚŽĨ ŚĞĂůƚŚ-related 
quality of life questionnaire, which was used in the other study.  The strategy 
used by Holland et al., is considered more specific to walking capacity since 
health-related quality of life has been shown not to have good correlation 
with the 6MWT (de Torres et al., 2002). 
1.9.2.1.5 6MWT in patients with COPD 
Tests of exercise capacity (for example the 6MWT and the ISWT) are useful in 
the assessment of COPD and can detect significant improvement post 
rehabilitation intervention; however the long term benefits of these test are 
not know (Bolton et al., 2013, Rejbi et al., 2010).  The 6MWT can detect 
improvements of functional status post rehabilitation as well as 
pharmacological intervention and reflect on the nature of improvements 
(Rejbi et al., 2010, Singh et al., 2014).  The frequency and duration of the 
resting periods are believed to be an important part in the 6MWT.  In a 
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retrospective chart review of 211 COPD patients, participants were grouped 
as Resters and Nonresters and measurements were taken pre and post 4-
week rehabilitation (Wong et al., 2010).  The results showed that Resters 
improved their 6MWD by reducing the frequency and duration of resting time 
(increasing the walking time); whereas, Nonresters improved their distance by 
increasing the average walking speed.  It was suggested that the 
improvement in speed for the Nonresters group might reflect on the 
cardiovascular or peripheral muscle improvements during the rehabilitation 
program; whilst, the reduction in the frequency and the duration of the 
resting periods may be a reflection on the pacing technique which, in-turn, 
improves endurance. 
A longitudinal three year study following 576 patients with COPD, reported 
the 6MWT as an independent predictor of respiratory-related mortality 
(Casanova et al., 2008).  In the study, relative risk of 1.007 (95% CI: 1.005-
1.009) was associated with every one metre decrease in the 6MWD.  
Similarly, 6MWT was found to be better predictor of mortality than FEV1 in a 
2-year longitudinal study of 198 COPD patients and 41 healthy participants 
(controls) (Pinto-Plata et al., 2004).  The risk ratio of mortality found in the 
study was 0.82 (0.72-0.94, 95% CI) for each 50m increase in the 6MWD. 
The size of learning effect in patients with COPD varies from 2.6% -  or 15m - 
(Troosters et al., 2002)  to approximately 9% - or 108m - difference between 
the first and second, same day, 6MWT (Stevens D. et al., 1999).  The relatively 
small size effect (2.6%) was most likely due to the inclusion criteria where the 
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authors recruited individuals who had already experienced the 6MWT prior to 
the conduction of the study.  Based on literature, it is most probable that the 
size effect would be higher if the participants had never experienced the 
6MWT before.  This size effect may vary among studies depending on 
numerous factors, for example, the condition of the subjects, the 
methodology used in research studies (including/exclusion criteria), frequency 
and intensity of encouragements, and other psychological factors such as 
depression (Spruit et al., 2010, Enright et al., 2003, de Torres et al., 2002).  
The 6MWT, unlike the shuttle walking test, is not responsive to medication.  
In a randomised double-blind study of 14 patients with COPD asked to 
perform two 6MWT and two endurance shuttle walk test post either 500mcg 
of ipratropium bromide of a placebo (Pepin et al., 2006).  The study results 
showed that the endurance shuttle walk test was responsive to medications 
but not the 6MWD.  A recently published systematic review of field walking 
tests in patients with chronic respiratory disease showed that the effect of 
medications (bronchodilators) on the 6MWD is minimal, not clinically 
significant (Singh et al., 2014).  These findings strongly emphasise the 
importance of understanding and assessing both the pulmonary and the non-
pulmonary aspects of COPD.  Such findings led some researchers to imply that 
patients with mild COPD and poor 6MWD might indicate that health providers 
should look at extra-pulmonary rather than intra-pulmonary causes (Spruit et 
al., 2010).  
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According to the American Thoracic Society (ATS)/European Respiratory 
Society (ERS) guidelines, a pulmonary rehabilitation programme has to be 
patient-centred because improvement in performance capacity is exercise 
specific and ŝŵƉƌŽǀĞŵĞŶƚ ŝŶ ƚŚĞ ŐĞŶĞƌĂů ĨŝƚŶĞƐƐ ĚŽĞƐŶ ?ƚnecessarily reflect 
improvement in everyday activities (Nici et al., 2006).  The 6MWT lacks the 
ability to reflect certain important characteristics of patients with COPD such 
ĂƐƚŚĞĂďŝůŝƚǇƚŽƐƚĂŶĚĨƌŽŵĂƐĞĂƚĞĚƉŽƐŝƚŝŽŶĂŶĚƚŽƐŝƚďĂĐŬĂŐĂŝŶ ?ƉĂƚŝĞŶƚƐ ?
coordination ability in changing direction while walking, which in turn reflects 
on risks of falling in COPD patients.  However, the 6MWT was the preferred 
walking test over other walking tests owing to its simplicity, tolerability and 
safety - no reports of any injuries were found even in studies including 
patients with moderate to very severe cases of COPD (de Torres et al., 2002, 
Spruit et al., 2010, Enright et al., 2003). 
1.9.2.2 Incremental shuttle walking test 
This test was first introduced in patients with COPD as an objective measure 
of functional capacity.  The incremental shuttle walking test (ISWT) was 
modified from the downgraded 10 level protocol to a modified 12 level 
protocol as the levels in the former might not be enough to stress patients 
with mild form of COPD to reveal their maximum functional capacity (Singh S. 
et al., 1992).  Unlike self-paced test, ISWT can detect symptoms related 
limitation at maximal performance, which allows direct measurements of 
performance in patients with COPD (Singh S. et al., 1992).   
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1.9.2.2.1 The nature of the incremental shuttle walking test 
ISWT requires patients to walk between two cones  W placed on a ten metres 
course - within a set time that is indicated by pre-set beeps played on a 
recorded audiotape.  The number of laps is recorded and the time starts very 
slow and progresses with each minute.  The test ends when the subject is too 
breathlessness or cannot maintain the required speed (Singh S. et al., 1992).  
Learning effect is present in the ISWT and one practice test is recommended 
with a minimum of 30 minutes in between each performance (Singh S. et al., 
1992, Vagaggini et al., 2003, Fowler et al., 2005). 
ISWT has been used in number of conditions including COPD, cardiac patients, 
following coronary artery bypass surgery, evaluation of lung resection 
candidate, advanced cancer, and pulmonary rehabilitation (Lewis et al., 2001, 
Singh S. et al., 1992, Roberto P. Benzoa, 2010, Booth and Adams, 2001, 
Griffiths et al., 2000, Fowler et al., 2005). 
1.9.2.2.2 Validity 
When Singh et al., developed the ISWT, they investigated the test-retest 
reliability of the ISWT and the validity of the test against the 6MWT in COPD 
population (Singh S. et al., 1992).  The results showed moderate correlation 
(r= 0.68) in the distance covered in both tests and graded cardiovascular 
response was obtained by the ISWT and not the 6MWT. 
Singh et al., investigated the association of ISWT to the maximum oxygen 
uptake ( O2 peak)  W which is an index of cardiorespiratory capacity - during 
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treadmill test in 19 patients with chronic airflow limitation (Singh et al., 1994).  
The study demonstrated a strong correlation between the distance covered 
during the ISWT and O2 peak during treadmill test (r=0.88) determined by the 
following regression equation: 
     o2max = 4.19 + 0.025 (distance) 
Fowler et al., have used similar methods to investigate the validity of the 
ISWT against standard measurements of O2 peak - measured by gas analysis 
during incremental treadmill test - in 39 patients 6-8 weeks after coronary 
artery bypass surgery and prior to rehabilitation (Fowler et al., 2005).  They 
showed strong associations between the ISWTs (distance covered) and 
O2 peak measured by gas analysis during incremental treadmill test (r = 0.79, 
r = 0.86 and r = 0.87 for Tests 1 W3, respectively).  The maximum oxygen 
uptake obtained from the ISWT can be used to adjust the walking pace of the 
Endurance Shuttle Walk Test (ESWT), which is an externally paced field test 
developed to assess endurance capacity in patients with COPD (Revill et al., 
1999). 
1.9.2.2.3 Reliability 
The study conducted by Singh et al., (mentioned in  p 29) 10 patients were 
examined for the test-retest reliability by performing three ISWT trials (Singh 
S. et al., 1992).  All patients in their study completed the ISWT reaching level 
three to eight and no one finished the test at level 12.  The study results 
showed significant differences when the first trial was compared to the 
second and third trials; whilst no difference was found between the second 
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and third trials (345m, 376m, and 378m; respectively), which emphasise the 
learning effect in the ISWT.  Similarly, high reliability of the ISWT was found in 
number of conditions other than COPD, for example, patients with 
pacemakers (Payne and Skehan, 1996) and patients with advanced cancer 
(Booth and Adams, 2001). 
1.9.2.2.4 Minimal Clinically Important Difference 
In COPD, the minimal clinical important difference for the ISWT was, recently, 
established by investigating patients attending a seven week pulmonary 
rehabilitation programme (Singh S. et al., 2008).  In the study, 372 patients 
with confirmed COPD (mean (SD) FEV1= 1.06 (0.53)L FEV1/FVC ratio 50.8 
(18.1)% and a mean (SD) age of 69(4)years underwent ISWTs before and after 
the programme.  Exercise tolerance was assessed after the ISWT using a 5-
ƉŽŝŶƚ >ŝŬĞƌƚ ƐĐĂůĞ  ?ƌĂŶŐĞ ĨƌŽŵ  “ďĞƚƚĞƌ ? ƚŽ  “ǁŽƌƐĞ ? ? ? Patients who reported 
 “ďĞƚƚĞƌ ? ƐŚŽǁĞĚ ŝŵƉƌŽǀĞŵĞŶƚ ŝŶ ƚŚĞir exercise tolerance after the 
rehabilitation programme with a mean distance of 78.7m (95% CI, 70.5 to 
 ? ? ? ? ? ĂŶĚ ƚŚŽƐĞ ǁŚŽ ƌĞƉŽƌƚĞĚ  “ƐůŝŐŚƚůǇ ďĞƚƚĞƌ ? ƚŚĞǇ ŝŵƉƌŽǀĞĚ ďǇ  ? ? ? ?ŵ
(95%CI, 38.6 to 56.5).  Therefore, a change of 47.5m in the ISWT is recognised 
as a MCID where an improvement of 78.7m is suggested to be an indication of 
additional benefits. 
1.9.2.2.5 Conclusion 
The ISWT is a well-tolerated test of maximal exercise capacity in different 
chronic conditions.  It is considered to be less expensive than other 
conventional tests  W for example the ergometers  W as the ISWT only requires 
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minimal equipment.  Although it is standardised to perform one practice test, 
the use of audio-recorded external pace minimise in the ISWT minimises the 
degree of learning effect. 
1.9.2.3 Short Physical Performance Battery (SPPB) 
The ability of the exercise test to evaluate real life functional activities urged 
researchers to develop an accurate, reliable, sensitive, easier to perform, and 
less time and space consuming test which can relate to different dimensions 
of physical performance, for example the short physical performance battery 
(SPPB). 
1.9.2.3.1 Nature of the short physical performance battery test 
SPPB was first introduced by Guralnik et al., using data from the Established 
Populations for Epidemiologic Studies of the Elderly study (Guralnik et al., 
1994).  It is a simple and short test that was designed to measure three 
different types of manoeuvres: balance, gait speed and chair stand test.  Each 
physical manoeuvre of the test is timed and scaled separately starting with 
standing balance test and ending with chair stand test.  The entire test should 
not take more than 10 minutes to complete.  Moreover, the SPPB is an 
inexpensive test; it only requires a standard chair and a stopwatch for timing.  
The short-distance walk (8-feet) in the SPPB test makes the test feasible to 
perform in a small space. 
The SPPB consists of 5 points scale ranging from 0, not being able to perform 
the task, to 4 which is the highest performance score (Guralnik et al., 1994).  
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The full summed score ranges from 0 to 12 with 12 being the SPPB summary 
test of the highest possible performance score. 
1.9.2.3.2 Validity 
Guralnik et al., tested the validity of the SPPB test by investigating the 
following: its association to self-report measurements, its ability to measure 
performance along the entire functional spectrum (not only at the disabled 
end), and its ability to predict mortality and nursing home admissions 
(Guralnik et al., 1994).  In a study of over  ? ? ? ?ƉĂƌƚŝĐŝƉĂŶƚƐ ?ĂŐĞĚA? ? ?ǇĞĂƌƐ ?
who were recruited from the general population, showed that SPPB was 
positively related to self-reported measurements and inversely related to 
aging.  In COPD, the Functional, Living, Outcome, and Work (FLOW) cohort 
study investigated the impact of COPD on physical performance limitations by 
comparing 1202 patients with COPD to 302 healthy controls, both groups 
were matched for age, gender and race (Eisner et al., 2008).  The study 
showed that the SPPB score was 1.0 point less (9% decrease in the SPPB 
score) in the COPD group compared to the controls group, which was similar 
to the 6MWT where the COPD group walked 334 feet (20%) less than the 
controls group.  Another study by Kon et al., showed that slow 4m gait speed 
component of the SPPB was strongly associated with reduced ISWT and 
higher MRC score and SGRQ in >500 patients with COPD; this was 
independence of the degree of airway obstruction (FEV1% predicted (Kon et 
al., 2013). 
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1.9.2.3.3 Reliability 
To investigate the reliability of the SPPB test, it was necessary to examine the 
three components of the test as well as the SPPB summary test. 
o Reliability of the SPPB summary test:  
Ostir et al., investigated the test-retest reliability in a 3-year prospective 
cohort study of over 1,000 moderately to severely disable older women in 
three different occasions - 5-6, 12-13, and 19-20 weeks  W showing high Intra-
class Correlation Coefficient (ICC) = 0.92, 0.88, and 0.91, respectively (Ostir et 
al., 2002).  Another study of 52 African American older adults showed SPPB 
test-retest repeatability (ICC= 0.81) over one week (Mangione et al., 2010). 
o Reliability of the gait speed test: 
High reliability of the 4m gait test with ICC of 0.86, 0.80, and 0.89, 
respectively, was presented in the tŽŵĞŶ ?Ɛ,ĞĂůƚŚĂŶĚŐŝŶŐ^ƚƵĚǇ(WHAS) 
study investigating disabled older women (Ostir et al., 2002).  In another 
study, the 4m gait speed was also found to have high test-retest (r= 0.97, 
within 24hr and 48hr periods) and inter-observer (r= 0.99) reliability in 
patients with COPD (Kon et al., 2014). 
o Reliability of the chair stand test: 
Again, high reliability of the chair stand test was shown in the WHAS study; 
ICC 0.76, 0.86, and 0.90, respectively.  Similar results of high reliability were 
shown in another population (age 35-71 years) with significant physical 
limitation; ICC= 0.80   (Curb et al., 2006). 
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o Reliability of the balance test: 
The WHAS study showed ICC of 0.71 (5-6 weeks), 0.82 (12-13 weeks), and 
0.70 (19-20 weeks) for the balance test (Ostir et al., 2002).  The study by Curb 
et al., showed no reliability for the side-by-side and semi-tandem standing 
positions and only low reliability of the full tandem test with ICC of 0.22 (Curb 
et al., 2006).  The main difference between the two studies was that the 
average age in the WHAS study was higher than the oldest participant in the 
Curb et al., 2006 study.  Moreover, not only did Curb et al., recruit younger 
adults, but they also included only a high functioning Japanese American 
population who have an active life expectancy higher than any other ethnic 
groups (Tsuji et al., 1995).  Therefore, the full tandem, which is the most 
difficult standing position among the three (Freeman et al., 2008), was the 
only challenging task for balance in this group of people.  
1.9.2.3.4 Minimal Clinical Important Difference 
Perera et al., have adopted the anchor-based approach trying to measure the 
minimal clinical important difference in the SPPB on community dwelling 
older adults and sub-acute stroke survivors (Perera et al., 2006).  They 
showed small meaningful and substantial changes of 0.54 and 1.34, 
respectively, for the SPPB.  Furthermore, in a longitudinal study following 542 
community-ĚǁĞůůŝŶŐĂĚƵůƚƐ ?ĂŐĞĚA? ? ?ǇĞĂƌƐŽůĚ ?ĨŽƌthree years using SPPB as 
a tool to predict the ability to walk 400m (Vasunilashorn et al., 2009).  The 
results showed that ^WW ƐĐŽƌĞ ŽĨ A? ? ? ƉŽŝŶƚƐ ǁĂƐa significant indicator of 
future disability, SPPB score of A? ?ƉŽŝŶƚƐwas associated with increased risk 
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(26.9 times) of developing disability when compared to SPPB score of 12 
points and SPPB score of A? ? ?was with increased risk (3.4 times) to develop 
mobility disability when compared to SPPB score of 12 points. 
1.9.2.3.5 SPPB in Patients with COPD 
The FLOW study, mentioned earlier, is the largest cohort study investigating 
broad range of physical limitations in COPD patients (Eisner et al., 2008).  The 
study shows consistency of the SPPB test with the 6MWT and self-reports.  
Although SPPB test and the 6MWT were used for the assessment of the lower 
extremity limitations and the submaximal exercise performance, respectively, 
the study population was only limited to younger adults (40-65 year-old) and; 
therefore, findings cannot be applied to older adults where the impact of 
COPD on the physical limitation might be underestimated.  
One of the disadvantages of the SPPB test is that it has a ceiling effect for high 
functioning individuals.  This was discussed in the earlier section when 
different findings were obtained from the WHAS and Curb et al., studies.  This 
ceiling effect might be misleading specially when trying to detect early and 
more subtle impairments in patients with COPD (Curb et al., 2006).  
1.9.2.4 Timed Up and Go (TUG) test 
TUG is one of the tests that have been developed to measure basic physical 
performance in the elderly. 
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1.9.2.4.1 The Nature of the TUG Test 
TUG test is adapted from the  “'Ğƚ-ƵƉĂŶĚ'Ž ?test which was developed in 
1986 by Mathias et al., on balance function (Mathias et al., 1986).  /ƚǁĂƐŶ ?ƚ
until 1991 when a modified, timed (seconds) version was introduced to 
ŽǀĞƌĐŽŵĞƚŚĞƐƵďũĞĐƚŝǀŝƚǇŽĨ “'Ğƚ-ƵƉĂŶĚ'Ž ?ƚĞƐƚ(Podsiadlo and Richardson, 
1991).  The American College of Rheumatology recommended the use of a 
standard arm chair for the TUG test - seat height of 46cm and arm height of 
64cm (Rheumatology., 2014), as the chair height might have an influence on 
the subjects performing the TUG test (Heung and Shamay, 2009).   Meta-
analysis of 21 studies showed that the mean time to complete the test for 
participants (60 year-old or above) was 9.4s (95% CI, 8.9-9.9) (Bohannon, 
2006). 
1.9.2.4.2 Validity 
Since falls and balance impairments are common in patients with COPD 
(Beauchamp et al., 2009), it is necessary to validate a test which can 
discriminate between those who are at risk of falls and those who are not.  In 
a study of 60 community-dwelling patients (mean age 79.5 years), Podsialdo 
and Richardson presented a good correlation between the TUG test and Berg 
balance scale, r= -0.81 (Podsiadlo and Richardson, 1991).  Moreover, the 
validity of the TUG test and stair climbing power test was examined in a small 
cross sectional study of 21 patients with COPD (moderate-severe stage) and 
21 healthy controls (Roig et al., 2010).  The study showed moderate 
association (r= -0.46) between stair climbing power test and the TUG test in 
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this group of patients.  In addition, validity was found between gait time 
(10m) and the TUG tests in an observational study of 79 orthopaedic patients 
(61-84 years old) entering rehabilitation program (r=0.75 on admission and 
r=0.82 on discharge) (Freter and Fruchter, 2000). 
1.9.2.4.3 Reliability 
Same day test-retest reliability of the TUG test was found to be high, ICC > 
0.90, in older adults across several studies including those with balance 
deficits, patients with neurological disorder, patients with COPD, and 
community-dwelling healthy individuals (Bennie S, 2003, Salarian A et al., 
2010, Roig et al., 2010, Steffen et al., 2002, Podsiadlo and Richardson, 1991, 
Mesquita et al., 2013).  Recently, Mesquita et al., showed high same day test-
retest reliability of the TUG test in patients with advanced COPD (ICC= 0.85, 
95%CI: 0.76-0.91), chronic heart failure (CHR) (ICC= 0.94, 95% CI: 0.87-0.97) 
and chronic renal failure (CRF) (ICC= 0.91, 95% CI: 0.78-0.96) (Mesquita et al., 
2013). 
1.9.2.4.4 Sensitivity and specificity 
Researchers have altered the TUG test either by measuring the time required 
by patients to perform each subcomponent of the test separately (Salarian A 
et al., 2010, Wall C., 2000) or by adding an extra task (dual-task) to the test 
(TUGcognitive, and TUGmanual), for example, holding a glass of water while 
performing the TUG test (Shumway-Cook et al., 2000).  Regardless of the 
different approaches used, the sensitivity and specificity of the single-task 
version of TUG test have been evidenced in these stu
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make any modification which might interfere with the simplicity and 
objectivity of the test (Nordin et al., 2008, Gyrd Thrane, 2007, Kristensen et 
al., 2007).  In a study to compare the sensitivity and specificity of the single-
task TUG test and dual-task TUGcognitive, and TUGmanual in community-dwelling 
elderly persons who are susceptible to falling, 15 older adults (mean (SD) age 
78 (6)years) with no history of falls, and 15 older adults (age 86 (6) years) with 
history of two or more falls within six months prior to the study were 
examined (Shumway-Cook et al., 2000). The study used a cut-off time of 
A? ? ? ? ?s which gave 87% sensitivity and 87% specificity for the single-task TUG 
test to identify community-dwelling elderly people who are prone to fall 
without any significant difference when compared to results obtained from 
the other dual-task tests. 
1.9.2.4.5 Minimal Clinical Important Difference 
The minimal clinical important difference for the TUG test was investigated in 
a prospective study of patients with hip osteoarthritis undergoing 
physiotherapy treatment (9-weeks) (Wright A, 2011).  Using three different 
methods (sensitivity and specificity based approach, within-patients score 
change approach and between patients score approach), the results showed 
TUG minimal clinical important difference of equal or less than 0.8s, 1.4s and 
1.2s, respectively.  To our knowledge the minimal clinical important 
difference for the TUG test in patients with COPD has not been established 
yet. 
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1.9.2.4.6 TUG cut-off values looking at mobility and falls 
Literature shows different cut-off times of the TUG test when investigating 
different conditions ?ĨŽƌĞǆĂŵƉůĞ ?dh'ŽĨA? ? ?ƐĞĐŽŶĚŝŶĐŽŵŵƵŶŝƚǇ-dwelling 
elderly women was established to identify normal mobility (Bischoff et al., 
2003),  dh' ŽĨ A? ? ? ? ? ƐĞĐŽŶĚ ŝŶ ĐŽŵŵƵŶŝƚǇ-dwelling elderly who were 
susceptible of falling using assistive devices, 18 second for those using a cane, 
and 34 seconds for those using wheeled-walker (Shumway-Cook et al., 2000). 
Gender might have a role in the mentioned cut-off values as in Bischoff et al., 
study only female participants were included; whereas, the Shumway-Cook et 
al., study included both genders (Bischoff et al., 2003, Shumway-Cook et al., 
2000).  Similarly, a two second difference was also found in a longitudinal 
population-based study (The Tromso study) investigating the association 
between the TUG test and history of falls in 974 participants (42.7% males) 
with the mean (SD) age of all participants was 78 (2) years (Gyrd Thrane, 
2007).  The results of the study support the gender differences where the 
mean (SD) time for men and women to complete the TUG test were 12 (5.4)s 
and 13.3 (7.1)s, respectively.  Moreover, there is evidence in literature shows 
an association between the TUG test and age.  Steffen et al., have shown an 
age-related trend of the TUG test in their study: 60-69 years = 8s (95% CI= 7-
9), 70-79 years = 9s (95% CI= 7-11), and 80-89 years = 10s (95% CI= 9-12) 
(Steffen et al., 2002). 
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1.9.2.4.7 TUG in patients with COPD 
In literature, the studies investigating the TUG test in patients with COPD are 
limited (Table 1.1).  Roig et al., showed that muscle strength (assessed by stair 
climb power test) and mobility (assessed by 6MWD and TUG tests) were 
impaired in patients with COPD in comparison to healthy controls (Roig et al., 
2010).  However, their finding are not generalisable to the general COPD 
population as they used small (n=21) and convenient sample of patients with 
COPD - Global Initiative for Obstructive Lung Disease (GOLD) stage II and III. 
Beauchamp et al., found that TUG is a useful test to differentiate between 
fallers and non-fallers in patients with COPD (Beauchamp et al., 2009).  
However, the authors did not use healthy comparators and did not 
investigate TUG association to the frequency of fall amongst COPD fallers.  In 
comparison to non-fallers, fallers in their study also had greater functional 
limitations defined by a higher Medical Research Council (MRC) dyspnoea 
score, and lower walked distance in the 6MWT. 
Janssen et al., investigated patients with advanced COPD and Chronic heart 
failure (CHF) and showed that TUG was inversely related to the general health 
status (Janssen et al., 2011) 
 4
3 
   
Table 1.1: Studies Investigating TUG in Patients with COPD 
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1.9.2.4.8 TUG test in research and clinical practice 
The TUG is a valid and reliable test that has been shown to be a useful tool to 
detect limitations of physical performance and balance, risks of fall and 
improvement post-rehabilitation intervention in healthy subjects as well as 
number of medical conditions including, but not limited to patients with 
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?ŽƐƚĞŽƉŽƌŽƐŝƐĂŶĚKW(Podsiadlo and Richardson, 1991, 
Beauchamp et al., 2009, Madureira et al., 2007, Shumway-Cook et al., 2000).  
Currently, the most commonly used field walking tests have a number of 
limitations, mainly in the required time and space, which limit their use in 
research or clinical practice.  For example, the 6MWD and ISW tests require 
certain space (walking track of 30m and 10m, respectively) and time to 
perform one practice and one actual test (Singh et al., 2014).  The SPPB is a 
multi-task test of physical performance which requires small space, but is 
limited by ceiling effect (Curb et al., 2006).  The TUG test, on the other hand, 
is a continuous multi-task test of physical performance that requires small 
space and short time to perform.  It can also be used as an objective measure 
of risk of falls as well as balance impairment along with Borg Balance Scale.  
Moreover, literature showed that the TUG test has better prognostic power 
to predict future incidence of falls in community-dwelling older adults than 
other fall assessment tests such as muscle strength assessment and balance 
assessment tests including Borg Balance Scale (Bhatt et al., 2011). 
These advantages of the TUG test make it superior over other physical 
performance tests to be used in the research unit environment, clinical 
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practice and in the community, for example, detecting improvement in tele-
rehabilitation programme.  Although the TUG test does not reflect exercise 
capacity or maximum oxygen uptake as the 6MWD and ISWT do, health care 
providers might, potentially, use the TUG test as streaming tool of physical 
performance prior to referring to these field walking tests. 
Future studies may show that the TUG test adds value in the assessment of 
patients with COPD to detect reduced physical performance, improvement 
over time (for example post-rehabilitation intervention) and risks of fall.  
Furthermore, the TUG test might be used as an initial assessment of physical 
performance by which a decision of further investigation using other field 
walking test can be made.  The multi-task components associated with the 
TUG test, for example standing from a seated position, turning and sitting 
down on the chair, may also be beneficial to assess strength, balance and 
coordination in patients with COPD as it requires more cognitive involvement.  
This research may help reveal the potential benefits of the TUG test in the 
assessment of patients with COPD and fulfil the gap in literature which 
highlights the need for a physical performance test which requires small space 
and time in the assessment of patients with COPD. 
1.9.2.4.9 Conclusion 
The TUG is a simple test of functional mobility that can be used in clinical 
settings as well as the community for functional assessments of patients with 
COPD.  It is a continuous multi-task test measured in seconds with no ceiling 
effects.  The studies investigating the TUG ability to detect functional 
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impairments and self-reported previous falls used small sample and 
convenient sample of patients with COPD.  The reliability of the TUG in 
patients with COPD has been established using same day test-retest 
reliability.  Same day inter-observer and different day intra-observer reliability 
of the TUG test have not been investigated.  
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1.10 Hypothesis 
- The Time Up and Go (TUG) test is increased in patients with COPD 
compared to age- and gender-matched controls reflecting impaired 
physical performance in patients 
- The TUG test is inversely related to the six minute walking distance 
(6MWD) in patients with COPD 
- The TUG test is a simple test with high inter- and intra-observer 
reliability in patients with COPD 
- The TUG is a useful test to differentiate between fallers and non-
fallers in patients with COPD 
- Impaired physical performance, as measured by TUG and/or 6MWT is 
a significant determinant of the increased aortic stiffness in patients 
with COPD, independent of age, gender and lung function 
- Aortic stiffness is inversely related to self-reported physical activity in 
patients with COPD 
- Patients with COPD have abnormal profile of 24-hour aortic pulse 
wave velocity when compared to age- and gender-matched controls 
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Chapter 2 
Methods 
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2.1 Setting  
This was a single centre, cross-sectional study that was undertaken at the 
Nottingham Respiratory Research Unit (NRRU) at Nottingham City Hospital.  
Each participant was invited to attend one study visit, which lasted 
approximately 120 minutes. 
2.2 Sample size 
To test the main hypothesis, the target recruitment number was 180 subjects 
with a smoking history of greater than 10 pack years: 120 patients with 
clinically stable COPD and 60 controls without COPD matched for age and 
gender.  Dr Charlotte Bolton performed the statistical power calculation to 
determine sample size using G power software during the designing stage of 
the study.  The calculation was based on mean (SD) TUG time of 15 (4.3) 
seconds for patients with COPD with no control arm group (Beauchamp et al., 
2010).  A two-tailed t-test was then used with an effect size of 0.52 and alpha 
of 0.05.  This yielded a power of 90.8% to detect a 15% (2.25 second) 
difference between patients with COPD and control groups. 
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2.3 Recruitment 
Three sources of recruitment were used for this study: 
x Out-Patients: Patients attending Respiratory Out-Patient clinic at 
Nottingham University Hospitals (NHS) Trust were introduced to the 
study by one of the respiratory consultants.  If patients were willing to 
consider the study, study information sheets (Appendix 1) were sent 
out and further discussion ensued. 
x Databases: Potential patients were identified using the Nottingham 
Respiratory Research Database.  This is a database of volunteers with 
and without respiratory diseases that have consented to have their 
details stored and to be contacted for future studies.  Subjects are 
entered onto the database from clinics, rehabilitation and additionally 
from poster, web page (www.nrru.org) and formerly a Facebook link.  
These volunteers were contacted to be giver brief overview of the 
study followed by information sheets. 
x Advertisements: Ethics allowed study specific posters to be placed 
across both the University of Nottingham and NUH NHS Trust as well 
as in local newspapers and on websites.  Further, COPD posters 
regarding research in general at the NRRU permit a further source.  
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2.4 Ethics  
This study was approved by the Nottingham Research Ethics Service (NRES): 
 “The association of lung function and cardiovascular risk ?10/H0406/65.  This 
ethical permission allows a large population of people with smoking history 
with and without COPD to be studied.  An ethical amendment to permit the 
further specifics of this project was approved in January 2012.  The studies 
and patients recruited for this study form a specific group for the purposes of 
this thesis and body of work.  
2.5 Inclusion/exclusion criteria 
The inclusion criteria for this study include  
x Male and female subjects  
x 40-85 years old 
x >10 pack years history smoking (ex-smokers or current smokers) 
x European ancestry.  This latter inclusion was set because of the likely 
genetic, body composition, lung function and CV differences/ 
influences between subjects of different ethnic origin. 
The exclusion criteria include: 
x Terminal disease where mortality is expected within a 6-week period.  
x Malignancy whether active or suspected,  
x <ŶŽǁŶɲ ?ĂŶƚŝƚƌǇƉƐŝŶĚĞĨŝĐŝĞŶĐǇ 
x Pregnancy for female participants.  
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Subjects were studied at clinical stability defined as A?4 weeks free from a 
course of antibiotics for an exacerbation of COPD or change in symptoms 
suggesting an exacerbation.  This was not an exclusion criterion as 
appointments could be rearranged and deferred.  Subjects presenting with 
previously diagnosed CV disease or diabetes were not excluded in either 
group. 
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2.6 Process 
All subjects received the study information sheet and given sufficient time (up 
to two weeks) to read through the information sheet and ask questions 
regarding their participation in the study.  They were then contacted to assess 
whether they were willing to participate.  A suitable date was arranged and 
an appointment letter, a map of the City Hospital and directions to the NRRU 
were sent.  A taxi was offered to the subjects or alternatively the cost of 
travel and parking was reimbursed.  
2.6.1 Informed consent 
Upon arrival, the objectives of the study and the required tests to be 
performed during the study visit were discussed.  
Consent allowed the opportunity for the subject to ask questions, the 
researcher to outline the nature of participation and specify the use of the 
obtained samples and confirmed the agreement to take part in the study.  
The consent also included optional points, which the participants may choose 
whether to agree on including consent for 24 hour ambulatory BP monitor in 
the subgroup (Appendix 2). 
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2.6.2 WĂƚŝĞŶƚƐ ?ĚĞƚĂŝůƐĂŶĚƋƵĞƐƚŝŽŶŶĂŝƌĞƐ 
ĞƚĂŝůĞĚŝŶĨŽƌŵĂƚŝŽŶƌĞŐĂƌĚŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐƉŚǇƐŝĐĂůĂĐƚŝǀŝƚǇ ?ƐŵŽŬŝŶŐŚŝƐƚŽƌǇ
and occupational exposure, history of falls, detailed lung related conditions, 
and other general medical conditions were recorded. 
Further, subjects were asked to complete three respiratory related 
questionnaires during the study visit: 
2.6.2.1 ^ƚ'ĞŽƌŐĞ ?ƐZĞƐƉŝƌĂƚŽƌǇYƵĞƐƚŝŽŶŶĂŝƌĞ ?^'ZY ? 
dŚĞ ^'ZY ĂƐƐĞƐƐĞƐ ŚŽǁ ƉĂƚŝĞŶƚƐ ? ǀŝĞǁ ƚŚĞŝƌ ŝůůŶĞƐƐ (Jones et al., 1992). The 
SGRQ consists of three parts  W symptoms, activity, and impacts of COPD 
(Appendix 3).  Each part is calculated separately and the total score is 
calculated where higher scores indicate worse health status. 
In a quiet clinical setting, subjects were given sufficient time to complete the 
questionnaire independently.  Subjects were allowed to ask clarification 
questions as needed regarding the questionnaire.  Once completed, the 
questionnaire was checked for missing or uncompleted answers and the 
scores calculated.  
2.6.2.2 Medical Research Council (MRC) dyspnoea scale 
The MRC dyspnoea scale is a graded scale to assĞƐƐƉĂƚŝĞŶƚ ?ƐďƌĞĂƚŚůĞƐƐŶĞƐƐ 
(Appendix 4).  It consists of five sentences  W numbered 1 to 5 - where the 
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patient is asked to tick the sentence which best describes his/her dyspnoea 
(Fletcher, 1960). 
2.6.3 Height and weight measurements 
Measurements of height (metres) and weight (kilograms) were obtained using 
Seca scales device (Seca, Germany).  Subjects were asked to stand on the 
weight scale barefoot and without outdoor clothing on.  From this, the body 
mass index (BMI) was calculated: weight/square of height (in metres).  BMI is 
a widely accepted index to classify underweight, overweight, and obesity in 
adults (WHO, 2006).  
2.6.4  Body composition 
Bioelectrical Impedance Analysis (BIA) body (Tanita BC-418, UK) was used to 
measure the body composition including, but not limited to, fat and fat-free 
mass (Appendix 5).  dŚĞƉĂƌƚŝĐŝƉĂŶƚ ?ƐĂŐĞ ?ŚĞŝŐŚƚĂŶĚ gender were inputted in 
the BIA before he/she was asked to stand on the device to obtain the 
measurements.  Subjects were asked to empty their bladder and be bare foot 
so removing all socks/stockings.  Contradictions to BIA include pacemakers 
and implantable cardiac defibrillator.  Other contraindications for BIA such as 
pregnancy were excluded as part of the exclusion criteria for the main study. 
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2.6.5 Haemodynamic profile 
Haemodynamic measurements preceded many investigations in order to 
avoid the effect of beta2-agonist drugs - used during the lung function test - 
or exhaustion after the 6MWT.  Subjects were also asked to refrain from 
caffeine substances and other respiratory medications prior to their visit.   
2.6.5.1 Peripheral blood pressure (BP) measurements 
Subjects were asked to sit and resting time was allowed for a period of >10 
minutes.  The appropriate sized cuff was placed on the upper part of the right 
arm with the bladder placed over the brachial artery.  The BP was measured 
on three occasions following detailed Standard Operating Procedures (SOP) 
using a British Hypertension Society (BHS) validated BP monitor (Omron 
705IT, UK).  The average of the three systolic and diastolic measures was used 
to determine seated BP.  From these, the peripheral pulse pressure (PPP) and 
peripheral mean arterial pressure (MAP) were calculated 
The subject was asked to lay down supine with one pillow in a comfortable 
position for >10 minutes allowing haemodynamic stability before taking 
further BP measurements for supine assessment.  The same method to 
determine supine peripheral BP was undertaken.  
2.6.5.2 Central haemodynamics  
Central haemodynamics were taken with the subject both seated and supine 
using the Vicorder apparatus (Skidmore Medical, UK).  The Vicorder cuff was 
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placed on the right brachial artery and systolic, diastolic, MAP, augmentation 
index (Aix), and heart rate were measured on three occasions and the 
average recorded following >10 minutes rest in the seated and then supine 
position. 
2.6.5.3 Pulse wave velocity (PWV) 
The aPWV was performed using Vicorder apparatus (Skidmore Medical, UK) 
which is non-invasive and a simple device that has been validated for 
measuring the PWV (Hickson et al., 2009) (although further methodological 
amendments have been made following discussion with the authors of this 
paper and the company). 
In a supine position and after a period of rest - >10 minutes - in a quiet room, 
aPWV was performed by placing a standard vascular cuff around the right 
upper femoral artery and a bladder over ƚŚĞ ƐƵďũĞĐƚ ?Ɛcarotid artery on the 
site of the carotid artery (Appendix 6).  
Path length was measured starting from the suprasternal notch to the top of 
the femoral cuff and adding five centimetres (to represent the distance to the 
middle of the cuff where the maximum inflation point is and provide more 
accurate measurements of the length path.  Transit time (TT)  W the time in 
which the pulse wave travels between two arterial sites - was calculated by 
the Vicorder.  The aPWV was calculated as path length/TT (m/s) (Appendix 7).  
Measurement of aPWV of <4.7m/s is considered inaccurate and any such 
values were excluded from analysis. 
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2.6.6 Spirometry measurements 
A three-litre syringe was used to calibrate the Micro-medical spirometer 
(MicroLab MK6) on the day of each visit.  All subjects were asked to refrain 
from respiratory inhalers six hours prior to their visit.  Before performing the 
test, subjects were checked for any contraindications such as 
abdominal/thoracic/eye surgery or myocardial infarction within the past 
three months, unstable angina, uncontrolled hypertension, glaucoma, 
perforated eardrum, aneurysm, haemoptysis, and steroids/antibiotics for the 
chest within the past four weeks.  
Pre and post bronchodilator measurements were determined while subjects 
were seated upright on a chair with arms.  ^ƵďũĞĐƚ ?ƐĚĞƚĂŝůƐǁĞƌĞŝŶƉƵƚƚĞĚŝŶ
the spirometer including the age, gender and height and the procedure of 
how to perform the test was explained.  Subjects were instructed to take a 
deep breath in and blow it out as fast and as long as possible while making a 
good seal with his/her mouth around the mouth piece of the spirometer.  
With each blow, subjects received continuous encouragements by saying 
 “ŬĞĞƉŐŽŝŶŐ ?ƵŶƚŝůƐƵďũĞĐƚƐcould not blow anymore.  
Three repeatable pre-bronchodilator attempts were taken according to the 
American Thoracic Society (ATS) and the European Respiratory Society (ERS) 
criteria (Miller et al., 2005). 
Reversibility testing was performed by administering 400mcg Salbutamol via 
an MDI and spacer.  Fifteen to twenty minutes were allowed before the 
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postbronchodilator test was performed.  For pre and post bronchodilator 
spirometry , measurements of actual value of FEV1, FEV1% predicted, actual 
value of forced vital capacity (FVC), FVC% predicted, and the FEV1/FVC ratio 
were measured against the predicted values based on gender, age and height.  
Only Post-bronchodilator measurements were used in the analysis. 
Severity of airflow obstruction (FEV1/FVC <0.7) in subjects with COPD was 
classified using the NICE criteria (Table 2.1) (NICE, 2010). 
 
 Table 2.1 NICE Classification of the Severity of COPD (NICE, 2010) 
Abbreviation: Forced expiratory volume in one second (FEV1) 
Stage 
Post-bronchodilator Predicted value of 
FEV1% 
Mild FEV1 A? ? ?A? (and symptoms) 
Moderate FEV1 50-79% 
Severe FEV1 30-49% 
Very severe FEV1  <30% 
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2.6.7 Carbon monoxide measurement 
The level of exhaled carbon monoxide (CO) was determined using Clement 
Clarke Smokerlyzer CO monitor.  The obstacle some patients might encounter 
during this test is the 15 seconds breath hold.  The recommended technique 
for using CO test is to ask the patients to hold their breath for few seconds 
and not to use the exact number 15 seconds (Covita., 2013).  Thus, each 
subject was instructed to take a deep breath in and hold it for few seconds 
then breathe it out normally through the mouthpiece of the CO monitor.  On 
a scale of 1-80 showing on the monitor, current smokers would likely exceed 
10. 
2.6.8  Venepuncture  
^ƵďũĞĐƚƐ ? ĞůŝŐŝďŝůŝƚǇ ĨŽƌ ďůŽŽĚ ƐĂŵƉůĞ ǁĂƐ ĂƐƐĞƐƐĞĚ ĂŶĚ ƉƌŽĐĞĚƵƌĞƐ ǁĞƌĞ
explained.  Following the aseptic non-touch technique, up to two attempts 
(maximum) were performed on each subject; if both attempts failed, subject 
was taken to phlebotomy for venepuncture.  For each subject, plasma (EDTA 
and Lithium Heparin) and serum was taken.  Serum was sent for immediate 
biochemistry analysis (lipid profile) and further aliquots centrifuged and 
stored at -80 degrees Celsius for later research analysis (not covered in this 
Ph.D).  
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2.6.9 Field walking and physical performance tests 
This was assessed objectively by asking the subject to perform two tests - the 
6 minute-walk test (6MWT) and the Time Up and Go (TUG) test. 
2.6.9.1 Six minute walk test (6MWT) 
Oxygen saturation and heart rate (Konica Minolta Pulsox-300) were 
monitored before, during and immediately after the test.  Self-reported level 
of breathlessness - measured by Borg scale (Burdon et al., 1982) (Appendix 8) 
 W was recorded before and immediately after the test (ATS, 2002). 
In a quiet enclosed corridor, subjects were asked to walk for six minutes on a 
10-metre marked course with one cone placed at each end where the subject 
should turn around and continue his/her walk.  One cone was placed at 0.5 
and 9.5 to allow turning being 10 metres.  Subjects were allowed to rest - if 
needed (chairs at either end of walking course) - and continue walking during 
the allocated time.  Subjects were allowed to use any gait aid throughout the 
test. 
2.6.9.2 Time Up and Go 
Following the original procedures of the test, subjects were instructed to 
stand up from a seated position on a standard armed chair (46cm), walk for 
three metres, turn, return, and sit down (Figure 1.1) (Podsiadlo and 
Richardson, 1991). 
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Using one phrase, each subjects was instructed as follow: on the word go, I 
want you to stand up, walk at a regular pace to the line on the floor, turn, 
walk back to the chair and sit down,  The timing of the test starts on the word 
 “'K ? ǁŚŝůĞsubjects in sitting position and ends when returning to initial 
sitting position.  Usage of gait aids were allowed as needed and subjects were 
instructed to walk at their comfortable pace during the test. 
 
 
  
2.6.10 Ambulatory 24 hour blood pressure and arterial stiffness 
The Mobil-O-Graph 24-hour ambulatory BP monitor was used to measure 
haemodynamics during daytime and overnight via a pre-set protocol 
(Appendix 9). 
The diurnal and nocturnal systolic BP measurements were used to detect 
nocturnal dip; by which, subjects can be classified into inverse dippers: 
systolic nocturnal dip of <0%; non-dippers: systolic nocturnal dip of <10%; 
dippers: systolic nocturnal dip <20%; and extreme dippers: systolic nocturnal 
dip of A? ? ?A? (Kario et al., 2001a).  Due to our small sample size, we grouped 
Figure 1.1: Diagram of the Time Up and Go Test 
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inverse and non-dippers together, and then grouped dippers and extreme 
dippers together.  
This was an exploratory study where an arbitrary 40 subjects (20 patients and 
20 controls) were initially planned to recruit; however, 46 were invited to 
undertake this test.  Subjects were taught how to use the device and initial 
reading was taken during the visit by placing the cuff on the upper arm.  The 
cuff was pre-set to inflate intermittently - twice per hour during the daytime 
and once per hour during nighttime - to record the BP and other 
haemodynamic measures.  On the return day, stored readings in the machine 
were transferred to a software programs in a password protected laptop 
provided by the University of Nottingham (Appendix 10). 
2.6.11 Oxygen saturations 
Oxygen saturation was measured by pulse oximeter with the patients 
breathing room air and rested for >20min (Konica Minolta Pulsox-300).  
2.6.12 Composite COPD measures 
The BMI, airway obstruction, dyspnoea and exercise capacity (BODE) index is 
a multidimensional grading system which helps to predict disease outcome in 
patients with COPD (Celli et al., 2004).  In this index, systemic components of 
the disease such as exercise capacity and BMI are accounted for.  BODE scale 
ranges from a minimum score of 0 to a maximum score of 10.  Each of the 
four components of the BODE index is given a score range 0-3 except for the 
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BMI score which can only be 0-1 depends on the degree of impairment of 
each component (Appendix 11). 
 The ADO index on the other hand was developed to predict 3-year mortality 
and prognosis of COPD (Puhan et al., 2009).  Each component of the ADO 
index is scored differently, for example, a score range of 0-5 is used for the 
age component, a score of 0-3 is used for MRC dyspnoea scale and a score of 
0-2 is used for the airway obstruction (Appendix 12). 
2.6.13 Assessment of self-reported physical activity 
Self-reported physical activity questionnaires were divided into three parts: 
first is the frequency of doing mild, moderate and vigorous activity per week 
 ?A? ?ƚŝŵĞƐ ?ǁŬ ? ?-2 times/ wk, 1-3 times/ month or almost never), second is the 
time (hrs/wk) each subject spends doing mild, moderate and vigorous activity, 
and finally is the time each subject spent walking outside home/workplace in 
the past week by reporting an average walking time (minutes) for each 
weekday as well as each weekend day. 
Mild activity includes, but not limited to, walking, gardening, playing darts and 
housework.  Moderate activity includes, but not limited to, scrubbing, 
polishing car, dancing, golf, cycling, decorating, lawn mowing and leisure 
swimming.  Finally the vigorous activity includes, but not limited to, running, 
tennis, squash, digging and hard swimming.  
 65 
 
2.6.14 Self-reported co-morbidity score 
Co-morbidities were recorded in all subjects.  From this, one point was given 
to each self-reported co-morbid condition listed in Charlson Co-morbidity 
Index which includes myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, COPD, 
connective tissue disease, peptic ulcer disease, diabetes mellitus, hemiplegia, 
malignant lymphoma, solid tumor, liver disease and acquired immune 
deficiency syndrome (AIDS) (Charlson et al., 1987).  The nature of co-
morbidity history taking in the design of our study did not allow for the 
accurate use of Charlson Co-morbidity Index.  Also to note some of the 
comorbidities used in Charlson Co-morbidity Index were exclusion criteria for 
this study. 
2.6.15 Post visit 
After each visit, a thank you letter was sent showing appreciation to the 
participant for taking part in the study.  A travel expenses form was 
completed if required ĂŶĚĂ ůĞƚƚĞƌŽĨ ƚŚĞƉĂƚŝĞŶƚ ?ƐƉĂƌƚŝĐŝƉĂƚŝŽŶǁĂƐƐĞŶƚ ƚŽ
the general practitioner (GP) along with clinically relevant results (spirometry, 
carbon monoxide, pulse oximetry, MRC dyspnoea scale, BP, and blood 
results).  Any abnormalities in the results were highlighted and assessed by 
the chief investigator prior to posting the letter to the GP. 
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2.7 Confidentiality 
^ƵďũĞĐƚ ?ƐĨƵůůŶĂŵĞ ?ĚĂƚĞŽĨďŝƌƚŚ ?ĐŽŶƚĂĐƚĚĞƚĂŝůƐ ?ƐƚƵĚǇĐŽĚĞŶƵŵďĞƌ ?ĚĂƚĞŽĨ
the visit, and the GP address were documented separately from the Case 
Report File.  The Case Report File included limited personal information such 
as the subject initials, date of birth and a study code number thus 
anonymising the data, but allowing tracking of for example biochemistry 
results.  All Case Report Files were stored in a locked office at the Clinical 
Sciences Building at the City Hospital and only the chief investigator, research 
team and authorised personnel from relevant regulatory authorities had 
access to these files.  Anonymised electronic data was saved on a password-
protected laptop, which was provided by the University of Nottingham 
2.8 Statistics  
Statistical package of the Social Sciences (SPSS) version 21 was used for data 
analysis.  For normally distributed data parametric tests were used: Chi squire 
test was used to statistically compare two categorical variables.  Independent 
t-test was used to look for differences of a continuous variable between 
groups and one way ANOVA (Post Hoc, Tukey) for a categorical variable with 
more than two groups).  WĞĂƌƐŽŶ ?Ɛ ƚĞƐƚǁĂƐƵƐĞĚ ƚŽ ĂŶĂůǇƐĞ ƚŚĞ ĐŽƌƌĞůĂƚŝŽŶ
between two continuous variables.  Inter-class correlation coefficient (ICC) 
with 95% confident interval (CI) was used to test for reliability of a measure.  
Bland-Altman plot was used to investigate the level of agreement between 
two measurements.  A stepwise linear regression was used to examine 
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independent confounders for a specific variable where the variable of interest 
was the dependent variable and the potential confounders were the 
independent variables.  For non-normally distributed data non-parametric 
tests were used: Mann-Whitney and Kruskal-Wallis tests were used to look 
for differences of a continuous variable between two groups (Mann-Whitney) 
or more than two groups (Kruskal-tĂůůŝƐ ? ?^ƉĞĂƌŵĂŶ ?ƐƚĞƐƚǁĂƐƵƐĞĚƚŽůŽŽŬ
for correlation between two continuous variables. 
Area under the receiver operating characteristic (ROC) curve (AUC) was used 
to assess the sensitivity and specificity of the TUG time and look for the 
optimal absolute time (seconds) of the TUG test that is related to self-
reported fallers and non-fallers in the past year.  In all analyses, a p<0.05 was 
considered statistically significant. 
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Chapter 3  
 
The Time Up and Go in 
Patients with COPD 
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3.1 Introduction 
There is increasing evidence in literature relating impaired physical function 
to the burden of chronic obstructive pulmonary disease (COPD) (Pinto-Plata 
et al., 2004, Pitta et al., 2005a, Herman et al., 2011, Peruzza S, 2003).  The 
standard and most commonly used measure of physical performance in 
patients with COPD is the Six-Minute Walk Test (6MWT) (Kario et al., 2001b).  
However, in the real world of clinical practice, the 6MWT takes time to 
perform, needs space (at least 10m and 30 metres recommended), and 
requires a practice walk followed by a resting period (ATS, 2002).  Therefore, 
simple measures of physical performance that require less time and space to 
perform are required and that could be implemented into COPD assessments.   
The Timed-Up and Go (TUG) is a physical performance test that was 
developed by Podsialdo and Richardson, to assess mobility and balance in frail 
elderly (Podsiadlo and Richardson, 1991).  Owing to its simplicity, validity, and 
high reliability, TUG has become widespread in different research areas of 
interest and in different health conditions (van Hedel et al., 2005, Podsiadlo 
and Richardson, 1991, Mesquita et al., 2013, Kristensen et al., 2007, Bischoff 
et al., 2003).  
There are studies investigating TUG in patients with COPD but they were 
limited by either small sample size or not having control comparators.  These 
studies showed that the TUG test was inversely related to general health 
(Janssen et al., 2011), was useful test to detect limitation of physical 
 70 
 
performance in patients with COPD in comparison to healthy controls (Roig et 
al., 2010) and to differentiate between patient fallers and non-fallers 
(Beauchamp et al., 2009).  There were some studies investigating 
performance and balance in patients with COPD using TUG and 6MWT, but 
the relationship between these two tests was not assessed (Butcher et al., 
2004, Beauchamp et al., 2009, Roig et al., 2010).   
Recently, same day test-retest reliability and practice effects of the TUG test 
in patients with advanced COPD, CHF, and chronic renal failure (CRF) was 
explored (Mesquita et al., 2013). Each patient was asked to perform three 
consecutive TUG trials on the same day.  Their results showed good 
correlations between the tests in all subjects as well as in each group defined 
by their medical condition (COPD, CHF or CRF).  High reliability was found 
between the first two TUG trials, and no additional information found from 
the third trial.  Same day inter-observer as well as different day intra-observer 
reliability test of TUG in patients with COPD was not available.  In all of these 
studies, detailed comparison with healthy subjects has not been reported 
(Mesquita et al., 2013, Beauchamp et al., 2009, Menard-Rothe, 1997).  
Exploring the relationship of TUG to the established measure of physical 
performance in COPD  W the 6MWT  W is important.   
Taken together, there is opportunity to further explore the potential role of 
TUG in patients with COPD in relation to controls, explore parameters 
affecting the TUG and assess its validity.  
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3.2 Hypothesis 
- The Time Up and Go (TUG) test is increased in patients with COPD 
compared to age- and gender-matched controls reflecting impaired 
physical performance in patients 
- The TUG test is inversely related to the six minute walking distance 
(6MWD) in patients with COPD 
- The TUG test is a simple test with high inter- and intra-observer 
reliability in patients with COPD 
- The TUG is a useful test to differentiate between fallers and non-
fallers in patients with COPD 
3.3 Methods 
This was a single centre cross-sectional study to investigate the potential 
application of the TUG test in COPD physical performance assessment and 
with a comparator group of controls. 
3.3.1  Study objectives 
To: 
- Compare TUG in patients with COPD and controls 
- Investigate the association of baseline factors 
- Explore  the relationship between TUG and Six-Minute Walk Distance 
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- Investigate ability for TUG to differentiate between fallers and non-
fallers in patients with COPD 
- Investigate practice effect of TUG in patients and controls 
- Assess the relationship of TUG to quality of life questionnaires 
- Assess the relationship of TUG to self-reported physical activity 
- Explore inter- and intra-observer reliability of the TUG test 
3.3.2 Ethics 
The study was approved by the National Research Ethics Service (NRES) 
(Methods, p 51)  
3.3.3 Sample size 
Subjects (n=181) were consented and included in the analysis of this study 
(Methods, P 49). 
3.3.4  Inclusion and exclusion criteria 
Details of inclusion and exclusion criteria are mentioned in the Methods, p 51.  
Subjects were allowed to use walking aids and oxygen supplement as needed.  
In order to have a representative sample of the general COPD group, a wide 
range of patients with different GOLD stages and with/without co-morbidities 
were included. 
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3.3.5 Procedure 
3.3.5.1  Informed consent  
Informed consent was obtained (Methods, p 53). 
3.3.5.2 Timed-Up and Go (TUG) test 
Each subject was instructed to stand up from a regular armed chair (46cm), 
walk for three metres indicated on the floor, turn around, go back to the 
chair, and sit down (Podsiadlo and Richardson, 1991).  Using a regular stop 
ǁĂƚĐŚ ? ƚŝŵĞ ǁĂƐ ƚĂŬĞŶ ƐƚĂƌƚŝŶŐ ĨƌŽŵ ƚŚĞ ǁŽƌĚ  “'Ž ? ĂŶĚ ƐƚŽƉƉĞĚ ǁŚĞŶ ƚŚĞ
subject returned and sat down on the chair like the starting position.  As per 
protocol, two TUG trials were performed at each study visit with opportunity 
to recover in between the two trials.  The time for the first practice TUG was 
only recorded in 141 subjects.  
3.3.5.3 Six-Minute Walk Distance (6MWD) 
After a minimum period of 60 minutes rest post the TUG test, subjects were 
asked to perform the six-minute walk distance (6MWD) (Methods, p 61) 
3.3.5.4  Fall Assessment 
All subjects were asked to report any experience of fall in the past year.  Fall 
ǁĂƐ ĚĞĨŝŶĞĚ ĂƐ  “ǁŚĞŶ ǇŽƵ ĨŝŶĚ ǇŽƵƌƐĞůĨ ƐƵĚĚĞŶůǇ ŽŶ ƚŚĞ ŐƌŽƵŶĚ ? ǁŝƚŚŽƵƚ
intending to get there, after you were in either a lying, sitting or standing 
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ƉŽƐŝƚŝŽŶ ? (Cwikel et al., 1998).  dŚŝƐǁĂƐƌĞĐŽƌĚĞĚĂƐ ? ? ? ? ? ? ? ? ? ? ?A? ?ĨĂůůƐin the 
last year) and for analysis purposes ŐƌŽƵƉĞĚĂƐ ? ? ? ? ? ?A? ?ĨĂůůƐ. 
3.3.5.5 Self-Reported Physical Activity 
Physical activity was classified based on intensity into mild, moderate, and 
vigorous energetic activity.  Each activity level was described in Methods, p 
64.  Subjects were asked to report their activity level (mild, moderate, and 
vigorous), frequency of engaging in each activity level per week (never, 1/3 
ƚŝŵĞ ?ǁŬ ? ? ? ?ƚŝŵĞ ?ǁŬ ?A? ?ƚŝŵĞ ?ǁŬ ?ĂŶĚƚŚĞĂǀĞƌĂŐĞŚŽƵƌƐƚŚ ǇƐƉĞŶĚŝŶƐƵĐŚ
activity per week. 
3.3.5.6 Quality of life and respiratory questionnaires 
^ƚ ? 'ĞŽƌŐĞ ?Ɛ ZĞƐƉŝƌĂƚŽƌǇ YƵĞƐƚŝŽŶŶĂŝƌĞƐ  ?^'ZY ? ĂŶĚ DZĚǇƐƉnoea scale 
were assessed (Methods, p 54).  
3.3.5.7 Inter- and Intra-observer reliability tests 
TUG reliability was assessed using two methods: inter- and intra-observer 
reliability tests.  In the inter-observer reliability, two observers were assigned 
to take measurements of the TUG test at the same time.  The intra-observer 
repeatability test was performed by a single observer taking two TUG 
readings on different days (two to seven days between each test). 
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3.3.5.8 Other baseline variables 
Other variables, body composition (Body Mass Index (BMI), and Fat Free Mass 
Index (FFMI)), oxygen saturation, and spirometry were assessed (Methods, p 
55).  Baseline variables also included smoking history and co-morbidities -  the 
co-morbidity score was calculated for each subject based on the reported 
conditions by assigning one point for each medical condition referred to in 
the Charlson Co-morbidity Index  (Charlson et al., 1987) (Methods, p 65). 
3.3.6 Statistics 
Statistical Package of the Social Science (SPSS) version 21 was used for data 
analysis.  Any difference was considered statistically significant if p-value 
A? ? ? ? ? ? Chi squire test was used for analysis of categorical variables.  
Independent t-test was used for comparison between the two groups where 
data was continuous and normally distributed.  One way ANOVA was used 
when more than two groups and a continuous variable.  Pearson (r) was used 
to assess correlations for continuous variables where normally distributed.  
Inter-class correlation coefficient (ICC) and Bland-Altman plot were used to 
demonstrate the level of agreement between two measurements when 
analysing different day  ‘ŝŶƚƌĂ-ŽďƐĞƌǀĞƌ ? reliability ĂŶĚ ƐĂŵĞ ƚĞƐƚ  ‘ŝŶƚĞƌ-
ŽďƐĞƌǀĞƌ ?ƌĞůŝĂďŝůŝƚǇof the TUG test.  A stepwise linear regression analysis was 
performed to detect factors influencing TUG and fall.  Receiver operating 
characteristic (ROC) curve was used for sensitivity and specificity analysis of 
TUG test and self-reported fall incidence. 
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3.4 Results 
From April 2012 to September 2013, 181 of the 238 subjects who were 
contacted by telephone calls and email messages attended a study visit.  The 
main reasons for those who did not participate are listed in Figure 3.1.  Out of 
the 181, four subjects who attended the clinic study had respiratory 
conditions other than COPD; therefore, study analysis included 177 subjects 
(Figure 3.1). 
Patients and controls were matched for age, gender, and body mass index 
(BMI); however, both groups differed significantly in resting oxygen saturation 
and spirometric parameters (Table 3.1). 
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*Reasons for exclusion: smoking history <10 pack/year, and prior 
participation in the study 
Figure 3.1: Flowchart of Study Recruitment  
Contacted 
n= 238 
Screened 
n= 181 
Patients with 
COPD 
n= 119 
Controls 
n= 58 
Not suitable at phone call 
stage Æ n= 8* 
Not interested Æ n= 43 
Chest infection Æ n= 6 
Suitable 
n= 177 
Excluded because of other 
respiratory conditions Æ n= 4 
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Table 3.1: Demographics of Study Groups - Patients and Controls 
 
Mean (SD) unless otherwise 
indicated 
COPD 
n=119 
Controls 
n=58 
p-value 
Male n (%) 
74 (62) 38 (66) 0.67 
Age (years) 68 (8) 66 (9) 0.15 
BMI (kg/m
2
)  27.3 (6.0) 28.6 (5.2) 0.15 
FFMI (kg/m
2
)  ? Patients n= 114 / 
Controls n=58 
18.4 (3.0) 19.2 (2.4) 0.12 
Smoking history (pack years) 46 (26) 31 (20) <0.001 
Smoking status  ? n (current/ex-
smoker) 
39/80 8/50 <0.01 
FEV1 (L) 1.60 (0.57) 2.80 (0.61) <0.001 
FEV1% predicted 59 (18) 100 (15) <0.001 
FVC (L) 3.25 (0.84) 3.79 (0.89) <0.001 
FVC% predicted 96 (19) 108 (19) <0.001 
FEV1/FVC ratio 49 (13) 74 (7) <0.001 
SpO2 (%) 95 (2) 96 (1) <0.001 
TUG time (seconds) 11.9 (3.7) 9.5 (1.8) <0.001 
6MWD (m)  ? Patients n=117 / 
Controls n=58 
291 (97) 380 (76) <0.001 
Abbreviations: Body mass index (BMI), fat free mass index (FFMI), forced 
expiratory volume in 1 second (FEV1), forced vital capacity (FVC), oxygen 
saturation (SpO2), Timed-Up and Go (TUG), six-minute walk distance (6MWD). 
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3.4.1 Time Up and Go in patients and controls 
Patients had significantly increased mean (SD) TUG time of 11.9 (3.7)s compared 
to controls 9.5 (1.8)s; p<0.001 (Figure 3.2).  The difference remained significant 
when adjusting for age and gender. 
 
 
Figure 3.2: TUG Time in Patients and Controls 
 
 
 
 *significance at p<0.001 
Error bars show ±1 standard deviation 
 
* 
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3.4.2 Potential confounders of Time Up and Go test 
3.4.2.1 3.4.2.1 Age 
Pearson ?Ɛ correlation test did not show any significant association between TUG 
and age in all subjects; r= 0.11, p= 0.16.  ,ŽǁĞǀĞƌ ?ǁŝƚŚŝŶŐƌŽƵƉƐ ?ĂŶĂůǇƐŝƐƐŚŽǁĞĚ
significant association between TUG and age in controls (r= 0.33, p= 0.01) but not 
in patients (r= 0.01, p= 0.89). 
3.4.2.2  Gender 
Independent t-test analysis for the association between TUG and gender in all 
subjects as well as within - patients and controls - showed no significant 
difference; p= 0.74, and p=0.76, and p= 0.12; respectively. 
3.4.2.3 Body composition 
3.4.2.3.1 Body Mass Index 
Analysis showed no significant correlation between TUG and BMI in all 
subjects (r= 0.14, p= 0.06) and controls (r= 0.21, p= 0.12); however, the 
correlation just reached significance in patients; r= 0.19, p= 0.04. 
3.4.2.3.2 Fat Free Mass Index 
WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐŚŽǁĞĚŶŽĂƐƐŽĐŝĂƚŝŽn between TUG and FFMI in all 
subjects, in patients alone, or in controls alone; p=0.30, p= 0.12, and 
p=0.82, respectively.  
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3.4.2.4 Smoking history (pack year) 
The association between TUG and smoking history (pack years) did not reach 
significance; r= 0.15, p= 0.05 in all subjects, nor patients and controls separately; 
r= 0.03, p= 0.72, and r= 0.22, p= 0.09; respectively. 
3.4.2.5 Oxygen saturation (at rest) 
The TUG test was inversely associated with resting oxygen saturation (SpO2) in all 
subjects (r= -0.28, p< 0.001) as well as in patients (r= -0.20, p= 0.03); but not in 
controls (r= -0.10, p= 0.44).  All subjects performed the TUG test on room air.  
Resting SpO2 measurements of all subjects were taken after 20 minutes on room 
air. 
3.4.2.6 Self-reported co-morbidity score 
A co-morbidity score was increased in patients with COPD compared to controls: 
median (IQR): 1 (1-2), and 0 (0-1), respectively; p<0.001.  When not accounting 
for  “COPD ? in the score, both groups were similar in self-reported co-morbidity 
score:  median (IQR) for patients 0 (0-1) and for controls 0 (0-1), p= 0.38. 
Male patients (n= 74) reported significantly more co-morbidities 1 (1-2) 
compared to female patients (n= 45) median (IQR) 1 (1-2), p= 0.03; but no gender 
difference was found in self-reported co-morbidities in controls, p= 0.52.  There 
was no association between age and self-reported co-morbidity score in patients, 
p= 0.11, or controls, p= 0.30.  Correlation of the TUG test to self-reported co-
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morbidity score was significant in patients (r= 0.26, p=0.004), and in controls 
(r=0.28, p=0.031). 
3.4.2.7 Spirometry 
Within group analysis showed no correlation between TUG time and any 
spirometer parameters with exception to FEV1/FVC ratio in the control, but not in 
patients (Table 3.2). 
 
 
Table 3.2: Correlations between TUG and Spirometric Lung Function 
 COPD Controls 
Correlation (r) P-value Correlation (r) P-value 
FEV1 (L) 0.04 0.64 -0.19 0.15 
FEV1% predicted 0.004 0.96 0.26 0.05 
FVC (L) -0.09 0.32 -0.26 0.05 
FVC% predicted -0.05 0.62 0.06 0.64 
FEV1/FVC 0.06 0.55 0.27 0.04 
Abbreviations: Forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC). 
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3.4.2.7.1 Time Up and Go test and GOLD stages of COPD 
According to GOLD classification of COPD, only three patients were classified as 
GOLD IV stage and; therefore, GOLD III and GOLD IV were combined for analysis 
purposes.  The mean time to complete TUG in each GOLD stage of COPD is shown 
in Table 3.3.  One way ANOVA did not show significant difference between TUG 
test and different GOLD stages (GOLD I, GOLD II, and GOLD III/IV combined).  
 
 
 
Table 3.3: Mean TUG test in Different Stages of COPD Based on GOLD 
 
- n TUG time (seconds) 
GOLD I 13 13.0 (3.6) 
GOLD II 68 11.7 (4.0) 
GOLD III/IV 38 12.0 (3.3) 
Abbreviations: Time Up and Go (TUG), Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) 
Results are mean ±SD. 
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3.4.2.8 Regression analysis of the potential factors affecting TUG 
A step-wise linear regression was performed where TUG was the dependent 
variable and the independent variables entered into the model were: age, 
gender, self-reported co-morbidity and resting oxygen saturation; only self-
reported co-morbidity and resting oxygen saturations was found to be a 
significant variable, accounting for 9.3% of the variation between them. 
3.4.3 Six-Minute Walk Distance 
Two out of the 119 patients were not able to perform the 6MWD; therefore, 117 
patients and 58 controls were included in the analysis.  The mean (SD) 6MWD 
was decreased in patients, 291 (97)m, compared to control, 380 (76)m, p<0.001. 
An inverse correlation was found between TUG and 6MWD in all subjects; r= -
0.76, p<0.001 (Figure 3.3a).  Similar associations were found for TUG and 6MWD 
when patients and controls were analysed separately; r= -0.74, p< 0.001, and r= -
0.71, p< 0.001, respectively (Figure 3.3b, c). 
3.4.4 Time Up and Go and BODE in Patients 
Of the 119 patients, two did not complete the 6MWD and, therefore, BODE was 
calculated in 117 patients.  The mean (SD) BODE score was 4 (2).  Correlation 
analysis showed significant association between TUG and the BODE score, r= 
0.53, p<0.001. 
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For the BODE index patients were classified as follows: BODE 0-2 (n=33), BODE 3-
4 (n=28), BODE 5-6 (n=37) and BODE 7-10 (n=19).  One way ANOVA (post HOC, 
Tukey) showed that TUG was significantly associated to the BODE index (Figure 
3.4). 
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Figure 3.3: Inverse Association between TUG and 6MWD 
 
a. All Subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. COPD 
 
 
 
 
 
 
 
 
 
 
 
 
c. Controls 
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Error bars represent ±1 standard deviation 
*Significance at p< 0.05 
**Significance at p< 0.01 
***Significance at p<0.001 
Abbreviation: BODE - Body mass index, airway Obstruction, Dyspnoea and 
Exercise capacity 
Figure 3.4: Association of Time Up and Go to the BODE Index in Patients 
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3.4.5 Physical performance tests and self-reported falls 
3.4.5.1 Physical performance tests associations to fallers and non-fallers 
Fall assessment was missing in eight patients; therefore, 111 patients and 58 
controls were included.  In addition, two other patients did not perform the 
6MWT; thus, 109 patients were included in the 6MWT analysis of this section. 
Patient fallers in the past year (n= 27) took significantly longer time to complete 
the TUG than patient non-fallers (n= 84), p= 0.02 (Table 3.4).  In the control 
group, there was no significant difference between fallers and non-fallers, p= 
 ? ? ? ? ?ŚŽǁĞǀĞƌ ?ƚŚĞƌĞǁĞƌĞĨĞǁƐƵďũĞĐƚƐƌĞƉŽƌƚĞĚA?ŽŶĞĨĂůů ŝŶƚŚĞƉĂƐƚǇĞĂƌ  ?ŶA?
11). 
Similarly, patient fallers in the past year covered significantly less distance in the 
6MWT (233 (95)m) than patient non-fallers (311 (91)m), p< 0.001.  Whereas, the 
6MWT showed no significant difference in the controls group between fallers 
(372 (102)m) and non-fallers (382 (70)m), p= 0.71. 
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Table 3.4: Within Groups Analysis of Fallers and Non-fallers to Physical 
Performance Tests 
 
 
Mean (SD) unless 
otherwise 
indicated 
COPD 
(n=111) 
Controls 
(n=58) 
Fallers 
Non-
Fallers 
P Fallers 
Non-
Fallers 
P 
n 27 84 - 11 47 - 
Age (years) 66 (8) 69 (6) 0.11 65 (6) 66 (9) 0.63 
Male  ? n (%) 16 (59) 53 (63) 0.72 4 (36) 34 (71) 0.02 
TUG (seconds) 
14.5 
(5.2) 
11.0 
(2.7) 
0.02 
10.4 
(2.3) 
9.3 
(1.6) 
0.07 
6MWD (m) 
Patients= 109 
Controls= 58 
233 
(95) 
311 
(91) 
(n=82) 
0.001 
372 
(102) 
382 
(70) 
0.71 
Abbreviations: Six-Minute Walk Distance (6MWD), Time Up and Go (TUG) 
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3.4.5.2 Time Up and Go and fall frequency 
In the 111 patients and 58 controls included in this section, there were more 
ƉĂƚŝĞŶƚƐƌĞƉŽƌƚĞĚA? ?ĨĂůůƐƚŚĂŶĐŽŶƚƌŽůƐ (Table 3.5). 
There was a trend of direct relationship between TUG and fall frequency in 
patients with COPD.  This relationship was not seen in controls, which might be 
because only three subjects reported more than one fall in the past year.  In 
Patients, one way ANOVA (Post Hoc, Tukey) test showed a significant increase of 
TUG tŝŵĞŝŶƚŚŽƐĞǁŚŽƌĞƉŽƌƚĞĚA? ?ĨĂůůƐĐŽŵƉĂƌĞĚƚŽƚŚŽƐĞǁŚŽƌĞƉŽƌƚĞĚŶŽĨĂůů
in the past year, p<0.001. 
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Table 3.5: Self-Reported Fall Frequency in the past year and TUG Test in 
Patients and Controls 
 
Abbreviation: Time Up and Go (TUG) 
Mean (SD) unless 
otherwise indicated 
No fall 1 Fall 2 Falls A? ?&ĂůůƐ 
COPD - n (%) 
TUG (seconds) 
84 (76) 
11.0 (2.7) 
12 (11) 
13.4 (2.9) 
9 (8) 
14.0 (4.7) 
6 (5) 
17.4 (8.6) 
Controls  ? n (%) 
TUG (seconds) 
47 (81) 
9.3 (1.6) 
8 (14) 
10.4 (2.3) 
1 (2) 
13.4 
2 (3) 
8.9 (1.1) 
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3.4.6 Sensitivity and specificity of the Time Up and Go test in patients 
with COPD 
Of the 111 patients ROC curve showed that TUG test was a good predictor of self-
reported falls giving area under the ROC curve (AUC) for TUG time and reported 
falls in the past year of 0.77.  An absolute cut-off time of 12 seconds provided 
74% sensitivity and specificity to detect patients who reported one or more falls 
in the past year.  74% of patient fallers completed the TUG test in A? ? ?ƐĞĐŽŶĚƐ
and 74% of patient non-faller completed the TUG test in <12 second.  Dividing 
patients into two groups based on this cut-off time of 12 seconds showed no age 
or gender differences.  Patients who completed the TUG test in <12 seconds had 
lower values of BMI, MRC dyspnoea score, self-reported co-morbidity score and 
higher resting oxygen saturation and longer 6MWD than patients who completed 
the TUG test ŝŶA? ? ?ƐĞĐŽŶĚƐ ?Table 3.6).  
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Table 3.6: TUG Cut-off Time of 12 seconds and Risk of Falls in Patients with 
COPD 
 
Mean (SD) unless otherwise 
indicated 
Time Up and Go 
<12 seconds A? ? ? seconds P 
n 68 43 - 
Male n (%) 43 (63) 26 (60) 0.772 
Age (years) 68 (6) 68 (8) 0.998 
BMI (kg/m
2
) 25.9 (5.0) 29.1 (6.5) 0.005 
Resting SpO2 (%) 95 (2) 94 (2) 0.002 
MRC dyspnoea scale  ? median (IQR) 2 (2-4) 4 (3-4) 0.011 
Self-reported co-morbidity score -
median (IQR) 
1 (1-2) 2 (1-2) 0.001 
6MWD (m) 346 (64) 208 (80) <0.001 
Abbreviations: Body mass index (BMI), oxygen saturation (SpO2) and Medical 
Research Council (MRC). 
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3.4.7 Time Up and Go practice effect 
A TUG practice was performed in all subjects but the time was recorded in 87 
patients and 54 controls.  There was a correlation between the first and second 
TUG trials in all subjects, in patients and in controls (Figure 3.5 and Table 3.7).  
Patients and controls spent less time to complete the second trial than the first 
trial (Table 3.7).  The mean (SD) difference between the TUG trials (2nd trial  W 1st 
trial) was -0.6 (0.9)s in all subjects and patient group and it was -0.5 (0.8)s in 
controls. 
The difference between TUG trials was not significantly different between 
patients and controls, although marginally greater practice effect was seen in 
patients compared controls (Table 3.7). 
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Figure 3.5: Association of First (Practice) and Second (measured) TUG Trials    
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Table 3.7: First (practice) and Second (measured) TUG Trials 
 
 
Mean (SD) 
First Trial 
(seconds) 
Second Trial 
(seconds) 
Correlation  
1
st
 and 2
nd
 
TUG trials (p-
value) 
Difference 
between the 
TUG trials 
(2
nd
-1
st
) 
(seconds) 
COPD  ? n= 87 12.2 (3.2) 11.6 (3.2) 0.96 (<0.001) -0.6 (0.9) 
Controls  ? n= 54 10.0 (2.1) 9.5 (1.8) 0.93 (<0.001) -0.5 (0.8) 
Total  ? n= 141 11.4 (3.0) 10.8 (2.9) 0.96 (<0.001) -0.6(0.9) 
Abbreviation: Time Up and Go (TUG) 
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Bland-Altman plot was constructed to assess the degree of agreement between 
both TUG trials within 2SD of the mean difference (Figure 3.6). 
The mean difference of both TUG trials (2nd TUG measured trial  W 1st TUG practice 
trial) in all subjects of -0.6s was used to construct the Bland-Altman plot.  The 
majority of subjects fall within 2SD of the difference of TUG trial.  Values falling 
outside the ±2SD limits in the Bland-Altman plot consist of five patients and one 
control, which appeared more disparate at higher TUG. 
 
 Figure 3.6: Bland-Altman Plot Showing the Agreement between the Two TUG 
Trials 
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3.4.8 Time Up and Go test and self-reported dyspnoea/Quality of Life 
3.4.8.1 Medical Research Council dyspnoea scale in patients with COPD 
There was a good distribution of patients along the spectrum of MRC dyspnoea 
scale (Table 3.8).  One way ANOVA (Post Hoc, Tukey) showed statistically 
significant correlation between TUG and MRC dyspnoea scale in patients with 
COPD.  The higher the score in the MRC dyspnoea scale, the longer the time 
required to complete the TUG test (Figure 3.7). 
 
 
 
Table 3.8: Number of Patients with COPD based on MRC Dyspnoea Scale 
 
- MRC 1 MRC 2 MRC 3 MRC 4 MRC 5 
COPD (n) 11 36 24 34 15 
Abbreviation: Medical Research Council (MRC) 
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Figure 3.7: TUG Test and MRC Dyspnoea Scale in Patients with COPD 
 
 
 
Abbreviation: Medical Respiratory Council (MRC)  
Error bars show ±1 standard deviation 
*Significant at p<0.05 
**Significant at p<0.01 
***Significant at p<0.001 
*** 
*** 
* 
* 
** 
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3.4.8.2 ^ƚ ?'ĞŽƌŐĞ ?ƐRespiratory Questionnaire (SGRQ) 
All patients completed the SGRQ with a mean (SD) of the total SGRQ score= 
57(28), activity domain= 41 (20), impact domain= 31 (20), and symptoms 
domain= 45 (21).  Correlation analysis showed significantly positive association 
between TUG and total SGRQ score, and all SGRQ domains (Table 3.9). 
 
 
Table 3.9: TUG Test and SGRQ Score in Patients with COPD 
 
 
Correlation (r) p-value 
SGRQ  ? Total score 0.43 <0.001 
SGRQ  ? Activity 0.49 <0.001 
SGRQ - Symptoms 0.20 0.03 
SGRQ - Impact 0.38 <0.001 
ďďƌĞǀŝĂƚŝŽŶ P^ƚ ?'ĞŽƌŐĞ ?ƐZĞspiratory Questionnaires (SGRQ) 
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3.4.9 Time Up and Go and self-reported physical activity 
The majority of patients and controls reported good engagement in mild and 
moderate activities but not to vigorous activity (Table 3.10).  There were few 
subjects reporting vigorous activity so statistical analysis was not possible and 
was therefore only performed on mild and moderate activities.  There was no 
association between age and self-reported physical activity (including the 
frequency and the amount of time (hrs/wk), and time of reported walk 
(hrs/wk) outside the home during weekdays or weekend) in patients and 
controls; p>0.05. 
3.4.9.1 Mild physical activity in patients and controls 
x Frequency per week  
The majority of patients reported doinŐŵŝůĚĂĐƚŝǀŝƚǇA? ?ƚŝŵĞ ?ǁk and 
only three reported 1-3 times/month or less (Table 3.10).  The 
majority of controls (n=56) reported ĚŽŝŶŐ ŵŝůĚ ĂĐƚŝǀŝƚǇ A? ? ƚŝŵĞƐ ?ǁk 
and only two controls reported a frequency of 1-2 times/wk.  There 
was no significant difference between male and female participants in 
the reported frequency of doing mild activity in patients group (p= 0.7) 
and in controls group (p= 0.6) 
x Duration (hours/week) 
The median (IQR) time of mild activity reported by patients was 8 (4-
18)hrs/wk compared to 14 (6-19)hrs/wk for controls.  Although it was 
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marginally higher in controls, it did not reach significance, p= 0.6.  The 
median (IQR) of self-reported time doing mild activity in males was 7 
(4-14)hrs/wk and in females was 14 (4-21)hrs/wk, p= 0.03.  In controls, 
there was no significant difference in self-reported time doing mild 
activity between males (14 (7-20)hrs/wk) and females (12 (6-
15)hrs/wk), p=0.6.  
x Time Up and Go and self-reported mild activity 
There were few (n= 3) patients who reported a frequency of doing 
mild activity 1-3 times/month or less (not included in this analysis); 
therefore, TUG was compared between subjects who reported a 
frequency of 1-2 times/wŬĂŶĚA? ?ƚŝŵĞƐ ?ǁk.  In patients, independent 
t-test showed that TUG was significantly increased (worse) in those 
who reported a frequency of 1-2 times/wk (TUG time= 14s) compared 
to A? ?ƚŝŵĞƐ ?ǁk (TUG time= 11s), p=0.03. 
There was a significant correlation between TUG and the time 
(hrs/wk) spent doing mild activity in patients, r= -0.21, p<0.01, but not 
in controls, r= -0.06, p= 0.9. 
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Table 3.10: Frequency of Self-Reported Physical Activity in Patients with 
COPD and Controls 
Activity level Frequency 
COPD 
n= 119 
Controls 
n= 58 
Mild activity 
A? ? ?ǁĞĞŬ 96 56 
1-2/week 20 2 
1-3/month 1 0 
Almost never 2 0 
Moderate activity 
A? ? ?ǁĞĞŬ 16 15 
1-2/week 29 22 
1-3/month 21 12 
Almost never 53 9 
Vigorous activity 
A? ? ?week 2 9 
1-2/week 4 2 
1-3/month 6 5 
Almost never 107 42 
Values represent the number of subjects reporting the frequency of doing 
mild, moderate and vigorous activity in each group. 
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oderate activity in patients and controls 
x Frequency per week 
The majŽƌŝƚǇŽĨƉĂƚŝĞŶƚƐ ?ŶA? ? ? ?ƌĞƉŽƌƚĞĚ “ĂůŵŽƐƚŶĞǀĞƌ ?ĨŽƌŵŽĚĞƌĂƚĞ
activity and the majority of controls (n=22) reported doing moderate 
activity 1-2 times/wk.  Patients did moderate activity on less occasions 
compared to controls, p<0.001 (Table 3.11).  There was no significant 
gender differences in patients and in controls when analysing the 
frequency of moderate activity; p= 0.30 and p= 0.06, respectively.   
x Duration (hours/week) 
The median (IQR) time spent on moderate activity was significantly 
less in patients 0(0-2)hrs/wk compared to controls 2(1-4)hrs/wk, 
p<0.001.  The median (IRQ) for self-reported moderate activity was 
1(0-4)hrs/wk in patient males and 0(0-2)hrs/wk in females, p=0.11.  In 
controls, males reported more time doing moderate activity, 4(2-
5)hrs/wk, compared to females, 1(0-2)hrs/wk, p<0.001. 
x Time Up and Go and self-reported moderate activity 
In all subjects, the results showed that TUG time increased as self-
reported moderate activity declined; however, this was not significant, 
r= -0.23, p= 0.9 (Table 3.11).  
There was an inverse association between TUG and reported 
moderate activity duration (hrs/wk) in patients (r= -0.27, p= 0.003), 
but not in controls (r= -0.26, p= 0.5). 
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 Table 3.11: TUG and Self-Reported Moderate Activity 
Median (IQR) 
COPD Controls 
n 
TUG 
(Second) 
n 
TUG 
(seconds) 
A? ?ƚŝŵĞƐ ?ǁĞĞŬ 16 10.2 (2.0) 15 8.6 (1.6) 
1-2 times/week 29 11.0 (2.4) 22 9.7 (1.9) 
1-3 times/month 21 11.8 (3.7) 12 9.6 (1.8) 
Almost never 53 13.0 (3.7) 9 10.5 (1.4) 
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3.4.9.2 Time Up and Go and self-reported weekdays/weekend walking 
x Weekdays walking 
The median (IQR) for the time spent in self-reported walk during each 
weekday in patients was 30(20-60)min/day, and in controls was 60(30-
90)min/day, p= 0.04.  There was no significant difference in the time 
spent walking during each weekday between male patients, 38(20-
90)min/day, and female patients, 30(15-60)min/day, p= 0.11.  
Similarly, in controls there were no gender differences found for the 
reported walking time - males: 60 (15-60)min/day and females: 50(20-
142)min/day, p= 0.72.  With regards to the TUG, there was association 
between TUG and self-reported weekdays walking in patients (r=-0.13, 
p<0.01, but not in controls, r= -0.13, p=0.31.  
x Weekend days walking 
The median (IQR) self-reported walking time in each weekend day in 
patients was 30(10-90)min/day and in controls was 60(30-60)min/day, 
p= 0.22.  There was borderline significant gender differences in self-
reported walking time during each weekend days in patients, males: 
30 (19-98)min/day and females: 30 (5-60)min/day, p= 0.049 but not in 
controls, males: 52(30-60)min/day and females: 60(13-90)min/day, p= 
0.72.  The time to complete the TUG test was significantly association 
with self-reported weekend days walking in patients (r= -0.20, p=0.03) 
but not in controls (r=-0.13, p= 0.34). 
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3.4.10 Time Up and Go intra-observer and Inter-observer reliability 
3.4.10.1 Same  ‘ƚĞƐƚ ?inter-observer reliability 
The mean (SD) difference between measurements obtained by the two 
observers in the same time was 0.4 (0.6)s and the duration to complete the 
test was 12.3 (4.4)s.  Reliability analysis of ICC revealed strong correlation 
between both observers ICC= 0.990, 95% CI: 0.977 - 0.996 (Figure 3.8A).  
Bland-Altman plot showed good agreement of the measurements of both 
observers where the majority of values, except for one subject, fall within 2SD 
of the mean difference (Figure 3.8B). 
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A: Two Observers at the Same Time  
B: Inter-observer Bland-Altman plot  
Figure 3.8: TUG Inter-observer Reliability 
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3.4.10.2 Different day intra-observer repeatability 
Thirteen healthy volunteers completed two TUG tests on different days within 
one week (two to seven days apart) preceded a practice test on each test day 
which was assessed by one observer.  The mean difference of TUG 
measurements between the two days (day 2  W day 1) was -0.4 (0.4)s with time 
of 8.5 (1.3)s indicating better TUG performance on day two.  There was a 
strong correlation between the two TUG tests, ICC = 0.958 with 95%CI: 0.868-
0.987 (Figure 3.9A).  Bland-Altman plot showed good agreement in TUG 
measurements taken on different days where all values fall within 2SD of the 
mean difference (Figure 3.9B). 
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B: Intra-observer (different days) Bland-Altman Plot 
A: Two TUG Trials on Different Days 
Figure 3.9: TUG Intra-Observer Repeatability 
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3.5 Discussion 
We reported that the Time Up and Go test was increased in clinically stable 
patients with COPD in comparison to age- and gender-matched controls and 
was inversely related to 6MWD reflecting impaired physical performance in 
patients with COPD.  The TUG was also increased in patients categorised as 
fallers in the past year compared to non-fallers and was directly associated 
with fall frequency, MRC dyspnoea scale, self-reported co-morbidity score, 
and worse SGRQ score.  On the other hand, in patients TUG was inversely 
related to the time spent in self-reported moderate activity (hrs/wk) and to 
the self-reported walking time (each weekday and each weekend day).  
Finally, TUG was found to have high same day inter- and different days intra-
observer reliability. 
There were two small studies reporting that TUG was increased in patients 
with COPD compared to controls (Butcher et al., 2004, Roig et al., 2010); 
however, the novelty of this current work was including a wide range of 
disease severity of patients with COPD, thus making it a representative 
sample of the general population of patients with COPD in the clinical 
practice.   
Generally, the findings of the earlier mentioned studies investigating TUG in 
patients with COPD and controls support our findings.  Roig et al, 2010 
conducted a relatively small study of patients with COPD (n=21) and controls 
(n=21) free from CV, neurological, and musculoskeletal problems; it was 
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reported that patients with COPD had increased TUG time and lower 6MWD 
compared to controls  W mean (SD) for the TUG test was 9.5 (2.3)s in patients 
and 7.7 (1.1)s in controls (Roig et al., 2010).  Similarly, we reported a two 
second increase of TUG time in patients with COPD compared to controls; 
however, the baseline values of TUG in the two studies vary.  Given Roig et 
al., excluded patients with co-morbid conditions could explain the lower TUG 
time in their study as we showed that co-morbidities were inversely related to 
the TUG test.  Moreover, they included healthy subjects but only those who 
reported no more than light activities in their daily lives, for example, slow 
walking.  This selection of a clinically convenient sample of patients (without 
co-morbidity) and controls (with limited activity) would minimize the actual 
difference between these populations.    
Butcher et al., explored TUG in a small population of patients (n=30) with 
active COPD with and without oxygen supplement during pulmonary 
rehabilitation programme (after a minimum enrolment of three weeks of 
pulmonary rehabilitation prior to the study) in comparison to healthy subjects 
(n=21) who used to exercise regularly (Butcher et al., 2004).  After adjusting 
for age, they reported increased mean (SD) TUG time in patients - 7.2 (0.4)s 
with oxygen supplement and 5.9 (0.4)s without oxygen supplement - 
compared to controls 5.4 (0.3)s.  These values again are lower than those 
demonstrated in our study.  One plausible reason might be because of the 
effect of exercise on performance as cardiopulmonary rehabilitation improves 
TUG in patients with COPD (Beauchamp et al., 2010, Bellet et al., 2013).  In 
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addition, they instructed patients to perform two trials and to walk as quick 
and safe as possible and the fastest attempt was recorded; in comparison, we 
followed the test protocol described by Podsialdo and Richardson, where 
subjects were instructed to walk at a regular pace and performed a practice 
followed by a second recorded trial (Podsiadlo and Richardson, 1991). 
Age has been associated with TUG and normative cut-off time was 
established for specific population, for example community dwelling elderly 
people (Steffen et al., 2002).  Similarly, we presented positive correlation 
between age and TUG in controls, but not in patients with COPD.  Unlike in 
healthy subjects, some studies found that TUG was not associated with age in 
patients with COPD (Khandelwal et al., 2013).  One explanation for this may 
be because of the muscle loss or possibly other factors caused by COPD, 
which in turn overrides physical mobility (Agusti et al., 2002).  There is an 
evidence in literature shows that the accelerated decline in muscle strength in 
healthy subjects  ?ĂŐĞĚA? ? ?ǇĞĂƌƐ ? has negative affect on mobility, suggesting 
that the muscle loss might be the reason of impaired physical performance 
rather than the age (Samson et al., 2000).  Celli et al. argued that the severity 
of COPD should not be driven by age; rather, it should be driven by the 
influential factors associated with COPD such as physical mobility and BMI 
(Celli et al., 2009).  We provided evidence to show positive association 
between TUG and BODE index and BODE score as well as with the 6MWD 
alone. 
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Other factors such as breathlessness, comorbidities, quality of life and oxygen 
saturation were more related to physical performance limitation in patients 
with COPD than age and gender.  Of these factors, breathlessness (measured 
by MRC dyspnoea scale) itself was shown to have the greatest contribution 
for poor quality of life caused by inactivity and to be inversely related to 
physical performance (Reardon et al., 2006).  This adds to the advantages of 
the TUG test in the COPD assessment as we have reported its direct 
association with dyspnoea and quality of life questionnaires.  Similar results 
were published in earlier studies looking at the association of physical 
performance  W using TUG - and balance to quality of life in elderly people 
(Hirano et al., 2013, Ozcan et al., 2005). 
Comorbidities such as CV diseases, hypertension, osteoporosis, diabetes, 
musculoskeletal dysfunction, and psychological disorders have been 
documented to be associated with COPD (Chatila et al., 2008, Sabit et al., 
2007, Sin et al., 2006).  We demonstrated positive association between TUG 
and self-reported co-morbidity suggesting that co-morbidity somehow has a 
negative effect on physical mobility in patients with COPD. 
We reported that TUG was highly related to 6MWD and both were associated 
with poor performance in patients with COPD compared to controls.  In 
patients witŚWĂƌŬŝŶƐŽŶ ?ƐŝƐĞĂƐĞ  ?W ? ?the TUG test was found to have the 
greatest influence on the 6MWT and this was independent of other variables, 
for example gender, balance and instability measures (Earhart, 2009).  The 
studies investigated TUG in patients with hypertension, cardiac rehabilitation, 
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and PD showed moderate correlation with the 6MWD (Pedrosa R, 2009, 
Bellet et al., Earhart, 2009).  Considering this high association between TUG 
and 6MWT, it might be useful to establish a cut-off time for TUG in patients 
with COPD to identify those patients who need further assessment of physical 
performance from those who do not.  Other studies used different cut-off 
time for different populations or different age-group including, but not 
limited to, risk of falls, frail elderly and patients with PD (Shumway-Cook et 
al., 2000, Thomas and Lane, 2005, Nocera et al., 2013, Steffen et al., 2002).  
The cut-off time of 12s used in our study to distinguish between fallers and 
non-fallers, gave a difference of 138m in the 6MWT in patients with COPD; 
which is greater than double the minimal clinically important difference 
(MCID) of the 6MWD in patients with COPD (Cote et al., 2008, Wise and 
Brown, 2005).  Other simple physical performance tests, for example the 
SPPB, have also been reported to be associated with the 6MWD in patients 
with COPD (Eisner et al., 2008); however, the SPPB has ceiling effects that 
limit the test to measure performance in active patients (Curb et al., 2006).  
On the other hand, the TUG test is a continuous, measured in seconds, and 
has no ceiling effect. 
It is important to note that we intended to recruit control comparators with 
smoking history who were free from any respiratory condition, but not from 
other health conditions; therefore, were not considered healthy controls.  
This, in part, could explain the difference of the physical performance we 
presented for our control group compared to the healthy group reported in 
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literature.  For example, the mean (SD) walking distance of our controls was 
380 (76)m, which was below the average walking distance (>500m) found in 
literature for healthy subjects (Casanova et al., 2011, Steffen et al., 2002).  In 
one of these studies, Casanova et al., included healthy subjects who were 
active; with no co-morbid condition that might influence their exercise 
capacity, and who was not on medications that affect the heart rate, and only 
3% of their subjects were smokers (Casanova et al., 2011).  In the other study, 
Steffen et al., excluded smokers, subjects with assistive devices and those 
who feel shortness of breath or leg, neck or back pain while walking (Steffen 
et al., 2002).  Whilst our aim was to include a control group who were 
representative of the general public and free from respiratory conditions only.  
Therefore, we included controls with smoking history  ?A? ? ? ƉĂĐŬ ǇĞĂƌ ?
regardless of their activity level, co-morbid condition (other than malignancy 
and alpha 1 antitrypsin deficiency) and use of medications.  Secondly, unlike 
the previous studies, we used a 10m course for the 6MWD rather than the 
recommended 30m walking course.  This might be another reason for our 
controls to cover less distance compared to the average walking distance 
presented in the previous studies as the 6MWD is positively related to the 
length of the walking course, which might be related to increased number of 
turns on the shorter walking track (ATS, 2002, Singh et al., 2014). 
Recently, increasing number of studies showed that patients with COPD are 
more prone to balance impairment and fall than healthy controls (Butcher et 
al., 2004, Chang et al., 2008, Lawlor et al., 2003).  The American Geriatric 
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Society and British Geriatric Society have listed balance as a risk factor of falls 
(AGS/BGS, 2010).  The U.S Preventative Service Task Force Clinical Guidelines 
recommends the use of TUG as a risk assessment tool in older adults, 
A? ? ?ǇĞĂƌƐ(Moyer, 2012).  Therefore, investigating the risk of falls in patients 
with COPD in comparison to healthy controls became an important area of 
interest in research (Roig et al., 2009).  
Previous work by Beauchamp et al., looked at the association of fall to TUG 
and balance related questionnaires in patients with COPD (Beauchamp et al., 
2009).  The authors used a cut-off time of 16s or more to discriminate 
ƉĂƚŝĞŶƚƐ ? fallers from non-fallers.  They showed that TUG was a useful 
ŵĞĂƐƵƌĞƚŽĚŝƐĐƌŝŵŝŶĂƚĞďĞƚǁĞĞŶƉĂƚŝĞŶƚƐ ?ĨĂůůĞƌƐĨƌŽŵŶŽŶ-fallers and a cut-
off time of 16s could identify 50% of the total number of fallers.  Although our 
results were consistent with those presented in Beauchamp et al., study 
regarding the relationship between TUG and falls, the absolute time to 
ĐŽŵƉůĞƚĞ ƚŚĞ dh' ƚĞƐƚ ĨŽƌƉĂƚŝĞŶƚƐ ? ĨĂůůĞƌƐĂŶĚŶŽŶ-fallers was lower in our 
study and using a cut-off time of 12s could identify 74% of the total number 
of fallers and non-fallers in patients with COPD, respectively.  The difference 
ŝŶ ƚŚĞ dh' ƌĞƐƵůƚƐ ŝƐ ĞǆƉĞĐƚĞĚ ďĞĐĂƵƐĞ ŽĨ ƚŚĞ ĚŝĨĨĞƌĞŶĐĞ ŝŶ ƉĂƚŝĞŶƚƐ ?
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ďĞƚǁĞĞŶ ƚŚĞ ƚǁŽ ƐƚƵĚŝĞƐ ?  /Ŷ ĐŽŵƉĂƌŝƐŽŶ ƚŽ ŽƵƌ ƉĂƚŝĞŶƚƐ ?
group, patients in Beauchamp et al., study were in more severe stage of COPD 
(FEV1% predicted = 42%), relatively older, and 46% were on oxygen 
supplement.  Perhaps the severity of the disease and age, as mentioned 
 118 
 
earlier, might not have an effect on TUG in patients with COPD; however, we 
demonstrated that oxygen saturation was inversely related to TUG. 
Recently, a large cross-sectional study of 16 National Foundation Centers of 
Excellence where over 2000 patients with PD were included to investigate the 
ability of the TUG test to identify fallers and non-fallers (Nocera et al., 2013).  
The researchers showed that TUG was able to detect accurately 70% of the 
patient fallers and non-fallers and a one second increase in TUG was 
associated with 5.4% increase in the risk of falls.  Currently, health care 
professionals rely on subjective methods for the assessment of falls; TUG as 
an objective to distinguish fallers from non-fallers was shown to be useful 
especially when space and time are limited.  These findings encourage further 
research to investigate a potential predictive ability of the TUG test to identify 
future risk of falls in patients with COPD. 
Physical activity was reduced in the patient group compared to the controls 
group of the present study.  This was expected as inactivity is one of the main 
characteristics of COPD patients (Troosters et al., 2010b, Pitta et al., 2005b).  
Few patients reported doing vigorous activity; therefore, analysis included the 
association of TUG to self-reported mild and moderate activity only.  TUG 
confirmed the association of physical performance to self-reported physical 
activity in patients with COPD.  Although there was a weak (borderline) 
association found between TUG and self-reported mild activity (hrs/wk), TUG 
was strongly associated to self-reported moderate activity (hrs/wk), self-
reported walking time.  The associated between physical performance and 
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physical activity is expected as it has been shown in previous literature using 
different functional tests in patients with COPD (Pitta et al., 2005b, DePew et 
al., 2013, Garcia-Aymerich et al., 2009).  This is consistent with previous 
findings of inverse correlation between TUG and physical energy 
expenditure/week in community-dwelling elderly people (Ewing et al., 2010).  
Previous literature showed high reliability of TUG ranging from ICC 0.85 to 
0.99  in the older people with and without co-morbid conditions (Bellet et al., 
van Hedel et al., 2005, Steffen et al., 2002, Mesquita et al., Podsiadlo and 
Richardson, 1991, Roig et al., 2010).  In COPD studies, Roig et al., and a 
recently published study by Mesquita et al., showed high same-day test-retest 
reliability of the TUG test using same assessors.  We reported similar TUG 
results in our patients with COPD to that published by Mesquita et al., 
however they had a more severe COPD population (Mesquita et al.).  It is 
imperative to note that the present study showed that TUG was not related 
to the severity of the disease.  Further, the majority of our controls (n=38) 
completed thĞ dh' ƚĞƐƚ ŝŶ A? ? ? ƐĞĐŽŶĚƐ ?  dŚĞƌĞĨŽƌĞ ? ŽƵƌ ŵĞĂŶ dh' ƚŝŵĞ ŽĨ
ĐŽŶƚƌŽůƐ ǁĂƐ ƐŝŵŝůĂƌ ƚŽ ƚŚĞ ŶŽƌŵĂů ǀĂůƵĞƐ  ?A? ? ? ƐĞĐŽŶĚƐ ? ŽĨ healthy elderly 
people that was reported by Podsialdo and Richardson, and by a meta-
analysis of 21 studies of healthy subjects <80 years old (Podsiadlo and 
Richardson, 1991, Bohannon, 2006).  Our study showed that the reliability of 
the TUG test remains high even when using two assessors and when using 
one assessor on different days. 
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3.5.1 Limitation 
The study was a cross-sectional study, which made findings limited to 
correlations amongst variables, and not the cause and effect.  Although the 
study was designed to include a wide range of disease severity of patients 
with COPD, few patients with GOLD stage IV were recruited.  Furthermore, 
using a 10m track for the 6MWD reduced the actual walking distance of our 
subjects, however it must be noted that establishing normal values of the 
6MWD was not the aim of our study.  The results of the 6MWD were 
collected to investigate the potential use of another test that requires shorter 
time and smaller space - TUG - in patients with COPD.  In the analysis of 
physical activity, there were few patients who reported vigorous activity, 
which made it difficult to compare this group with healthy volunteers with 
vigorous activity.  Further, physical activity was obtained using a subjective 
approach and the scope of this approach is limited to recall bias.  
Furthermore, the design of our study did not allow precise use of Charlson Co-
morbidity Index as some of the diseases in the index were exclusion criteria in 
this study.  Finally, data was collected retrospectively; therefore, the ability of 
the TUG test to predict future falls in patients with COPD still needs to be 
investigated in a prospective study.  
3.5.2 Conclusion 
The TUG test is a simple and reliable test used to detect physical mobility and 
risk of falls in patients with COPD.  Owing to the multiple components of the 
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TUG, it is a multi-physical performance as opposed to pure exercise test.  TUG 
is a continuous test where performance is measured over time and, 
therefore; it is not limited by a ceiling effect.  There was good correlation 
between TUG and 6MWT, with the advantage of TUG of being simple, 
tolerated, and consumed less time and space.  A cut-off time of 12s in the 
TUG test was a useful measure to detect self-reported falls in the past year 
and gave a difference of more than double the minimal clinical important 
difference of the 6MWD (138m) in patients with COPD.  This study does not 
suggest TUG as a replacement for 6MWT; rather, it has potential to be used 
as an initial evaluation of physical performance especially where time and 
space are of concerns. 
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4.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is strongly associated to 
cardiovascular (CV) morbidity and exercise limitation (Mannino et al., 2008, 
Agusti et al., 2003).  The rate of decline in physical performance in patients 
with COPD increases as the severity of disease progresses (Casanova et al., 
2007).  Some studies have investigated the relationship between 
haemodynamic measures and exercise intervention in patients with COPD 
(Vivodtzev et al., 2010, Gale et al., 2011); however, association of the same 
haemodynamic measures to physical performance, the nature of this 
relationship and the factors influencing this association still needs to be 
explored in patients with COPD. 
Arterial stiffness is a non-invasive haemodynamic measure which 
independently predicts CV events and it can be used to stratify high risk 
patients in general population (Boutouyrie et al., 2002, Ben-Shlomo et al., 
2014). The gold-standard method of measuring arterial stiffness is the 
carotid-femoral (aortic) pulse wave velocity (aPWV) (Laurent et al., 2006) and 
it has been shown to be increased in patients with COPD (Sabit et al., 2007, 
Maclay et al., 2009).  However, impaired physical performance in patients 
with COPD in relation to aPWV was not investigated in these studies. 
In healthy subjects, a large longitudinal study investigating the relationship of 
arterial stiffness to age and both subjective and objective measures of 
physical performance by following more than 5000 healthy subjects for more 
 124 
 
than 20 years, Bunner et al. showed that physical performance was inversly 
related to arterial stiffness; however, the mechanism of this association was 
not determined (Brunner et al., 2011).  Ageing, in healthy subjects (20-90 
years), is directly related to arterial stiffness; however, regular exercise can 
slow down the progression of arterial stiffness as we age (Vaitkevicius et al., 
1993).  Watson et al. reported that in older adults the association of arterial 
stiffness to physical performance was evidenced in people with pre-existing 
CV problems and peipheral arterial disease, but was not demonestrated in 
healthy subjects (Watson et al., 2011). 
Indeed, it is important to further investigate the relationships between 
arterial stiffness and physical performance in patients with COPD especially 
when impaired physical performance and additionally inactivity are 
commonly found in this group of patients (Pitta et al., 2005a, Pinto-Plata et 
al., 2004).   
In a small interventional study of patients with COPD (n=17) Vivodtezev et al. 
explored the association of exercise intervention to arterial stiffness where 
seven patients underwent four weeks exersice training and compared to the 
other 10 untrained patients (Vivodtzev et al., 2010).  The authors showed a 
10% improvement of aPWV as a result of a reduction in systolic BP in the 
trained group, and this improvement was proportional to their improvement 
in the exercise tests performance.  This was similarly shown in post-
rehabilitation improvement in aPWV in patients with COPD that was 
attributed to changes in blood pressure (Gale et al., 2011).  These studies 
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showed an indirect improvement of arterial stiffness post exercise 
intervention. 
This chapter aims to explore the relationship of aortic stiffness to physical 
performance in a large group of patients with COPD and controls. It will also 
consider aortic stiffness in relation to composite scores that include 
performance and self-reported co-morbidities. 
4.2 Hypothesis 
 Impaired physical performance, as measured by TUG and/or 6MWT is a 
significant determinant of the increased aortic stiffness in patients with COPD, 
independent of age, gender and lung function  
4.3 Methods 
This was a cross-sectional study inviting patients with COPD and controls for a 
single clinical visit at the Respiratory Clinical Trial Unit, City Hospital, 
Nottingham. 
4.3.1 Study objective 
- Explore the relationship of physical performance and aortic stiffness in 
patients with COPD compared to controls 
- Determining potential baseline factors affecting the relationship of 
aortic stiffness to physical performance 
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- Explore associations between aPWV and composite measures of COPD 
severity and self-reported co-morbidities  
4.3.2 Ethics 
The study was approved by the National Research Ethics Service (NRES) 
(Methods, p 51). 
4.3.3 Sample size 
Study sample size was based on the TUG calculation which included 181 
subjects (Methods, p 49). 
4.3.4 Inclusion and exclusion criteria 
The inclusion and exclusion criteria were mentioned earlier in Chapter 2 
(Methods, p 51).  Subjects were excluded from analysis if measurements of 
aPWV were <4.7m/s. 
4.3.5 Procedure 
4.3.5.1 Informed consent 
Informed written consent was obtained in all subjects (Methods, p 53). 
4.3.5.2 Haemodynamics 
- Aortic stiffness 
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The Vicorder was used to measure arterial stiffness while subjects were in a 
supine position (Laurent et al., 2006), see Methods, p 57.  An aPWV >10m/s 
cut-off was used to identify those who were at higher risk of cardiovascular 
events (Mancia et al., 2013, Van Bortel et al., 2012).   
- Perpheral Blood Pressure 
Peripheral blood pressure (BP) was measured using Omron (705IT, UK) while 
subjects were seated (Methods, p 56).  Mean arterial pressure (MAP) and 
pulse pressure (PP) were calculated (Methods, p 56). 
- Central Blood pressure 
Central BP was performed using the Vicorder (Skidmore Medical, UK) while 
subjected were seated (Methods, p 56). 
4.3.5.3 Time Up and Go (TUG) 
The TUG was performed following a practice trial, (Podsiadlo and Richardson, 
1991) (Methods, p 61). 
4.3.5.4 Six-Minute Walk Test  
The Six-Minute Walk Test (6MWT) was performed at the end of each visit 
after subjects rested for at least 60min prior to the test in order to assess the 
distance (6MWD)  (Methods, p 61).  
A cut-off of 350m in the 6MWD was used in the analysis (Casanova et al., 
2008, Torres et al., 2011).   
 128 
 
4.3.5.5 MRC Dyspnoea Scale 
All subjects completed the validated Medical Research Council (MRC) 
dysnpoea scale (Fletcher, 1960) (Methods, p 54). 
4.3.5.6 Self-reported co-morbidity score 
To assess measure self-reported co-morbidites, co-morbidity score was 
calculated for each subject based on the reported conditions by assigning one 
point for each medical condition referred to in the Charlson Co-morbidity 
Index  (Charlson et al., 1987) (Methods, p 65). 
4.3.5.7 Body composition 
Height and weight were measure using Seca Scales (Hamburg, Germany).  
From this BMI was calculated.  The fat free mass (FFM) was recorded using 
Tanita  scale (Illinois, USA) and from this, the height squared index: FFMI was 
calculated (Methods, p 55). 
4.3.5.8 Oxygen saturation at rest  
Resting oxygen saturation (SpO2) using Konica Minota Pulsox-300 (Tokyo, 
Japan) for each subject was measured (Methods, p 63). 
4.3.5.9 Spirometric measurements 
Post-bronchodilator spirometric measurements of lung function were 
obtained using micro-medical spirometer (MicroLab MK6).  The severity of 
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airflow obstruction was used to classify patients into different Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) stages following the GOLD and 
the 2010 updated NICE classification of the COPD severity (Global Initiative for 
Chronic Obstructive Lung Disease GOLD, 2011, NICE, 2010) (Methods, p 58). 
4.3.5.10 Composite COPD severity measures - BODE and ADO indices 
Both indices were assessed in patients with COPD only: 
- BODE index: BMI, airway Obstruction, Dyspnoea and Exercise capacity  
The BODE Index was calculated using scoring system which includes the four 
domains of BMI, FEV1, MRC dyspnoea scale and the 6MWD (Celli et al., 2004) 
(Appendix 11). 
- ADO index: Age, Dyspnoea and airway Obstruction  
The ADO index was calculated using the scoring table of each of its 
component: age, dyspnoea and airway obstruction (Puhan et al., 2009) 
(Appendix 12). 
4.3.6 Statistics 
Statistical Package of the Social Science (SPSS) version 21 was used for data 
analysis.  Independent t-test was used for comparison between the two 
groups where data was continuous and normally distributed.  Mann-Whitney 
test was used for statistical difference in non-normally distributed variable.  
Chi-squire test was used when analysing two categorical data.  One way 
ANOVA was used to look for significant differences between more than two 
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groups.  Pearson (r) was used to assess correlations for continuous variables 
where ŶŽƌŵĂůůǇ ĚŝƐƚƌŝďƵƚĞĚ ?  ^ƉĞĂƌŵĂŶ ?Ɛ ƚĞƐƚ ǁĂƐ ƉĞƌĨŽƌŵĞĚƚŽ ĂƐƐĞƐƐ
correlation of non-parametric distributed variable.  Stepwise linear regression 
analysis was performed to detect independent association of physical 
performance tests to aPWV.  A p-value of <0.05 was considered significant. 
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4.4 Results 
A total number of 181 subjects attended a study visit between April 2013 and 
September 2014.  Four out of the 181 subjects had respiratory conditions 
other than COPD giving 119 COPD and 58 controls.  Five patients were 
excluded because they had low aPWV (<4.7m/s).  Therefore, analysis was 
performed on 114 patients and 58 controls (Figure 4.1).  There were two 
patients did not complete the 6MWT, therefore, 112 patients were included 
in the analysis of the 6MWT and the BODE index. Body composition 
assessment were missing in four of the 114 patients because of machine 
technical issues; therefore, measurements of FFMI were obtained from 110 
patients.  
Patients with COPD and controls were matched for age and gender and also 
had similar BMI and FFMI (Table 4.1).  The mean (SD) aPWV was significantly 
higher in patients 10.0 (2.1)m/s than controls 9.2 (1.8)m/s, p=0.01.  As 
anticipated, patients had significantly lower spirometric and oxygen 
saturation measurements than controls.  Further, smoking pack years was 
greater in patients than controls, p <0.001.  Patients had significantly greater 
score in self-reported comorbidities compared to controls, p< 0.001 (Table 
4.1).  However, when analysing co-morbidity score without accounting for the 
COPD (co-morbidities - 1 in patients with COPD), patients and controls were 
not statistically different, p= 0.43.  Patients reported significantly more CV 
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morbidity than controls, p=0.03, but both were similar in self-reported 
diabetes mellitus, p=0.19 (Table 4.2). 
There was a significant difference between patients and controls in total 
cholestrol level, p= 0.04; but not in other serum concentration of high density 
lipoproteins (HDL), low density lipoproteins (LDL) and triglycerides, p >0.5 
(Table 4.2).   
There was no statistically significant difference in peripheral and central 
haemodynamic measurements between patients and controls, all p>0.05 
(Table 4.3). 
According to the severity of COPD, patients were divided into GOLD I (n=11), 
GOLD II (n=65), GOLD III (n=35) and GOLD IV (n=3).  For analysis patients were 
divided into two groups:  GOLD I and II and GOLD III and IV.  Both groups were 
similar in age (p= 0.61) and gender (p= 0.50) but differed significantly in BMI 
(GOLD I&II: 34.4 (5.2)kg/m2 and GOLD III&IV: 29.0 (5.8)kg/m2, p< 0.001).  The 
aPWV in GOLD I&II group was 9.9 (2.0)m/s and GOLD III&IV group was 10.4 
(2.2)m/s, p= 0.23. 
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Figure 4.1: Recruitment Flowchart 
Controls analysed 
n=58 
Other respiratory 
conditions 
n=4 
Suitable Subjects  
n=177 
Subjects recruited 
n=181 
COPD analysed 
n=114 
COPD 
n=119 
aPWV 
<4.7m/s 
n=5 
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Table 4.1: Demographics of Study Groups 
Mean (SD) unless otherwise 
indicated 
COPD Controls p-value 
n 114 58  
Male n (%) 71 (62) 38 (66) 0.68 
Age (years) 68 (8) 66 (9) 0.15 
BMI (kg/m
2
)  27.5 (6.0) 28.6 (5.2) 0.21 
FFMI (kg/m
2
) - 
patients n= 110, controls n = 
58 
18.5 (3.0) 19.2 (2.4) 0.17 
Smoking status  ? (current / 
ex-smokers) 
39 / 80 8 / 50 0.007 
Smoking history (pack year) 46 (26) 31 (20) <0.001 
FEV1 (L) 1.60 (0.57) 2.80 (0.61) <0.001 
FEV1% predicted 59 (18) 100 (15) <0.001 
FVC (L) 3.22 (0.84) 3.79 (0.89) <0.001 
FVC% predicted 95 (18) 108 (19) <0.001 
FEV1/FVC ratio 49 (13) 74 (7) <0.001 
Co-morbidities  ? median 
(IQR) 
1 (1-2) 0 (0-1) <0.001 
Resting SpO2 (%) 95 (2) 96 (1) <0.001 
TUG time (seconds) 12.0 (3.7) 9.5 (1.8) <0.001 
6MWD (m)  ?  
patients n =112, controls 
n=58 
287 (97) 380 (76) <0.001 
Abbreviations: Body mass index (BMI), fat free mass index (FFMI), forced 
expiratory volume in 1 second (FEV1), forced vital capacity (FVC), oxygen 
saturation (SpO2), Time Up and Go (TUG), Six-Minute Walk Distance (6MWD). 
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Table 4.2: Self-Reported Conditions, Medications, and Lipid Profile 
Abbreviations: High density lipoproteins (HDL), low density lipoproteins (LDL). 
*Self-reported cardiovascular problems include: myocardial infarction, heart 
failure, arrhythmia, angina, bypass surgery and pacemaker. 
Mean (SD) unless otherwise indicated 
COPD 
n=114 
Controls 
n=58 
p-value 
Self reported Cardiovascular disease n(%)* 30 (26) 7 (12) 0.03 
Self reported diabetes mellitus n(%) 18 (16) 5 (9) 0.19 
Cardiovascular 
Medications 
Angiotensin-converting-
enzyme inhibitor n(%) 
26 (23) 9 (16) 0.26 
Angiotensin receptor 
blockers n(%) 
5 (4) 3 (5) 0.82 
Beta blockers n(%) 11 (10) 9 (16) 0.26 
Statin n(%) 44 (39) 14 (24) 0.06 
Total Cholesterol (mmol/L)  5.1 (1.3) 5.5 (1.0) 0.04 
Triglycerides (mmol/L) 1.5 (0.8) 1.6 (0.8) 0.63 
HDL Cholesterol (mmol/L) 1.6 (0.5) 1.7 (0.4) 0.38 
LDL Cholesterol (mmol/L) 2.7 (1.1) 3.1 (1.0) 0.07 
Cholesterol:HDL ratio 3.3 (1.0) 3.4 (0.9) 0.37 
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Table 4.3: Peripheral and Central Haemodynamics 
 Abbreviations: Aortic pulse wave velocity (aPWV), blood pressure (BP) 
 
Mean (SD) COPD Controls p-value 
Peripheral systolic BP (mm Hg) 147 (23) 144 (15) 0.27 
Peripheral diastolic BP (mm Hg) 84 (12) 83 (10) 0.56 
Peripheral mean arterial pressure 
(mm Hg) 
105 (14) 103 (10) 0.34 
Peripheral pulse pressure (mm Hg) 63 (17) 61 (13) 0.42 
aPWV (m/s) 10.0 (2.1) 9.2 (1.8) 0.01 
Central systolic BP (mm Hg) 143 (23) 141 (14) 0.31 
Central diastolic BP (mm Hg) 84 (12) 83 (10) 0.54 
Central mean arterial pressure (mm 
Hg) 
110 (15) 109 (11) 0.41 
Central pulse pressure (mm Hg) 59 (17) 57 (13) 0.50 
Heart rate (beat/min) 74 (14) 70 (14) 0.09 
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4.4.1 Aortic PWV association to baseline variables: 
- Age, gender, BMI and FFMI 
Age was significantly associated to aPWV in patients (r= 0.47, p<0.001), 
controls (r= 0.45, p<0.001).  The mean (SD) aPWV was greater in male 
patients 10.6 (2.0)m/s compared to female patients 9.1 (1.9)m/s, p<0.001; 
but no difference found between gender in controls, p= 0.17.  There was no 
significant association of aPWV to either BMI or FFMI in patients or controls, 
p>0.05. 
- Spirometric measurements, smoking history, oxygen saturation and 
MRC dyspnoea scale 
In patients aPWV was inversely correlated with forced expiratory volume in 
one second (FEV1)/forced vital capacity (FVC) ratio; r= -0.20, p=0.04, but not 
in controls and not with other spirometric  parameters (Table 4.4).  There 
were no significant associations of aPWV to smoking pack years or to resting 
oxygen saturation in patients or control, p>0.05  In patients, there was no 
association between aPWV and MRC dyspnoea score, p= 0.51. 
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Table 4.4: Arterial Stiffness and Lung Function Correlations 
 
Abbreviations: Aortic pulse wave velocity (aPWV), forced expiratory volume 
in one second (FEV1), forced vital capacity (FVC). 
Pearson correlation   
(p-value) 
aPWV (m/s) 
COPD Controls 
FEV1 (L) -0.08 (0.42) -0.11 (0.43) 
FEV1 (%) predicted -0.09 (0.35) -0.09 (0.49) 
FVC (L) 0.14 (0.14) -0.06 (0.67) 
FVC (%) Predicted 0.05 (0.62) -0.15 (0.28) 
FEV1/FVC ratio -0.20 (0.04) -0.01 (0.97) 
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Peripheral (sitting) haemodynamic measurements 
The association of aPWV to heart rate was significant in patients: r=0.20, p= 
0.03, but not in controls: r= 0.14, p= 0.29. 
In patients, there was a significant association of aPWV to pulse pressure (PP) 
(r=0.26, p<0.01) and to mean arterial pressure (MAP) (r=0.41, p<0.001).  As 
expected, aPWV was associated to systolic BP (r=0.38) and diastolic BP 
(r=0.38), all with p<0.001. 
In controls, aPWV was significantly associated to PP (r=0.28, p=0.04), but not 
to MAP (r=0.19, p=0.16).  Again, aPWV was significantly associated to systolic 
BP (r=0.30, p=0.02), but not to diastolic BP (r=0.06, p=0.65). 
- Central (sitting) haemodynamic measurements 
In patients, there was a significant association of aPWV to PP (r=0.22, p=0.02) 
and to MAP (r=0.41, p<0.001).  Similar to peripheral measurements, aPWV 
was signification associated to systolic BP (r=0.36) and diastolic BP (r=0.37), all 
with p<0.001. 
In controls, aPWV was not significantly associated to PP (r=0.23, p=0.09) or to 
MAP (r=0.12, p=0.37).  There was no association of aPWV to either systolic BP 
(r=0.23, p=0.08) or to diastolic BP (r=0.04, p=0.78). 
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- Self-reported medical conditions, co-morbidity score and self-
reported medications  
The aPWV for patients with and without self-reported CV problems was not 
significant (10.1 (2.7)m/s and 10.0 (1.8)m/s, respectively, p=0.93).  Similarly, 
aPWV for patients with and without self-reported diabetes mellitus was not 
significantly different (10.8 (2.5)m/s and 9.9 (2.0)m/s, respectively, p= 0.11).   
There was no difference in aPWV between controls with and without self-
reported CV problems (9.4 (1.4)m/s and 9.2 (1.8)m/s, respectively, p=0.80.  
Again, aPWV was not significantly different in controls with and without self-
reported diabetes mellitus (9.8(2.6)m/s and 9.2 (1.7)m/s, resprectively, 
p=0.44.   
^ƉĞĂƌŵĂŶ ?Ɛ ƚĞƐƚ showed no correlation between aPWV and self-reported 
comorbidity score in patients (r= 0.14, p= 0.14) or in controls (r= 0.04, 
p=0.77). 
4.4.2 Aortic PWV and physical performance tests 
As reported in previous literature, patients covered less distance in the 6MWT 
and took longer time in TUG test than controls, p< 0.001 (Table 4.1).  In all 
subjects, there was an inverse relationship between aPWV and 6MWD, r= -
0.19, p= 0.01.  Correlation of aPWV to 6MWD was not found in patients alone 
(r= -0.09, p= 0.34) or controls alone (r= -0.22, p= 0.10), (Figure 4.2).  There 
was no association between aPWV and TUG in all subjects (r= 0.08, p= 0.27), 
in patients (r= -0.01, p= 0.93) or in controls (r= 0.16, p= 0.22).   A stepwise 
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linear regression analysis was performed where aPWV was the dependent 
variable and age, gender, MAP and 6MWD or TUG were the independent 
variables, only age and MAP were independent predictors of aPWV, 27% 
change attributed to age and 8% attributed to MAP.     
4.4.2.1 Aortic PWV cut-off point of 10m/s 
Dividing subjects according to aPWV cut-off point of 10m/s showed no 
significant difference in the number of patients (n=47 (41%)) and controls (n= 
17 (29%)) who had aPWV> 10m/s, p=0.13.   
There was no significant difference in the 6MWD based on aPWV cut-off point 
ŽĨ  ? ?ŵ ?Ɛ PƉĂƚŝĞŶƚƐǁŝƚŚĂWtsA? ? ?ŵ ?ƐĐŽǀĞƌĞĚĂĚŝƐƚĂŶĐĞŽĨ  ? ? ?  ? ? ? ?ŵĂŶĚ
patients with aPWV >10m/s covered a distance of 287 (98)m, p= 0.94, 
remaining insignificant after adjustment for age, gender and MAP.  Controls 
ǁŝƚŚĂWtsA? ? ?ŵ ?ƐĐŽǀĞƌĞĚĂĚŝƐƚĂŶĐĞŽĨ ? ? ? ? ? ? ?ŵĂŶĚĐŽŶƚƌŽůƐǁŝƚŚĂWts
>10m/s covered a distance of 358 (96)m, p= 0.17.   
Similarly, the aPWV cut-off point of 10m/s did not show a significant 
difference in completing the TUG test in either patients or controls: Patients 
(n=47) with aPWV>10m/s completed the TUG test in 11.8 (3.4)s; whilst, 
ƉĂƚŝĞŶƚƐ  ?ŶA? ? ? ? ǁŝƚŚ ĂWtsA? ? ?ŵ ?Ɛ ĐŽŵƉůĞƚĞĚthe TUG test in 12.2(4)s, 
p=0.61.  Similarly, controls (n=17) with aPWV>10m/s completed the TUG test 
in 10.2 (2.2)s; whilst, controls (n=41 ?ǁŝƚŚĂWtsA? ? ?ŵ ?ƐĐŽŵƉůĞƚĞĚƚŚĞdh'
test in 9.2 (1.5)s, p=0.07. 
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4.4.2.2 
Solid line shows and inverse relationship between aPWV and 6MWD in all subjects 
Figure 4.2: Aortic Stiffness and Six-Minute Walk Distance in Patients and Controls 
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4.4.2.2 Aortic stiffness according to 6MWD of more or less than 
350m 
According to 6MWD cut-off distance of 350m there were 33 patients and 42 
controls who covered >350m and 79 patients and 16 controls who covered 
A? ? ? ?ŵ  ?Figure 4.3).  The aPWV of patients who covered >350m was 9.4 
(1.5)m/s compared to 1 ? ? ?  ? ? ? ? ?ŵ ?Ɛ ŝŶ ƚŚŽƐĞ ǁŚŽ ĐŽǀĞƌĞĚ A? ? ? ?ŵ ? ƉA?  ? ? ? ? ?
and remained significant when adjusted for age, gender and MAP.  In 
controls, those who covered >350m had aPWV of 9.0 (1.7)m/s compared to 
 ? ? ?  ? ? ? ? ?ŵ ?Ɛ ĨŽƌ ƚŚŽƐĞ ǁŚŽ ĐŽǀĞƌĞĚ  A? ? ? ?ŵ ŝŶ ƚŚĞ  ?Dt ? ƉA?  ? ? ? ? ?
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Figure 4.3: Aortic Stiffness according to 6MWD group in Patients and Controls  
Error bars represent ± 1 standard deviation 
P= 0.02 
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4.4.3 Aortic PWV and BODE index in patients 
The median (IQR) for the BODE in patients was 4 (2-6).  There was no 
significant associated between aPWV and BODE, p= 0.67.  Similarly, one way 
ANOVA (post Hoc) test showed no significant association between aPWV and 
BODE categories  (Table 4.5). 
 
Table 4.5: Aortic PWV and BODE Index in Patients 
Mean (SD) n aPWV (m/s)  
BODE Index 
classification 
0-2 31 9.8 (1.9) 
3-4 27 10.2 (2.5) 
5-6 35 10.3 (1.7) 
7-10 19 9.7 (2.4) 
Abbreviations: Aortic pulse wave velocty (aPWV), BMI, airway obstruction, 
dyspnoea, exercise capacity (BODE). 
 
4.4.3 Aortic PWV and ADO index 
The median (IQR) score in patients was 4 (4-5).  There was a significant 
association between aPWV and ADO index (r= 0.27, p=0.004) 
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4.5 Discussion 
This study showed that aortic stiffness was increased in patients with COPD 
compared to age- and gender matched controls; whilst, it was inversely 
associated to physical performance measures in all subjects, it was not in 
patients with COPD alone.  However, the 6MWD of 350m could significantly 
distinguish between patients with normal and increased arterial stiffness.  
Finally, we showed that arterial stiffness was positively related to age and 
ADO index, but not the BODE index. 
Arterial stiffness has been repeatedly shown to be increased in patients with 
COPD compared to age matched controls (Sabit et al., 2007, Mills et al., 
2008).  Arterial stiffness has also been positively related to disease severity 
based on GOLD classification system (Sabit et al., 2007, McAllister et al., 
2007).  Our results confirmed previous findings where arterial stiffness was 
increased in patients compared to controls; yet, we did not find any 
association to disease severity in modified GOLD groups or when using single 
parameter of FEV1% predicted.  There were some characteristics differences 
where in Sabit et al, subjects with CV and metabolic or inflammatory 
conditions were excluded, unlike our study.  Furthermore, the majority of our 
patients were GOLD II and only three were GOLD stage IV compared to Sabit 
et al. where nine out of 75 patients were in GOLD IV (Sabit et al., 2007).  Bhatt 
et al., presented similar to our finding when investigating determinants of 
arterial stiffness by comparing patients with moderate (GOLD II) COPD to 
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patients with severe (GOLD III) and very severe (GOLD IV) COPD (Bhatt et al., 
2014).  The authors showed no difference in aPWV when comparing patients 
in GOLD stage II to patients in GOLD stage III and IV - both groups were similar 
in CV and cerebrovascular diseases. 
It is important to note that our controls were not necessarily healthy subjects 
as they were similar to our patients in self-reported co-morbidities as 
described by Charlson index.   Moreover, both groups were similar in self-
reported use of CV medications.  This could due to the fact that COPD is 
associated with increased arterial stiffness.  This could play a part in 
explaining the similarity in other haemodynamics such as BP, PP and MAP 
readings in both groups, although the readings were marginally greater in 
patients, but not significant.  Nevertheless, the measurement of aPWV was 
the only haemodynamic measure that was significantly increased in patients 
compared to controls.  MAP is a contributing factor of aPWV (McEniery et al., 
2005), therefore showing increased aPWV in patients compared to controls 
despite similar MAP is of heightened importance. 
A previous study has demonstrated that exercise capacity as measured by 
6MWT was inversely related to arterial stiffness in patients with COPD; 
therefore, suggesting that patients with COPD could benefit from CV risk 
screening in pulmonary rehabilitation programme (Castagna et al., 2008).  The 
main aim of Castagna et al., study was looking at peripheral artery disease in 
patients with COPD rather than specific markers of arterial stiffness.  
Adjustment analysis was not reported so it is not known which confounding 
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variables account for the association.  Compared to our study, patients in 
Castagna et al. study were in more severe stage of COPD, mean (standard 
error (SE)) FEV1% predicted was 37 (6), with mean (SE) 6MWD (291 (41)m); 
which is similar to the distance presented in our study.  There is evidence in 
literature showing that  the prognostic power of 6MWD to predict mortality 
in patients with COPD is dependable on the severity of the disease and it 
becomes strongest in patients in the severe stages of COPD (Casanova et al., 
2008).  It is possible that the severity of COPD, also, has an influence on the 
strength of the association between the physical performance and arterial 
stiffness and, hence, having only few patients in the severe stages of COPD in 
our study might have obscured this association.  If this is the case, it supports 
our findings that patients at high risk group of mortality according to their 
physical performance have significantly increased arterial stiffness compared 
to patients in the low risk group. 
We reported no associations of arterial stiffness to the BODE or to any of its 
components unlike the apparent association with the ADO index.  The 
association of age to arterial stiffness in patients with COPD and in general 
population has been repeatedly shown in literature (Sabit et al., 2007, Bhatt 
et al., 2014) as well as in the present study; therefore, the presence of age as 
one of the components of the ADO index might be the primary factor of such 
significance.  It is important to note that age is not a disease specific but a 
common risk factor of mortality in the general public (Celli et al., 2009, 
Vaitkevicius et al., 1993); however, ADO has been validated to accurately 
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predicts 3-year mortality and a useful index for the assessment of medical 
intervention in patients with COPD (Puhan et al., 2012).  Both BODE and ADO 
are individually useful indices and are important in the management of COPD. 
As both indices include an exercise component, better understanding of the 
effect of exercise on arterial stiffness in patients with COPD will increase the 
beneficial values of these indices. 
In general, the relationship between physical performance and arterial 
stiffness in patients with COPD is still not clear and needs more investigations.  
Only two recently published studies by Vivodtzev et al. and Gale et al., 
showed that physical exercise improved BP which in turn improved aPWV 
(Vivodtzev et al., 2010, Gale et al., 2011).  Given that the determinants of 
arterial stiffness differ from those for BP, more studies investigating in details 
the nature of the relationship between physical performance and arterial 
stiffness are warranted.    
4.5.1 Limitation 
The nature of this cross-sectional study did not allow detecting the cause and 
effect of arterial stiffness and physical performance in our population.  The 
majority of the patients were in mild-moderate stage of the COPD, this might 
be a reason for the insignificant relationship between arterial stiffness and 
the severity of the disease.  Second, because of the lack of space we used a 
10m track for the 6MWD rather than the recommended 30m track (ATS, 
2002).  This, most likely, influenced the distance covered by our subjects and, 
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therefore, might have an effect on the lack of association between arterial 
stiffness and physical performance. 
4.5.2 Conclusion and future plan 
In a representative sample of patients with COPD and controls, we showed 
that COPD is an independent predictor of arterial stiffness and it was 
significantly increased in patients compared to age- and gender-matched 
controls and there was no difference in the self-reported co-morbidities in 
both groups.  Although no association between arterial stiffness and physical 
performance in COPD was found in our study, we showed that there is a 
potential benefit of expanding the use of the 6MWD cut-off in identifying 
patients with high arterial stiffness. 
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Chapter 5  
 
 
Physical Activity and 
Arterial Stiffness 
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5.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a respiratory condition with 
systemic complications including, but not limited to, muscle wasting and 
inactivity (Mannino et al., 2008, Schols et al., 2005, Pitta et al., 2005a).  
Muscle wasting and dysfunction in patients with COPD was shown to be 
affected by airway obstruction, hypoxemia and inactivity (Degens, 2007).  
Understanding the relationship between COPD and physical inactivity is 
important as inactivity is independently associated with hospitalisation and 
increased mortality rate in patients with COPD (Waschki et al., 2011, Garcia-
Rio et al., 2012, Watz et al., 2014). 
In general population physical inactivity is related to increased risk of 
developing serious conditions like cardiovascular (CV) diseases and 
hypertension (Kesaniemi YK, 2001).  In the general population, one estimation 
of disease-specific death showed that physical inactivity was responsible for 
approximately 1 in 10 deaths due to coronary heart disease, similar to that of 
high blood cholesterol, high blood pressure and cigarette smoking (Lloyd-
Jones et al., 2010).  Whilst, reduction of physical activity in the USA alone was 
responsible for the increass of mortality rate of over 17,000 deaths from the 
year of 1980 to 2000 (Lloyd-Jones et al., 2010).  Similarly, sedentary life-style 
even in healthy subjects is a leading cause of mortality, disability and serious 
conditions, for example, cardiovascular diseases and diabetes (Prakash, 2014).  
Therefore, the World Health Organisation (WHO) (WHO, 2010) as well as  the 
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American college of Sports and Medicine and the American Heart Association 
(AHA) recommended 30min of moderate activity for 5 days/wk or 75min/wk 
of vigorous activity to reduce CV risks (Nelson et al., 2007). 
When compared to healthy subjects, patients with COPD are less physically 
active (Pitta et al., 2005a, Vorrink et al., 2011) and have an accelerated 
decline of activity level over time (Vaes et al., 2014).  Furthermore, patients 
with COPD spend more time lying down during the day, cover less walking 
distance and walk a slower pace in comparison to healthy controls (Pitta et 
al., 2005a).  Even when compared to patients with other chronic conditions 
such as rheumatoid arthritis and diabetes, patients with COPD were found to 
be significantly less physically active (Arne et al., 2009).  Therefore, better 
understanding of the determinants and consequences of physical inactivity in 
patients with COPD is necessary especially when the prevalence of inactivity is 
high amongst COPD patients. 
Aortic stiffness is an independent predictor of CV diseases (Boutouyrie et al., 
2002, Ben-Shlomo et al., 2014).  Currently, the optimal non-invasive method 
of measuring arterial stiffness is the carotid-femoral pulse wave velocity 
(aPWV) (Laurent et al., 2006), and it has been found to be increased in 
patients with COPD when compared to healthy controls (Sabit et al., 2007). 
In healthy population, literature shows that physical inactivity is related to 
increased arterial stiffness (Tanaka et al., 2000, Boreham et al., 2004).  There 
is one small study by Stickland et al. exploring the association of physical 
activity  W assessed by SenseWear® Pro3 Armband - to arterial stiffness   W 
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assessed by carotid-radial PWV  W in patients with COPD (n=33) and age-
matched healthy controls (n=10) (Stickland, 2013).  They found that arterial 
stiffness was significantly lower in controls in comparison to inactive COPD 
patients, but not to active COPD patients.  In COPD alone, they demonstrated 
that physical activity and exercise tolerance were inversely related to arterial 
stiffness and that was independent of lung function; therefore, the authors 
concluded that increased stiffness in patients with COPD was related to the 
substantial decrease of physical activity rather than the impaired lung 
function. 
The aim of our study was to investigate whether self-reported physical 
activity was a determinant of aortic stiffness in a large, representative sample 
of patients with COPD.   
5.2 Hypothesis 
Aortic stiffness is inversely related to self-reported physical activity in patients 
with COPD 
5.3 Objectives 
- To determine self-reported physical activity in patients with COPD 
- To explore the association of self-reported physical activity to 
haemodynamic measurements in patients with COPD and contribution 
of confounding variables 
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5.4 Methods 
This cross-sectional study invited patients with COPD during their stability to 
attend a single study visit at the Clinical Trial Unit, City Hospital, Nottingham.  
The study includes two groups of patients with COPD: patients with confirmed 
diagnoses of COPD  W I presented in previous chapters - and patients with 
COPD recruited previously by a colleague using the same physical activity 
questionnaire and arterial stiffness measurements with the same inclusion 
and exclusion criteria.  There was no overlap in subjects. 
5.4.1 Ethics 
The study was approved by the National Research Ethics Service (NRES) 
(Chapter 2, p 51). 
5.4.2 Sample Size 
The sample size of this study included the patients recruited and analysed in 
previous chapters as well as patients recruited by colleagues in the 
department using the same inclusion and exclusion criteria.  We therefore 
used this large pragmatic size (n=167) of patients with COPD.  
5.4.3 Procedure 
5.4.3.1  Informed consent 
Written informed consent was obtained in subjects (Methods, p 53). 
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5.4.3.2 Tests 
5.4.3.2.1 Spirometric measurements 
Subjects performed post-bronchodilator spirometry (MicroLab MK6) 
(Methods, p 58)  (Miller et al., 2005). Patients were categorised according to 
GOLD stages (Methods, P 58) (Decramer et al., 2014).   
5.4.3.2.2 Self-reported physical activity 
Subjects were asked to report the time (hrs/wk) they spent doing mild, 
moderate and vigorous activity (Methods, P 64). 
Based on the WHO guidelines (WHO, 2010),  patients who reported doing 
A? ? ? ?ŵŝŶ/wk (for example 30 minutes for five days per week) of combined 
moderate and vigorous (active) activities were compared to those who 
reported <150min/wk of the same activity levels (inactive); then, patients 
ǁŚŽ ƌĞƉŽƌƚĞĚ ĚŽŝŶŐ A? ? ?ŵŝŶ ?ǁk of vigorous activity only were compared to 
those who reported <75min/wk of the same activity level. 
5.4.3.2.3 Self-reported walking time 
Patients were asked to report the average time (min/day) spent in walking 
outside the house/workplace for each weekday and weekend day in the past 
week (Methods, p 64).  In the statistical analysis of this section, the average 
walking time per week was calculated as (5 x weekday) + (2 x weekend) using 
the self-reported walk time in each weekday and the average of self-reported 
walk time in each weekend day. 
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5.4.3.2.4 Haemodynamic measurements 
Sitting peripheral (Omron) and central (Vicorder) blood pressure (BP), mean 
arterial pressure (MAP), pulse pressure (PP) and heart rate were obtained  
(Methods, p 56). 
Arterial stiffness measurements were taken using the Vicorder according to 
the gold-standard method aPWV while subjects were in a supine position 
(Laurent et al., 2006).  Aortic PWV measuremeŶƚŽĨA? ? ? ?ŵ ?ƐǁĂƐĐŽŶƐŝĚĞƌĞĚ
invalid and subjects were excluded (Methods, p 57). 
5.4.3.2.5 Body composition 
Height (metres) and weight (kilograms) were obtained (Seca, Germany).  From 
this, body mass index (BMI) was calculated.  The fat free mass (FFM) and the 
height squared index of fat free mass index (FFMI) were calculated using 
bioelectrical impedance (Tanita, USA) (Methods, p 55). 
5.4.3.2.6 Resting oxygen saturation 
Oxygen saturation was taken while subjects at rest (Konica Minolta pulsox-
300, Japan). 
5.4.3.2.7 Medical Research Council (MRC) dyspnoea scale 
All subjects were asked to complete the MRC dyspnoea scale (Methods, p 54).  
Detailed medical history including self-reported use of CV medications and 
smoking history were recorded. 
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5.4.4 Statistics 
Statistical Package for Social Sciences (SPSS) version 21 was used for data 
analysis (Chicago, IL).  Where variables were normally distributed: Chi squire 
test was used for comparison between two categorical variables; independent 
t-test to investigate if a continuous variable is statistically different between 
two groups.  For non-parametric variables the median (interquartile range 
 ?/YZ ? ?ǁĂƐƵƐĞĚƚŽĚĞƐĐƌŝďĞǀĂƌŝĂďůĞƐ ?^ƉĞĂƌŵĂŶ ?ƐƚĞƐƚǁĂ ƵƐĞĚƚŽassess the 
correlation of two continuous variables.  If non-normally distributed, Mann-
Whitney U test was used to investigate if a continuous variable is significantly 
different between two groups, where Kruskal-Wallis was used when 
comparing a continuous variable across more than two groups.  A stepwise 
regression analysis was used to determine factors affecting aortic stiffness in 
patients with COPD.  A p-value <0.05 was considered significant. 
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5.5 Results 
Of the 172 patients, five patients were excluded becĂƵƐĞŽĨĂWtsA? ? ? ?ŵ ?Ɛ ?
therefore 167 patients included.  The demographics and lung physiology 
parameters is presented in Table 5.1.  Central and peripheral haemodynamics 
including aPWV are presented in Table 5.2.  Both genders had similar FEV1% 
predicted and MRC score, all with p>0.05.  In all subjects, aPWV was positively 
related to age (r=0.43, p<0.001), heart rate (r=0.22, p<0.01) and central MAP 
(r=0.32, p<0.001), but not to FEV1% predicted, MRC dyspnoea scale and FFMI, 
all with p>0.05. 
According to GOLD stages, only seven patients were classified as GOLD IV and, 
therefore, an adapted GOLD stages of GOLD I (n=17), GOLD II (98) and GOLD 
III and IV (n=52) was used for statistical analysis.  Out of the 167 patients, 31 
patients reported having ischemic heart disease (IHD) and 23 patients 
reported having diabetes mellitus.  Patients self-reports of CV medications 
include angiotensin-converting enzyme inhibitor (n= 32), angiotensin receptor 
inhibitor (n= 15), beta blockers (n= 14) and statin (n= 100). 
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Table 5.1: Demographics of Patients with COPD 
Abbreviations: Body mass index (BMI), fat free mass index (FFMI), 
forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC), oxygen saturation (SpO2), Medical Research Council (MRC) 
Mean (SD) unless otherwise indicated  
n 167 
Age (years) 68 (8) 
BMI (kg/m
2
) 27.1 (5.6) 
FFMI (kg/m
2
) - n=158 18.4 (2.8) 
Smoking history (pack years) 44 (25) 
Smoking status - n (current/ex-smoker) 50/117 
FEV1 (L) 1.6 (0.6) 
FEV1% predicted 59 (19) 
FVC (L) 3.2 (0.9) 
FVC% predicted 95 (19) 
FEV1/FVC ratio 49 (13) 
Resting SpO2 (%) 95 (2) 
MRC dyspnoea scale  ? median (IQR) 3 (2-4) 
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Table 5.2: Haemodynamic Measurements in Patients with COPD 
 
Mean (SD)  
Peripheral systolic BP (mmHg) 141 (21) 
Peripheral diastolic BP (mmHg) 80 (11) 
Peripheral MAP (mmHg) 101 (13) 
Peripheral PP (mmHg) 61 (16) 
Heart rate (beat/min) 75 (15) 
aPWV (m/s) 10.3 (2.1) 
Central systolic BP (mmHg) 141 (21) 
Central diastolic BP (mmHg) 84 (13) 
Central MAP (mmHg) 110 (15) 
Central PP (mmHg) 58 (17) 
Abbreviations: Blood pressure (BP), mean arterial pressure (MAP), pulse 
pressure (PP) and aortic pulse wave velocity (aPWV) 
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5.5.1 Self-reported physical activity and haemodynamic 
measurements 
5.5.1.1 Self-reported physical activity (hrs/wk) 
^ƉĞĂƌŵĂŶ ?Ɛ ƚĞƐƚ ƐŚŽǁĞĚ ŶŽ ƐŝŐŶŝĨŝĐĂŶƚ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ ĂWts ƚŽ Ă ĐŽŵďŝŶĞĚ
mild, moderate and vigorous activity (hrs/wk) (r=0.10, p=0.21) or to a 
combined moderate and vigorous activity (hrs/wk) (r=0.02, p=0.84). 
Both the combined mild, moderate and vigorous activity (hrs/wk) and the 
combined moderate and vigorous activity (hrs/wk) were inversely related to 
peripheral pulse pressure (r=0.15 and r=0.16, respectively, p<0.05), but they 
were not related to other haemodynamic measurements including central 
and peripheral systolic BP, diastolic BP, MAP, heart rate and central pulse 
pressure, all with p>0.05. 
5.5.1.2 Self-reported physical activity based on WHO guidelines 
The vast majority of patients (n=125) do A? ? ? ?ŵŝŶ ?ǁk of combined moderate 
and vigorous activity had mean (SD) aPWV of 10.3 (1.8)m/s compared to 
those who do <150min/wk (n= 42), 10.2 (2.1)m/s, p=0.79.  Similarly, patients 
(n=8) who reporƚĞĚ ǀŝŐŽƌŽƵƐ ĂĐƚŝǀŝƚǇ A? ? ?ŵŝŶ ?ǁk had mean aPWV of 11.3 
(1.0)m/s compared to 10.2 (2.1)m/s for those (n=159) who reported vigorous 
activity <75min/wk, p=0.14. 
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There was no statistical difference in peripheral and central haemodynamic 
measurements including heart rate, based on the cut-off of the 150min/wk 
(combined moderate and vigorous) or the 75min/wk (vigorous activity only), 
all with p>0.05. 
5.5.1.3 Self-ƌĞƉŽƌƚĞĚ ƉŚǇƐŝĐĂů ĂĐƚŝǀŝƚǇ ďĂƐĞĚ ŽŶ ĨƌĞƋƵĞŶĐǇ ŽĨ ш ?
times/week 
Patients who reportĞĚA? ?ƚŝŵĞƐ ?ǁk of physical activity had mean (SD) aPWV 
of 10.2 (2.1)m/s and those with <3 times/wk had aPWV of 10.7 (2.0)m/s, 
p=0.24.  There was no statistical difference in peripheral and central 
haemodynamic measurements when patients where compared based on self-
reported >3times/wk of physical activity. 
5.5.1.4 Self-reported walking time (minute/week) 
^ƉĞĂƌŵĂŶ ?Ɛ ƚĞƐƚ ƐŚŽǁĞĚ ǁĞĂŬ ďƵƚ ƐŝŐŶŝĨŝĐĂŶƚ ĂƐƐŽĐŝĂƚŝŽŶ ďĞƚǁĞĞŶ ƐĞůĨ-
reported walk time and both peripheral and central systolic BP (r= 0.16, 
p=0.04 and r= 0.18, p=0.02, respectively), but not between self-reported walk 
time and aPWV (r=0.11, p=0.14) (Figure 5.1).  Analysis of other 
haemodynamic measures showed that self-reported walking time was 
associated with peripheral MAP (r=0.16, p=0.04), but not with other 
peripheral or central haemodynamic measures, p>0.05. 
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A: Aortic Stiffness and Self-Reported Walking Time 
 
 
 
 
 
 
 
B: Peripheral Systolic Blood Pressure and Self-Reported Walking Time 
 
 
 
 
Figure 5.1: Association of Haemodynamic Measurements to Self-reported Walking Time 
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5.5.2 Self-reported mild, moderate and vigorous activity 
(minute/week) 
The median (IQR) time (min/wk) of self-reported combined mild, moderate 
and vigorous activity was 720 (300-1260)min/wk; and for the combined 
moderate and vigorous activity alone was 30 (0-150)min/wk.   
5.5.2.1 Self-reported physical activity and GOLD stages of airflow 
obstruction and MRC dyspnoea scale 
Kruskal-Wallis test showed significant difference between GOLD stages and 
the combined self-reported mild, moderate and vigorous activity (mins/wk) 
(p=0.02) (Figure 5.2), as well as between GOLD stages and the combined 
moderate and vigorous activity only, median (IQR) GOLD I: 30 (0-120)min/wk, 
GOLD II: 60 (0-240)min/wk, GOLD III and IV: 0 (0-60)min/wk, p= 0.02. 
Likewise, Kruskal-Wallis test showed significant difference between MRC 
dyspnoea scale and the combined mild, moderate and vigorous self-reported 
physical activity (min/wk), p<0.001 (Figure 5.3), as well as the combined 
moderate and vigorous activities alone, median (IQR) MRC 1: 120 (0-
720)min/wk, MRC 2: 90 (0-240)min/wk, MRC 3: 0 (0-60)min/wk, MRC 4: 0 (0-
120)min/wk and MRC 5: 0 (0-18)min/wk, p<0.001. 
5.5.2.2 Self-reported physical activity and other potential confounders 
Other potential factors influencing self-reported physical activity to explore 
were age, gender, FEV1% predicted, resting oxygen saturation and FFMI.  
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^ƉĞĂƌŵĂŶ ?ƐƚĞƐƚƐŚŽǁĞĚŶŽƐŝŐŶŝĨŝĐĂŶƚĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶĂŐĞĂŶĚŶĞŝƚŚĞƌĂ
combined self-reported mild, moderate and vigorous activity (min/wk) (r= 
0.14) or the combined moderate and vigorous activity only (r= 0.14), both 
p>0.05. 
Mann-Whitney U tests showed no gender differences in self-reported 
combined mild, moderate and vigorous activity (min/wk), p>0.05; however, 
males reported significantly more time with a median (IQR), 60 (0-
240)min/wk, doing combined moderate and vigorous activity than females, 0 
(0-120)min/wk, p=0.001. 
The combined mild, moderate and vigorous activity (min/wk) was associated 
to FEV1% predicted (r= 0.32, p<0.001); but it was not associated to resting 
oxygen saturation, smoking history (pack year) or FFMI, all with p>0.05. 
Comparable results were found when analysing the combined self-reported 
moderate and vigorous activity as it was associated to FEV1% predicted 
(r=0.19, p=0.01), but it was also associated to FFMI (r=0.24, p=0.003).  There 
was no significant association between the combined self-reported moderate 
and vigorous activity and the measurements of resting oxygen saturation or 
smoking history (pack year), all with p>0.05.   
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Error bars represent IQR 
Abbreviation: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
 
Figure 5.2: Self-reported Mild, Moderate and Vigorous Physical Activity Time and 
GOLD Stages 
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Error bars represent IQR 
Abbreviation Medical research council (MRC) 
MRC 1: n=13, MRC 2: n=65, MRC 3: n=35, MRC 4: n=39 and MRC 5: n=15 
Figure 5.3: Self-reported Mild, Moderate and Vigorous Physical Activity Time and 
MRC Scale 
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5.5.3 Comparison between active and inactive patients based on 
WHO guidelines for physical activity 
Chi squared test showed that the proportion of patients who reported 
moderate and vigorous physical activity of A? ? ? ?ŵŝŶ ?ǁŬ  ?ĂĐƚŝǀĞ ƉĂƚŝĞŶƚƐ ?
decreases as the severity of COPD  W according to GOLD stages  W increases, 
p=0.001 (Figure 5.4) (WHO, 2010). 
Similarly, as the MRC worsened the percentages of the inactive patients 
(<150min/wk of moderate and vigorous activity) became higher than the 
percentages of the active patients (150min/wk of moderate and vigorous 
activity), p<0.001 (Figure 5.5). 
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Abbreviation Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
ĐƚŝǀĞŐƌŽƵƉ PA? ? ? ?ŵŝŶ ?ǁĞĞŬ 
Inactive group: <150min/week 
 
 
  
Figure 5.4: Proportion of Patients Classified as Inactive according to GOLD 
stages  
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Abbreviation: Medical Research Council (MRC) 
ĐƚŝǀĞŐƌŽƵƉ PA? ? ?0min/week 
Inactive group: <150min/week 
 
 
 
 
 
 
 
 
Figure 5.5: Proportion of Patients Classified as Inacitve according to MRC Dyspnoea 
Scale 
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5.5.4 Self-reported physical activity based on a cut-off of 3 
times/week 
13 ?ƉĂƚŝĞŶƚƐƌĞƉŽƌƚĞĚA? ?ƚŝŵĞƐ ?ǁk whilst 32 patients reported <3 times/wk of 
mild, moderate or vigorous physical activity.  Both groups were similar in age 
and gender, p>0.05.  Chi squire test showed that the proportion of patients 
reporting doing physical activity A? ? ƚŝŵĞƐ ?ǁk decreases as the severity of 
COPD based on GOLD stages increased, p=0.01 (Figure 5.6). 
Similarly, Chi squire test showed that the proportion of patients who reported 
A? ?ƚŝŵĞƐ ?ǁk decreases as the MRC score increased, p=0.001 (Figure 5.7). 
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Abbreviation: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Figure 5.6: GOLD Stages and Self-reported Frequency of Mild, Moderate and 
Vigorous Physical Activity 
n= 17 n= 98 n= 52 
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Abbreviation: Medical research council (MRC) 
MRC 1: n= 13, MRC 2: n= 65, MRC 3: n= 35, MRC 4: n=39 and MRC 5: n= 15 
Figure 5.7: MRC Dyspnoea Scale and Self-reported Mild, Moderate and 
Vigorous Physical Activity 
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5.5.5 Self-reported walking time 
The median (IQR) of self-reported walking time was 210 (105-490)min/wk.  
Kruskal-Wallis test showed that self-reported walking time per week was not 
significantly different amongst the GOLD stages, p=0.15; but it was 
significantly different amongst the MRC dyspnoea scale, p=0.01 (Figure 5.8).  
In Figure 5.8 the unexpectedly high walking time in MRC score 5 could be 
explained by 2/15 of the patients reporting unexpectedly high walking time 
and their results being outliers. 
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Bars represent the median time (min/week) of self-reported walking time 
Error bars represent the IQR 
Abbreviation: Medical research council (MRC) 
MRC 1: n= 13, MRC 2: n= 65, MRC 3: n= 35, MRC 4: n= 39 and MRC 5: n= 15 
Figure 5.8: Self-reported Walking Time (minute/week) across the MRC Dyspnoea 
Scale 
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5.6  Discussion 
The current study did not find an association between self-reported physical 
activity and aortic stiffness.  Assessing patients during disease stability 
showed that the severity of COPD  W assessed by GOLD stages  W and dyspnoea 
 W assessed by the MRC dyspnoea scale  W were inversely related to the physical 
activity. 
Expanding our understanding of the potential effects of daily life physical 
activity on arterial stiffness is important and might play crucial role in the 
future medical intervention to reduce death of cardiovascular diseases and 
reduce functional decline (Lloyd-Jones et al., 2010) in general public as well as 
in patients with COPD.  Furthermore, previous studies showed that physical 
activity is an independent predictor of mortality in healthy subjects (Vaes et 
al., 2014) and in patients with COPD (Troosters et al., 2013, Garcia-Rio et al., 
2012, Waschki et al., 2011, Vaes et al., 2014).  Physical activity is a modifiable 
factor which can be improved and, therefore, provides long term benefits 
ƌĞŐĂƌĚŝŶŐƉĂƚŝĞŶƚƐ ?ŚĞĂůƚŚ (Troosters et al., 2013). 
Stickland et al., looked at the relationship of physical activity to arterial 
stiffness in patients with COPD (20 inactive and 13 active) in comparison to 10 
age-matched controls (Stickland, 2013).  They showed an inverse association 
of time spent in moderate activity as well as the step counts to arterial 
stiffness when the total subjects were analysed and the authors suggested 
that physical activity may play a bigger role as a determinant of arterial 
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stiffness than does the lung function.  The association of physical activity to 
arterial stiffness, undoubtedly, needs further investigation given that the 
sample of patients included in Stickland et al., study was not representative of 
the COPD population as the authors included patients with mild and 
moderate stage of COPD and without co-morbidities, for example diabetes, 
CV- and connective tissue diseases.  Moreover, the authors relied on the 
brachial PWV - carotid-radial method of measuring PWV - instead of the 
carotid-femoral (aortic), where the latter is recognised to be an independent 
predicted of CV events (Laurent et al., 2006).  This might be one explanation 
of the lack of association between arterial stiffness and age in their study; 
whereas,  we reported with consistency to previous literature a positive 
association between age and aortic stiffness (Sabit et al., 2007).  However, 
there is increasing interest in exploring the relationship between physical 
activity and arterial stiffness and some recent articles and abstracts 
concerning overweight and obese sedentary young adults (Hawkins et al., 
2014) and community-dwelling older adult (Tanaka et al., 2014),  support 
Stickland et al regarding the association of physical activity on arterial 
stiffness (Stickland, 2013).  Compared to these studies, we did not find an 
association between aPWV and either self-reported physical activity or self-
reported walking time.  It should be noted that Stickland et al., study was 
published after we had conducted our work.  Using subjective approach of 
quantifying physical activity in our study is a less accurate measurement of 
physical activity and walking time; however, it is inexpensive and permits 
assessment of more patients with less time when compared to objective 
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measures.  Furthermore, the present study showed weak, but significant, 
association between physical activity and systolic blood pressure.  This is 
consistent with a previous literature showing vigorous physical activity has 
positive effect on body metabolism and lowers the change of having high 
blood pressure in the general population  (Janssen and Ross, 2012). 
Physical activity has been shown repeatedly to be related to airway 
obstruction, dyspnoea and disease severity in COPD (Gimeno-Santos et al., 
2014, Katajisto M, 2012, Troosters et al., 2010a, S. Barriga, 2014).  Our study 
supports these findings using a simple subjective measure of self-reported 
physical activity questionnaires.  A recently published study by Zogg et al., 
using physical activity monitor (SenseWear®) for 7 days showed that airway 
obstruction was positively related to daily steps count but not the level of 
physical activity (Zogg et al., 2014).   In the previously mentioned study by 
Stickland et al., the authors did not find an association between physical 
activity and airways obstruction in patients with COPD (Stickland, 2013), for 
the sample size (33 patients with COPD) and, as we highlighted earlier, using 
limited population of patients with COPD were probably the key factors for 
the lack of significance. 
Literature has highlighted some of the determinants of physical activity like 
age and gender in healthy subjects (Vern Seefeldt, 2002).  In our patients we 
did not find an association between age and physical activity; however, there 
were gender differences in self-reported moderate- and vigorous- but not in 
mild-activity.  Although both genders were similar in the degree of airway 
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obstruction and dyspnoea score male patients reported spending more time 
in moderate and vigorous activity than female patients.  This likely 
corresponds to the greater muscular mass found in male patients in relation 
to their measurements of the FFMI. 
5.6.1 Limitations 
Although we included large representative patients with COPD, only a few of 
them were in very severe stage of the disease which might be one of the 
factors to conceal the potential association between physical activity and 
arterial stiffness specially if we take into account the inverse association of 
the severity of COPD to physical activity as well as severity of COPD to arterial 
stiffness.  Although self-reported questionnaires is an accepted useful 
measure to assess physical activity (Troosters et al., 2013), it still can be 
ƵŶĚĞƌĞƐƚŝŵĂƚĞĚ Žƌ ŽǀĞƌĞƐƚŝŵĂƚĞĚ ĂƐ Ă ƌĞƐƵůƚƐ ŽĨ Ă ƌĞĐĂůů ďŝĂƐ Žƌ ƐƵďũĞĐƚƐ ?
interpretation in particularly in reporting physical activities which require 
ŚŝŐŚĞƌůĞǀĞůŽĨĞŶĞƌŐǇ ?ĨŽƌĞǆĂŵƉůĞ “ǀŝŐŽƌŽƵƐ ?ĂĐƚŝǀŝƚǇ(Prince et al., 2008). 
5.6.2 Conclusion 
Physical activity is, indeed, a modifiable risk factor and when properly 
managed can provide a long-term health benefits to patients with COPD.  In 
the present study, the association of physical activity - assessed by a 
subjective approach  W to arterial stiffness in patients with COPD did not reach 
significance.  To our knowledge, there is only one published study looking at 
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the relationship between physical activity and arterial stiffness  W using 
brachial PWV - in patients with COPD.  However, Further studies are needed 
using more accurate measures of arterial stiffness  W aPWV  W in a wide range 
of a representative patients with COPD. 
5.6.3 Future direction 
There is a growing literature exploring the effect of COPD on physical activity 
using objective measures, for example the SenseWear®.  Using a validated 
objective measure to explore the effects of daily life physical activity on 
arterial stiffness in representative patients with COPD is warranted; however 
expensive.  This new area could potentially enhance our understanding of 
COPD and may add beneficial values to COPD management. 
 182 
 
 
Chapter 6  
 
 
Ambulatory 
Haemodynamics in 
Patients with COPD 
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6.1 Introduction 
Chronic obstructive pulmonary disease (COPD) and its association to 
cardiovascular (CV) events has been extensively investigated in the past 
decade (Huiart et al., 2005, Sin and Man, 2003, Sabit et al., 2007, Curkendall 
et al., 2006).  Studies investigating the extent of hemodynamic changes in 
patients with COPD are largely limited to resting measurements taken in a 
clinical setting.  Depending on resting measurements alone may confine our 
understanding of the actual dynamic changes during daily life activities, 
where patients with COPD suffer exertion from seemingly simple tasks, for 
example walking down a corridor.  Ambulatory blood pressure machines 
(ABPM) are useful, effective, and an easy way to obtain an overview of blood 
pressure (BP) and aortic stiffness profile over 24-hours period.  Although 
ABPM measurements differ from those obtained from conventional BP 
monitors and might provide underestimated readings of some 
haemodynamics (Kallem et al., 2013, Luzardo et al., 2012), ABPM has been 
found to be superior to conventional BP monitors in predicting 
cerebrovascular and CV risks (Clement et al., 2003, Kario et al., 2001b, 
Verdecchia et al., 1994, Staessen et al., 1999, Shimada et al., 1990).  It is 
noteworthy to mention that ABPM provides a more accurate haemodynamic 
profile over 24-hour period and helps to overcome limitations of in-clinic BP 
measurements, for example while coat and masked hypertension (NICE, 
2011b, Pickering et al., 2002, Pickering et al., 2005).  Therefore, implementing 
ABPM in research and clinical practice may help to better understand the 
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similarities and differences of 24hr haemodynamic profile in patients with 
COPD as compared to controls.   
To our knowledge there is only one study investigating haemodynamic 
changes during 24-hour time period in patients with COPD with sleep 
desaturation using peripheral ambulatory BP (pABP) measurements (Aidar et 
al., 2009). This study showed that COPD alone was associated with increased 
peripheral BP measurements during the awake, night, and total 24-hr period 
compared to age- and BMI matched controls.  Further, patients with COPD 
had significantly less overnight blood pressure dip compared to controls. 
In addition to peripheral haemodynamic measurements, there has been 
interest in measurements of central haemodynamics such as central BP (cBP) 
and arterial, specifically aortic stiffness.  These predict vascular hypertrophy, 
atherosclerosis, and CV events better than peripheral BP measurements 
(Laurent et al., 2006, Roman et al., 2007).  Aortic stiffness, as measured by 
aortic pulse wave velocity is a gold standard, is increased in patients with 
COPD (Sabit et al., 2007) compared to smoker controls using tonometric 
(Sphygmocor®) and oscillometric (Vicorder®) devices (Sabit et al., 2007, John 
et al., 2013).  
Exploring 24-hour central ambulatory haemodynamics in patients with COPD 
is of interest in light of above in order to provide important information 
regarding dynamic changes during daily life activities and sleep.  The non-
invasive automated oscillometric device (Mobil-O-Graph) has been validated 
according to the British Hypertension Society (BHS) (Jones et al., 2000) and 
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permits central ambulatory BP (cABP) using a brachial-cuff with transfer 
function-like algorithm (Weber et al., 2011) and it has been confirmed against 
the Sphygmocor® tonometric device (Weiss et al., 2012).  
6.2 Hypothesis 
Patients with COPD have abnormal profile of 24-hour aortic pulse wave 
velocity when compared to age- and gender-matched controls  
6.3 Methods 
6.3.1 Study objectives 
x Assess the feasibility and acceptability of 24-hour BP monitor 
x Measure the peripheral, cABP and aortic stiffness profile of patients 
with COPD and controls over a 24-hour period using the Mobil-O-
Graph in a pilot study 
x Compare the recorded aortic pulse wave velocity (aPWV) using the 
gold standard carotid-femoral PWV (Vicorder) and the derived at rest 
(in-clinic) measurements of aPWV using 24-hour cABP machine 
(Mobil-O-Graph) 
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6.3.2 Ethics 
This sub-ƐƚƵĚǇ ǁĂƐ ĂƉƉƌŽǀĞĚ ĂƐ ĂŶ ĂŵĞŶĚŵĞŶƚ ƚŽ  “dŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ ůƵŶŐ
ĨƵŶĐƚŝŽŶ ĂŶĚ ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ƌŝƐŬ ?  ? ? ?, ? ? ? ? ? ? ? ? ďǇ ƚŚĞ Eational Research 
Ethics Service (NRES), Nottingham committee.  
6.3.3 Sample size and setting 
This pilot sub-study encompassed patients with COPD and controls.  As such a 
power calculation could not be performed but will inform for future studies.  
A pragmatic number of 20 patients and 20 controls with viable data were 
selected. 
 
6.3.4 Inclusion and exclusion criteria 
Detailed inclusion and exclusion criteria can be found in Methods, p 51. 
6.3.5 Procedure 
6.3.5.1 Informed Consent 
In addition to the standard consent for the main study (Methods, p 53), 
subjects were asked to sign consent for this section and affirmation of 
responsibility and return of the machine. 
 187 
 
Subjects were, consecutively, consented and asked for possible next day 
return of the cABP machine.  Subjects were not consented if the ambulatory 
24-hour machine was not available; e.g. had not yet returned from previous 
subject. 
6.3.5.2 Tests 
6.3.5.2.1 Ambulatory blood pressure  
Following detailed discussion with each subject as to how to use and wear the 
device, a manual recording at rest by the cABP machine was performed and 
followed by another automatic recording during the visit to ensure that the 
device was prepared.  These were performed seated after a period of rest.  
^ƵďũĞĐƚƐǁĞƌĞĂƐŬĞĚƚŽƉƌĞƐƐƚŚĞĚĂǇ ?ŶŝŐŚƚ “ŵĂƌŬĞƌ ?ďƵƚƚŽŶǁŚĞŶƚŚĞǇwent 
to bed and early morning when they first woke up.  Moreover, a small card 
was attached to the device as a reminder where the subject could write the 
 “ďĞĚ ? ƚŝŵĞ ĂŶĚ ƚŚĞ  “ĂǁĂŬĞ ? ƚŝŵĞ ŵĂŶƵĂůůǇ ŝĨ ŚĞ ?ƐŚĞ ĨŽƌŐ ƚ ƚŽ ƉƌĞƐƐ ƚŚĞ
day/night button.  Recordings of cABP were obtained following a Mobil-O-
Graph pre-set protocol, programmed to take two diurnal recordings/hour and 
one nocturnal recording/hour.  The subject was asked to return the device 
the following day and data downloaded. 
Measurements of peripheral and central mean arterial pressure that were 
taken by the ABPM  W in-clinic and over 24-hour period  W were calculated as 
(1/3systolic + 2/3diastolic).  Although the Mobil-O-Graph 24-hour PWV 
monitor provides measured recordings of peripheral MAP, we relied on 
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calculated measurements in our analysis for comparison purposes with 
measurements obtained from the Vicorder®.  This was essential for 
consistency as calculated and measured MAP readings are not 
interchangeable (Kiers et al., 2008). 
To investigate nocturnal haemodynamic differences between patients and 
controls, subjects in each group were classified as dippers (systolic nocturnal 
ĚŝƉ A? ? ?A? ? ĂŶĚ ŶŽŶ-dippers (systolic nocturnal dip <10%) adapted from 
systolic nocturnal dip classification: inverse dippers  <0%, non-dippers - <10%, 
ĚŝƉƉĞƌƐAM ? ?A? ?ĂŶĚĞǆƚƌĞŵĞĚŝƉƉĞƌƐA? ? ?A?(Kario et al., 2001a); for example, 
dippers (dippers and extreme dippers) and non-dippers (inverse dippers and 
non-dippers). 
6.3.5.2.2 In-clinic haemodynamic measurements 
As part of the main study, all subjects underwent detailed resting 
haemodynamic measurements including peripheral and central 
haemodynamic/ arterial stiffness measurements. 
- Peripheral blood pressure 
Peripheral resting BP was performed, Methods, p 56. 
- Pulse wave analysis and aortic stiffness  
Following the peripheral measurements, cBP and aPWV were attained at rest 
in a sitting position using the Vicorder (Method, p 57) 
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6.3.5.2.3 Spirometry 
All subjects performed spirometry to determine forced expiratory volume in 
the first second (FEV1), forced vital capacity (FVC) and the ratio.  Post 
bronchodilator readings in patients with COPD were recorded (Methods, p 
58)  
6.3.6 Statistics 
Statistical package of the Social Sciences (SPSS) version 21 was used for data 
analysis.  Comparison between the two groups was applied where data was 
continuous and normally distributed by parametric statistics e.g. independent 
t-test.  Chi-squire test was used for categorical data.  WĞĂƌƐŽŶ ?Žƌ^ƉĞĂƌŵĂŶ ?Ɛ
rank for non-parametric) was used to analyse relationship between two 
variables and p <0.05 was defined as significant.  Paired sample t-test was 
used to detect haemodynamic differences during diurnal and nocturnal 
measurements.  Bland-Altman plot was used for comparison between two 
different methods of measuring aPWV  W Vicorder and Mobil-O-Graph.  
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6.4 Results 
Study recruitment included 46 subjects - patients with COPD and smoker 
controls.  Out of the 46 participants, one was excluded because of respiratory 
condition other than COPD.  Thus, 25 COPD and 20 smoker controls were 
included in the demographics of this study.  However not all subjects were 
suitable for all the analyses (Figure 6.1). 
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Figure 6.1:  24-hour Ambulatory blood pressure/aortic stiffness Study 
flowchart 
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 Subjects were well-matched for age, gender and BMI (Table 6.1).  There were 
ƐŝŐŶŝĨŝĐĂŶƚůǇŐƌĞĂƚĞƌ “ĐƵƌƌĞŶƚ ?ƐŵŽŬĞƌƐĂŶĚƐŵŽŬŝŶŐƉĂĐŬǇĞĂƌƐŝŶKWŐƌŽƵƉ
than controls.  As expected, patients with COPD had lower FEV1% and 
FEV1/FVC ratio.  A chi square analysis showed no significant difference in self-
reported co-morbidities, although the values were low and analysis in results 
interpreted with caution (Table 6.1). 
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Table 6.1:  Study Demographics of All Subjects Recruited 
Abbreviations: Body mass index (BMI), forced expiratory volume in one 
second (FEV1), and forced expiratory volume (FVC). 
Mean (SD) unless otherwise stated 
COPD 
N= 25 
Controls 
N= 20 
P-
value 
Gender (m/f) - n 16/9 10/10 0.35 
Age (years) 68 (8) 64 (9) .0.13 
Smoking pack years 42 (19) 29 (11) <0.01 
Smoking status (current/ex) - n 11/14 3/17 0.04 
Carbon monoxide 8 (9) 4 (5) 0.03 
BMI (kg/m
2
) 28.6 (7.6) 30.4 (6.3) 0.4 
FEV1 (L) 1.68 (0.58) 2.62 (0.63) <0.001 
FEV1% predicted 62 (17) 100 (16) <0.001 
FEV1/FVC ratio 52 (15) 75 (7) <0.001 
Resting Oxygen saturation % 95 (2) 96 (2) 0.03 
Self-
reported 
Cardiovascular 
diseases (n)  
7 2 0.13 
Hypertension (n)  7 4 0.54 
Diabetes mellitus (n)  4 2 0.56 
Osteoporosis (n)  1 2 0.42 
Hypercholesterolemia 
(n)  
13 7 0.32 
Renal diseases (n)  0 1 0.26 
Cerebrovascular 
diseases (n)  
1 0 0.37 
Rheumatoid arthritis 
(n) 
2 3 0.46 
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6.4.1 Feasibility and acceptability of the Mobil-O-Graph 24-hour 
PWV monitor 
Feasibility was assessed objectively by evaluating the number of recordings 
over 24-hour period, which can be determined by the number of registered 
recordings and feedback.  Six out of the 45 participants: five out of 25 patients 
with COPD and one out of 20 controls did not have valid recording (minimum 
of three nocturnal and three diurnal measurements). 
Reasons for invalid recordings included subject intolerability: measurement 
aborted or machine switched off by user (n=1), pressure increased during 
ĚĞĨůĂƚŝŽŶ  “ŵŽǀĞŵĞŶƚ ? (n=4), and pressure decrease during inflation (n=1); 
and machine faults: movement artefact (n=20), heart rate increase beyond 
range (n=2), leakage (n=3) and/or exceeded time of measurement (n=3).  
There was no feedback report of skin irritation or bruises from cABP machine 
wearers.   
Movement artefact was the foremost reason accounting for 44% of all invalid 
measurements.  EĞǀĞƌƚŚĞůĞƐƐ ? ƚŚĞ ŽǀĞƌĂůů  “ǀĂůŝĚ ? ŵĞĂƐƵƌĞŵĞŶƚƐ ŽďƚĂŝŶĞĚ
from the machine were deemed acceptable.  The maximum possible pre-set 
recordings per patient over a 24 hour period was 38; however manual 
recordings could be performed over and above this.  The mean (SD) number 
recorded was 32 (12). 
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6.4.2 24-hour blood pressure and aortic stiffness profile in patients 
and controls 
Subjects with valid measurements obtained by 24-hour cABP machine were 
included in this part of the analysis.  Out of the 25 COPD subjects five were 
excluded: one did not have any 24-hour aPWV measurement and four others 
did not have nocturnal ambulatory aPWV measurements.  In controls, one 
subject was excluded due to missing nocturnal measurements.  Thus, 20 
patients with COPD and 19 controls where included in this analysis (Figure 
6.1).  
The mean values for the total 24-hour, diurnal, and nocturnal aPWV were 
constantly greater in patients with COPD than controls, but did not reach 
statistical significance (Figure 6.2 and Table 6.2). 
Other 24-hour, diurnal, and nocturnal haemodynamic measurements of 
patients and controls were demonstrated in Table 6.2.  Peripheral 
measurements of PP and MAP were similar between patients and controls, all 
with p>0.05.  Heart rate was consistently increased in patients compared to 
controls but was significant during the 24-hour and diurnal periods only, both 
with p<0.05. 
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Figure 6.2: Mean Ambulatory aPWV profile in Patients with COPD and 
Controls using 24-hour cABP machine 
 
Abbreviation: Aortic pulse wave velocity (aPWV) and central ambulatory 
blood pressure monitor (cABP) 
Error bars represent ±1SD 
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Table 6.2: 24-Hour, Diurnal, and Nocturnal Peripheral and Central Ambulatory Blood Pressure 
Measurements in Patients and Controls 
Abbreviations: Peripheral systolic blood pressure (pSBP), peripheral diastolic blood pressure (pDBP), mean arterial 
pressure (MAP), peripheral pulse pressure (PPP), central systolic blood pressure (cSBP), central diastolic blood pressure 
(cDBP), central mean arterial pressure (cMAP), central pulse pressure (cPP), aortic pulse wave velocity (aPWV) and central 
ambulatory blood pressure (cABP).  The p-values represent the comparison between patients and controls 
Mean value 
unless 
otherwise 
indicated 
24-hour 
p 
Diurnal 
p 
Nocturnal 
P 
COPD 
n= 20 
CONTROLS 
n= 19 
COPD 
N= 20 
CONTROLS 
n= 19 
COPD 
n= 20 
CONTROLS 
n= 19 
pSBP (mmHg) 133 (15) 127 (12) 0.19 137 (16) 130 (13) 0.19 119 (29) 119 (12) 0.99 
pDBP (mmHg) 79 (8) 78 (7) 0.55 82 (8) 81 (8) 0.59 72 (8) 72 (8) 0.68 
MAP (mmHg) 97 (9) 94 (7) 0.27 100 (10) 97 (8) 0.29 88 (13) 87 (8) 0.84 
PPP (mmHg) 54 (12) 49 (12) 0.26 54 (13) 50 (13) 0.25 46 (25) 47 (13) 0.87 
Heart rate 
(bpm) 
75 (10) 68 (10) 0.04 77 (11) 70 (10) 0.04 70 (10) 65 (11) 0.12 
cSBP (mmHg) 120 (12) 120 (13) 0.99 124 (14) 124 (15) 0.94 118 (22) 112 (13) 0.30 
cDBP (mmHg) 80 (8) 79 (7) 0.76 85 (9) 83 (8) 0.60 77 (18) 73 (10) 0.41 
cMAP (mmHg) 93 (9) 93 (7) 0.84 98 (10) 97 (9) 0.72 90 (19) 86 (9) 0.34 
cPP (mmHg) 40 (9) 40 (12) 0.84 39 (10) 41 (13) 0.76 42 (9) 39 (12) 0.50 
aPWV (m/s)  ? 
using the cABP 
machine 
8.9 (1.3) 8.3 (1.6) 0.63 9.0 (1.2) 8.4 (1.6) 0.65 8.8 (1.3) 8.0 (1.5) 0.07 
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The relationship of 24-hour, diurnal and nocturnal ambulatory aPWV to other 
haemodynamic measurements in patients and controls were presented in 
Table 6.3.  In patients, there were direct moderate correlations between 
ambulatory aPWV and cPP over the 24-hour and nocturnal measurements 
only.  In controls, there were direct moderate association between mean 
aPWV (24-hour and diurnal) and diurnal cSBP and between aPWV and cPP 
measurements over the 24-hour, diurnal- and nocturnal periods. 
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Table 6.3: Association of aPWV and Haemodynamic Measurements During 24-hour, 
Diurnal and Nocturnal time 
Abbreviations: Central systolic blood pressure (cSBP), central diastolic blood pressure 
(cDBP), central pulse pressure (cPP), central mean arterial pressure (cMAP) and aortic 
pulse wave velocity (aPWV). 
r (p-value) 
COPD Controls 
24-hr 
aPWV 
Diurnal 
aPWV 
Nocturn
al aPWV 
24-hr 
aPWV 
Diurnal 
aPWV 
Nocturn
al aPWV 
cSBP 
(mmHg) 
24-hr 0.33 (0.16) 0.35 (0.14) 0.44 (0.05) 0.42 (0.08) 0.45 (0.06) 0.36 (0.13) 
Diurnal 0.22 (0.36) 0.31 (0.19) 0.26 (0.27) 0.47 (0.04) 0.52 (0.02) 0.39 (0.1) 
Nocturnal 0.18 (0.44) 0.15 (0.54) 0.42 (0.07) 0.22 (0.37) 0.2 (0.41) 0.3 (0.21) 
cDBP 
(mmHg) 
24-hr 0.07 (0.78) 0.1 (0.69) 0.1 (0.68) -0.21 (0.4) 
-0.18 
(0.47) 
-0.27 
(0.26) 
Diurnal 0.06 (0.79) 0.15 (0.53) 0.01 (0.97) 0.06 (0.8) 0.11 (0.65) 
-0.04 
(0.88) 
Nocturnal 
-0.001 
(0.99) 
-0.02 
(0.92) 
0.21 (0.38) 
-0.42 
(0.08) 
-0.44 
(0.06) 
-0.3 (0.21) 
cMAP 
(mmHg) 
24-hr 0.19 (0.41) 0.22 (0.35) 0.27 (0.26) 0.11 (0.64) 0.15 (0.54) 0.04 (0.87) 
Diurnal 0.14 (0.55) 0.34 (0.32) 0.13 (0.59) 0.29 (0.22) 0.35 (0.14) 0.19 (0.44) 
Nocturnal 0.07 (0.77) 0.04 (0.86) 0.29 (0.21) 
-0.19 
(0.45) 
-0.21 
(0.38) 
-0.07 
(0.79) 
cPP (mmHg) 
24-hr 0.39 (0.09) 0.39 (0.09) 0.52 (0.02) 0.55 (0.02) 0.56 (0.01) 0.53 (0.02) 
Diurnal 0.24 (0.31) 0.28 (0.23) 0.35 (0.13) 0.53 (0.02) 0.56 (01) 0.5 (0.03) 
Nocturnal 
0.45 
(0.047) 
0.4 (0.08) 
0.61 
(0.004) 
0.58 (0.01) 
0.58 
(0.009) 
0.58 
(0.009) 
Heart rate 
(beat/min) 
24-hr 
-0.05 
(0.84) 
-0.13 
(0.58) 
-0.05 
(0.84) 
-0.17 (0.5) 
-0.12 
(0.61) 
-0.22 
(0.36) 
Diurnal -0.06 (0.8) 
-0.13 
(0.58) 
-0.08 
(0.74) 
-0.12 
(0.66) 
-0.07 
(0.79) 
-0.17 (0.5) 
Nocturnal 0.03 (0.9) 
-0.06 
(0.82) 
0.04 (0.87) 
-0.26 
(0.29) 
-0.23 
(0.34) 
-0.27 
(0.26) 
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6.4.3 Aortic stiffness: comparison between Vicorder and cABP 
machine - In-clinic measurements 
Subjects with valid aPWV measurements obtained by the Vicorder® and the 
(in-clinic) 24-hour cABP machine while at rest were included.  Of the 46 
subjects, eligible readings in both devices were determined in 41 subjects: 22 
patients and 19 controls (Figure 6.1).  The Vicorder® gave higher central 
readings of SBP, PP, MAP and lower readings of central DBP and heart rate 
than the cABP machine.  Both devices gave same measurements of aPWV, 
9.2m/s. (Table 6.4).  
To assess the level of agreement between the two devices in all subjects in 
measuring at rest aPWV, Bland-Altman plot was constructed.  The mean (SD) 
difference of the aPWV measurements obtained from the two devices 
(Vicorder aPWV  W cABP machine aPWV) was 0.1 (2.0)m/s.  Values for aPWV 
were within 2SD except for one subject (Figure 6.3a).  Vicorder measurements 
repeatedly showed increased cMAP compared to in-clinic cABP machine 
measurements, mean (SD) difference of MAP: Vicorder MAP  W cABP machine 
MAP = 6 (12)mm Hg.  Bland-Altman plot showed that values of MAP obtained 
from Vicorder and cABP machine fall were within 2SD except for one subject 
(Figure 6.3b). 
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Table 6.4: The mean values of central haemodynamic measurements taken 
using Vicorder and at rest measurement using (in-clinic) 24-hr Ambulatory 
Blood Pressure 
Mean (SD) 
Vicorder 
n=41 
24-hr ABPM 
(in-clinic) 
n=41 
SBP (mmHg) 146 (17) 133 (26) 
DBP (mmHg) 85 (11) 88 (14) 
PP (mmHg) 61 (16) 46 (23) 
MAP (mmHg) 112 (11) 103 (16) 
Heart rate (bpm) 69 (13) 73 (14) 
aPWV (m/s) 9.2 (1.9) 9.2 (1.6) 
Abbreviations: Ambulatory blood pressure monitor (ABPM), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), mean 
arterial pressure (MAP), aortic pulse wave velocity (aPWV). 
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Figure 6.3: Bland-Altman plot of Main Haemodynamic Measures  
6.3a: Aortic Pulse Wave Velocity 
Mean = 0.1m/s 
 2SD = 4.0m/s 
aPWV (Vicorder) =9.2 (1.9)m/s 
aPWV (cABP machine) =9.2 (1.6)m/s  
 
 
 
 
 
 
 
 
6.3b: Mean arterial pressure 
Mean = 6mmHg 
2SD = 24mmHg 
MAP (Vicorder) =112 (12)mmHg 
MAP (cABP machine) =103 (16)mmHg 
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6.4.1  Systolic nocturnal dip and nocturnal aPWV 
In our study there was a similar amount of systolic dippers in both the COPD 
(n=9) and control (n=10) groups, p=0.63.  Measurements of 24-hour-, diurnal 
and nocturnal aPWV were increased in patients compared to control; 
however this trend did not reach significance.  See Table 6.5.  The greatest 
nocturnal-diurnal difference in 24-hour ambulatory aPWV of 0.9m/s was in 
patients when the non-dippers were compared to dippers.  See Table 6.5. 
The greatest differences between patients and controls based on dipping 
status was nocturnal aPWV measurements, however differences were not 
statistically significant (Table 6.5).  In dippers, patients had an increase in the 
nocturnal aPWV by 0.7m/s compared to controls, p=0.30.  In non-dippers, 
patients had an increase nocturnal aPWV of 1.1m/s compared to controls, 
p=0.10.  
6.4.1.1 Diurnal and nocturnal cSBP and aPWV difference in patients 
with COPD and in controls 
Paired Sample Test showed significant difference of diurnal and nocturnal 
cSBP in controls: mean (SD): 124 (15)mmHg and 112 (13)mmHg, respectively, 
p=0.001, but not in patients: mean (SD):  124 (14)mmHg and 118 (22)mmHg, 
respectively, p=0.14.  Similarly, there was no significant difference between 
mean (SD) diurnal and nocturnal aPWV in patients, 9 (1.2)m/s, and 8.8 
(1.3)m/s, respectively; p=0.67.  In controls, there was an increased diurnal 
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aPWV measurements compared to nocturnal aPWV, mean (SD) = 8.4m/s 
(1.6), and 8.0m/s (1.5), respectively; p=0.001. 
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 Table 6.5: The 24-Hour, Diurnal, and Nocturnal Aortic Pulse Wave Velocity 
according to Systolic Dippers or Non-dippers 
 
Abbreviation: Aortic pulse wave velocity (aPWV) 
 
 
 
Mean (SD) unless 
otherwise 
indicated 
COPD Controls 
Non-
dippers 
n= 11 
Dippers 
n= 9 
P 
Non-
dippers 
n= 9 
Dippers 
n= 10 
P 
24-hour aPWV 
(m/s) 
9.2 (1.4) 8.6 (1.2) 0.33 8.3 (1.6) 8.2 (1.7) 0.92 
Diurnal aPWV 
(m/s) 
9.2 (1.4) 8.9 (1.2) 0.60 8.4 (1.7) 8.4 (1.7) 0.95 
Nocturnal aPWV 
(m/s) 
9.3 (1.4) 8.4 (1.1) 0.12 8.2 (1.4) 7.7 (1.7) 0.51 
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6.5 Discussion  
In this pilot study, the dynamic peripheral and central haemodynamics were 
assessed in patients with COPD compared to controls using the Mobil-O-
Graph 24-hour PWV/cABP machine.  The device was feasible to be used in this 
study in the vast majority of subjects and it provided acceptable number of 
recordings over 24-hour time.  Bland Altman plot showed good agreements of 
resting (in-clinic) cABP machine and the Vicorder® haemodynamic 
measurements.  As expected the cABP machine detected consistently higher 
values of 24-hour, diurnal, and nocturnal ambulatory aPWV in patients with 
COPD than controls as well as in patients and controls non-dippers compared 
to dippers, the differences were not statistically significant in this pilot study.  
Controls had significantly increased diurnal aPWV compared to nocturnal 
aPWV measurements.  Patients, on the other hand, did not have significant 
nocturnal aPWV drop compared to diurnal aPWV. 
dŚĞ ĨĞĂƐŝďŝůŝƚǇ ĂŶĚ ƚŚĞ ƵƐĞƌƐ ? ƚŽůĞƌĂďŝůŝƚǇ ŽĨ Ă ĚĞǀŝĐĞ ĐĂŶ ďĞ ĂƐƐĞƐƐĞĚ ƵƐŝŶŐ
subjective and/or objective approach.  Although subjective measurements 
sometimes demonstrate inconvenience use of the ABPM, objective 
measurements demonstrate good tolerability and acceptability of the device 
(Tropeano, 2006).  Viera et al., used ƚŚĞŵŽĚĞů ‘Oscar 2 ? ABPM on people with 
borderline clinic BP and reported that ambulatory BP wearers mostly 
complain of sleep disturbance (Viera et al., 2011).  Although our subjects did 
not complain of sleep disturbance, the majority of exclusion (13%) was 
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because of missing actual nocturnal haemodynamic measurements.  Using 
Subjective approach, Elliot and Iqbal., showed good tolerability of the 24-hour 
peripheral ABPM - Mobil-O-Graph - in patients who were referred for CV 
investigations (Elliot and Iqbal, 2003).  They reported that 95% of patients 
were willing to have a repeat of the ABPM.   
Previous work using static one-off aPWV measurements  as a marker of CV 
risks reported  increased aPWV in patients with COPD compared to healthy 
controls (Sabit et al., 2007).  Further, an improvement or a change of 1m/s in 
(at rest) measurement was shown to be associated with 14% higher risk of CV 
mortality and 15% higher risk of all-cause mortality (Vlachopoulos et al., 
2010).  With regards to ambulatory aPWV measurements, there is no 
established minimal threshold to rely on when interpreting an improvement 
or change in ambulatory aPWV.  Nevertheless, our findings of a trend of 
increased aPWV over the 24-hour, diurnal and nocturnal periods in patients 
with COPD compared to controls is consistent with previously established 
work where in-clinic static measurement of aPWV was increased in COPD 
compared to controls (Sabit et al., 2007). 
Only one study by Aidar et al., who looked at 24-hour peripheral 
haemodynamics in patients with COPD (n= 13) and age-matched controls (n= 
14), but not PWV (Aidar et al., 2009).  They showed significant increase of 
peripheral 24-hour, diurnal and nocturnal haemodynamic measurements in 
patients with COPD compared to controls.  In our pilot study we showed 
increased peripheral and central haemodynamic measurements over the 24-
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hour, diurnal and nocturnal periods in patients with COPD compared to 
controls, although the differences were not statistically significant.  The lack 
of significance in our study might be because of subjects baseline 
characteristics as the patients in Aidar el at., study were in more severe stages 
of the disease (GOLD III) and relatively older with a mean age of 70 years.  
This could justify the lack of significance in our study as the severity of COPD 
and age are factors influencing haemodynamic/aortic stiffness changes (Sabit 
et al., 2007, Franklin et al., 1997). 
Comparing in-clinic cABP measurements to a standardize measure of central 
haemodynamic/arterial stiffness  W Vicorder® - is an important part of our 
work as investigating of the potential application of dynamic central BP/aortic 
stiffness measurements in COPD population has not been explored.  
Luzardo et al., compared central haemodynamic/aortic stiffness 
measurements of Mobil-O-Graph 24-hour PWV monitor  W at rest and under 
ambulatory conditions - to measurements obtained by SphygmoCor at rest 
(Luzardo et al., 2012).  They showed good agreements of results obtained 
from both devices regardless of the study condition  W at rest or ambulatory.  
Our Bland Altman plot showed similar findings, although we used 
oscillometric device - Vicorder® - instead of the tonometric SphygmoCor. 
Superiority of ABPM over clinic or home BP monitoring has been well 
establish in previous literature, particular in the areas of diagnoses and drug 
intervention of hypertensive patients (Giles et al., 2011, Hodgkinson J, 2011).  
However, recently established work by Kallem et al., comparing two ABPMs 
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(Mobil-O-Graph [I.E.M., Stolberg, Germany] and Spacelabs 90207 [Spacelabs 
Medical, Issequal, WA]) found that both devices gave different 
haemodynamic measurements regardless of the side (dominant or non-
dominant hand) of measurements (Kallem et al., 2013).  They highlighted the 
importance of careful interpretations of the results and the necessity of 
references values for each device.   
Nocturnal systolic dip has been found to be associated with CV risks and non-
dippers are at higher CV risks than dippers regardless of in-clinic BP 
measurements (Huiart et al., 2005, Lekakis et al., 2005, Sin and Man, 2005, Sin 
and Man, 2003).  As a pilot study using small sample size, we did not expect to 
find significant differences between dippers and non-dippers in patients or in 
controls; however, the trend we showed of consistently increased aPWV over 
24-hour, diurnal and nocturnal periods in patients compared to controls 
encourages further investigation in this area.  Moreover, this is the first study 
to show that the nocturnal aPWV seen in controls was not evidenced in 
patients with COPD.  Although there was no difference in nocturnal cSBP 
between patients and controls, within group analysis showed that controls 
had significantly lower nocturnal cSBP compared to diurnal cSBP 
measurements, but this was not seen in patients. 
6.5.1 Limitation 
As a piloted study we used a small sample size and the majority of our 
patients with COPD were classified as moderate (GOLD II) stage which might 
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have an effect on minimizing some of haemodynamic/arterial stiffness 
differences between patients and controls.  This could also be a good reason 
for future work with bigger sample size and more severe cases to potentially 
find greater and significant differences between patients and controls and 
probably among different GOLD stages of the disease.  Another limitation was 
the difficulty of measuring subũĞĐƚƐ ? ƚŽůĞƌĂďŝůŝƚǇ ŽĨ ƚŚĞ ĐW ŵĂĐŚŝŶĞ as we 
depended on objective measures (the number of actually recordings over 24-
ŚŽƵƌ ?ĂŶĚƐƵďũĞĐƚƐ ?ǀĞƌďĂů ŝŶƐƚĞĂĚŽĨǁƌŝƚƚĞŶĨĞĞĚďĂĐŬƚŽƵƐĞĂƐĂƐƵďũĞĐƚŝǀĞ
measure. 
6.5.2 Conclusion 
This work objectively demonstrated that cABP machine is a feasible device to 
be used in patients with COPD and it provides useful and additional 
information over conventional BP.  Central haemodynamic/aortic stiffness 
measurements using cABP machine showed good agreement with the 
standardize method - the Vicorder® - for static aPWV.  Further, we showed 
that patients with COPD did not have nocturnal aPWV dip as it was observed 
in control comparators.   
Taking into account that aPWV is a better predictor of CV events and COPD is 
a systemic disease with high CV risks, all suggest the need for further 
investigation in this area looking at aortic stiffness over 24-hour, diurnal, and 
nocturnal time instead of at rest one-off measurements.  This puts the device 
in more favourable place for future work investigating this area.
 211 
 
 
Chapter 7  
 
 
Conclusions 
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7.1 Introduction 
Patients with COPD have compromised physical performance, physical activity 
and haemodynamics; therefore, the aim of this research was to explore the 
determinants and the potential use of a simple physical performance 
assessment test that requires small space and time (the TUG test) in patients 
with COPD as well as to explore the nature of haemodynamics profile in 
patients with COPD as compared to age and gender matched controls. 
7.2 Time Up and Go (TUG) in patients with COPD 
The study was designed to investigate the TUG test in a large representative 
population of patients with COPD.  The baseline parameters for patients and 
controls were similar in age, gender and self-reported co-morbidity - if not 
accounting for COPD).  This was important to minimise the potential effect of 
other confounders of physical performance and arterial stiffness, for example 
CV diseases, in our results. 
First, TUG was able to detect impairment of physical performance in patients 
with COPD when compared to controls.  Second, as a simple test with no 
ceiling effect, TUG was shown to be beneficial to be used as an initial 
assessment tool of physical performance and by which a decision might be 
decided of whether a further walking test is required.  Third, TUG was shown 
to have high sensitivity and specificity to differentiate between faller and non-
fallers in the past year in patients.  We presented a TUG cut-off time of 12s 
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which was more accurate with higher sensitivity and specificity to detect self-
reported previous falls.  Finally, TUG was found to have good same day inter- 
and different days intra-observer reliability. 
7.3 Physical performance and arterial stiffness 
We looked at the association of arterial stiffness to measurements of physical 
performance in all subjects (patients with COPD and controls) and in patients 
alone.  Aortic stiffness was assessed by the carotid-femoral pulse wave 
velocity (aPWV). 
Aortic stiffness was increased in patients compared to age-, gender-matched 
controls.  The association of physical performance and arterial stiffness did 
not reach significance in patients.  Distance of >350m in the 6MWT was 
associated with high measurements of arterial stiffness in patients with COPD. 
We should be careful when interpreting these results as the association of 
arterial stiffness to physical performance in our study could be concealed by 
the uneven distribution of patients across the spectrum of the GOLD stages of 
COPD. 
7.4 Physical activity and arterial stiffness 
We looked at the potential relationship between self-reported physical 
activity and aortic stiffness in a large population of patients with COPD.  A 
subjective measure (questionnaires) was used for the self-reported physical 
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activity.  Although increased arterial stiffness and declined physical activity 
independently are well established in patients with COPD, our results showed 
that self-reported physical activity was significantly associated to COPD 
airflow obstruction and dyspnoea, but not aortic stiffness. 
7.5 Ambulatory haemodynamic/arterial stiffness profile in 
patients with COPD 
This was a pilot study to explore the peripheral and central haemodynamic 
differences between patients with COPD and controls during 24-hour period.  
The Mobil-O-Graph machine was used to assess ambulatory 
haemodynamic/arterial stiffness measurements with the first measurements 
taken in-clinic while subjects at rest.  The results of the ABPM in-clinic 
measurements were compared to the Vicorder® measurements for validation 
analysis. 
Analysis of peripheral and central in-clinic haemodynamic measurements 
showed that results from the Mobil-O-Graph were in agreement with the 
results obtained from the Vicorder®. 
When ambulatory haemodynamic measurements were analysed, the 
differences of diurnal, nocturnal and 24-hour arterial stiffness measurements 
showed a trend of increased arterial stiffness measurements in patients; 
despite low numbers in each group.  Nocturnal aPWV dip was seen only in 
controls, but not in patients. 
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8.1 Physical performance assessment of patients with 
COPD 
This research presented TUG as a simple and a reliable test to detect self-
reported falls and impairment of physical performance in patients with COPD.  
A prospectively designed study is needed to evaluate the ability of the TUG 
test to detect future falls and whether it can be used as an objective measure 
of falls.  Further work looking at the potential of TUG to determine the effects 
of interventions is also needed. 
8.2 Association of physical performance to arterial stiffness 
This study showed that reduced physical performance and arterial stiffness 
were increased in patients with COPD compared to controls.  The association 
between the two was not statistically significant which could be due to the 
several factors.  One factor could be the lack of space which allowed 10m 
track to be used for the 6MWT instead of the recommended 30m track.  This 
could influence the actual walked distance and, therefore, affected its 
association to arterial stiffness.  Furthermore, a prospective cohort study 
looking at the direction of this association in terms of cause and effect is 
importance. 
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8.3 Self-reported physical activity and arterial stiffness 
Given that there was no association between self-reported physical activity 
and arterial stiffness; future studies to reassess this relationship using 
objective measures of physical activity alongside the aPWV in a wide range of 
patients with COPD are needed; as well as additional studies looking at pre 
and post interventions such as pulmonary rehabilitation. 
8.4 Ambulatory haemodynamics in patients with COPD 
Ambulatory haemodynamics profile including arterial stiffness is feasible and 
reveals important information over 24-hour period as opposed to in-clinic 
one-off measurements.  Future studies with a larger sample size are 
warranted.  The results of this study could be used in power calculations to 
determine a sample size for such future work.  Taking into consideration this 
finding could improve the assessment and management of COPD in terms of 
time, choice of medications and, possibly in the prediction of CV risks. 
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Appendix 1: Patient Information Sheet 
 
PATIENT INFORMATION SHEET  
 
Title: The association of lung function and cardiovascular risk  
Chief Investigator: Dr Charlotte Bolton  
 
Introduction 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why this research study is being conducted 
and what it will involve. Please take the time to read the following information 
carefully and discuss it with others if you wish. Please feel free to ask us if 
there is anything that is not clear or if you require any further information. You 
may keep this information for future reference.  
Purpose of the Study 
Previous studies have shown that people with poor lung function (who often 
have chronic lung disease) have an increased risk of cardiovascular disease 
(problems with the blood vessels) over and above the effects of smoking. 
However, at the moment we have a limited understanding of the reasons 
behind this.  
 
Researchers wish to study people with and without lung disease who currently 
VPRNH RU KDYH VPRNHG LQ WKH SDVW WR H[SORUH SHRSOH¶V Uisk of developing 
FDUGLRYDVFXODU GLVHDVH 5HVHDUFKHUV ZLOO PHDVXUH WKH VWLIIQHVV RI SHRSOH¶V
blood vessels and also look at levels of inflammation in the blood and 
FRPSDUH WKLVZLWK SHRSOH¶V OXQJ IXQFWLRQ )LQDOO\ UHVHDUFKHUVZLVK WR VHH LI
SHRSOH¶VNLGQHys are affected by the stiffening of the hearts main artery; the 
DRUWD,WLVKRSHGWKDWE\VWXG\LQJSHRSOH¶VEORRGYHVVHOVDQGOXQJIXQFWLRQLW
will lead to a greater understanding of why people with poor lung function 
(who often have chronic lung disease) have an increased risk of 
cardiovascular disease.  
Why have I been chosen? 
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You have been chosen because you:- 
x Have been diagnosed with COPD and are attending one of the 
researchers Respiratory Out-Patient Clinics. 
x Have previously consented to be included on the Nottingham 
Respiratory Research Database or Professor Ian Halls Volunteer 
Database and to contacted regarding future research studies.  
x Are replying to a poster or advertisement seeking volunteers.  
 
Please note; this study is only available to people of European Ancestry, as 
the tests used in this study are not valid in any other skin type at present.  
 
Do I have to take part? 
It is entirely up to you whether or not you decide to take part. If you do decide 
to take part you will be given this information sheet to keep and be asked to 
sign a consent form (you will be given a copy of this as well). If you decide to 
take part you are still free to withdraw at any time and without giving a reason. 
A decision to withdraw, or a decision not to take part, will not affect the 
standard of care you already receive.  
What will happen to me if I take part? 
You will be asked to attend for one study visit at the Respiratory Biomedical 
Unit at Nottingham City Hospital. During this time (approximately 120 minutes) 
you will need to have various tests/procedures.  
Visit 1  
If after reading this information sheet and talking to a member of the research 
team, you would like to take part in this study, we would ask you to sign a 
consent form.  
In addition we would like to conduct the following tests/procedures:- 
x Blood Sample: we would like to take a small amount of blood (25mls 
or the equivalent of 5 teaspoons) from your arm for further analysis. 
x Urine Analysis: we would like to take a sample of urine (10mls or the 
equivalent of 2 teaspoons), to analyse certain molecules.  
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x Questionnaires: You will be asked to fill out 3 short questionnaires 
about how your health affects your daily life. 
x Spirometry Test (blowing test); which is used to measure your lung 
function (the size of your lungs and how quickly you can empty them). 
You will be asked to breathe in and then blow out very fast into a 
mouth piece.  
x Carbon Monoxide Test: we would like to measure the level of a gas 
called carbon monoxide exhaled in your breath. This involves blowing 
into a machine which is a bit like an alcohol breathalyser to record the 
concentration of carbon monoxide. 
x Pulse Oximetry; a simple non-invasive test which measures oxygen 
saturation in your blood. 
x Blood Pressure (BP) 
x Arterial Stiffness Measurements: A non-invasive test which involves 
SODFLQJ D EORRG SUHVVXUH FXII DURXQG WKH SDUWLFLSDQW¶V XSSHU OHJ DQG
DUP WRPHDVXUH WKH VSHHG RI SXOVDWLRQ GRZQ WKH SDUWLFLSDQW¶V ERG\
which is related to the stiffness of the arteries. In addition, a small 
probe is placed on the side of the neck over the pulse.  Please be 
aware that all of the tests listed above will be performed by competent 
staff following standard operating procedures. Before starting any of 
the tests we will ensure that there are no reasons for the test not to be 
performed.   
x Skin Elasticity Measurements: A non-invasive test used to measure 
WKH PHFKDQLFDO SURSHUWLHV RI SHRSOH¶V VNLQ VNLQ HODVWLFLW\ 6NLQ
elasticity will be measured by applying a small suction force to the skin 
and measuring how the skin responds to this force.  
x Skin AGE Measurements: A non-invasive test used to measure 
peoples skin metabolism. This involves participants placing their arm 
onto the device, which then shines light onto the skin.  The reflected 
light is then measured and analysed.  
x Walking tests: One test will measure how far you walk in a 6 minute 
period. The other will assess how long it takes you to stand up from a 
chair, walk 3 metres, return to chair and sit. We will allow time for you 
to recover in between.  
x 24 hour blood pressure (BP) (optional). We are seeking a few 
subjects to have their BP recorded over a 24 hour period with a device 
that can be worn at home. You will be taught how to use the device 
and it will be fitted on the upper arm before you go home. Over the 24 
hour period, the cuff inflates on the arm intermittently and records your 
BP. On return of the machine, we download the information which  
gives information of your BP then when you are walking or doing other 
activities and whilst you are asleep.  
Please be aware that all of the tests listed above will be performed by 
competent staff following standard operating procedures. Before starting any 
of the tests we will ensure that there are no reasons for the tests not to be 
performed.   
Finally, we would like to record your past medical history; including your 
current medication and smoking history. 
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Follow-Up (Optional) 
With your consent we would like to contact you in the future to follow you up 
and perform some of these tests again, in order to create a longitudinal study 
(a study over a longer period of time) of cardiovascular risk in patients with 
and without lung disease, dependent on funding. Please be aware that a 
member of the study team will contact your GP to check your ongoing health 
status before contacting you.  
 
What do I have to do? 
You should continue to carry on with your normal daily activities and take your 
usual medication. We also ask that you attend the scheduled study visit 
(although there is some flexibility in terms of the days and times when this can 
occur) and complete the study paperwork. You may be asked to refrain from 
eating or drinking for six hours prior to your appointment, although your study 
doctor will advise you before you attend for your visit. If you agree to the 24 
hour BP test, we will need to arrange for a second visit to return the machine 
and review the data.  
Will any genetic tests be carried out? (Optional) 
Yes; it is hoped that the genetics part of the study (looking for differences in 
SHRSOH¶V JHQHV will lead to a greater understanding of the relationship 
between lung function and the blood vessels. Please be aware that the results 
of any genetic testing will be kept strictly confidential and will NOT be sent out 
to you as they do not have any clinical relevance and will not affect any 
private medical or life insurance policies you may have. Please note; this part 
of the study is optional and if you agree to take part in the genetics part of the 
study you will be asked to sign an optional clause on the consent form.  
What are the possible benefits of taking part? 
You will not benefit directly from taking part in this study, however, it is hoped 
that the results of this study will lead to a greater understanding of the 
relationship between lung function and cardiovascular disease.  
What are the possible disadvantages/risks of taking part? 
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As with all tests/procedures some people experience side effects, some of 
which are detailed below:- 
Blood Tests: Occasionally, some people feel faint during a blood test. If this 
occurs, please tell the person doing the test, as you should immediately lie 
down to prevent fainting. Sometimes after donating blood, a bruise develops 
where the needle was inserted.  
Will travel expenses be reimbursed?  
Participants will not be paid an inconvenience allowance to participate in the 
study. However, we will cover the cost of travelling to the hospital (maximum 
£10 allowance per visit). 
:KDWZLOOKDSSHQLI,GRQ¶WZDQWWRFDUU\RQZLWKWKHVWXG\" 
You are free to withdraw from this study at any time and without giving a 
reason. A decision to withdraw, will not affect the standard of care you already 
receive. However, please be aware, that should you wish to withdraw, the 
information collected so far cannot be erased and may still be used in the final 
project analysis. Any stored tissue samples that can still be identified as yours 
will be destroyed if you wish. 
Where will my data be stored and will my details be kept confidential? 
All data collected during the period of the study will be stored securely 
(password protected) on a dedicated trial database. Only the minimum 
required information for the purposes of the study shall be collected and this 
information will be subject to the same degree of confidentiality as your NHS 
notes. Access to the information will be limited to the research team and 
relevant regulatory authorities.  
Information on the storage and use of tissue samples for research 
Any tissue/blood sample you donate will be stored in a secure research facility 
at the University of Nottingham (Respiratory Biomedical Research Unit), for as 
long as is required for the purposes of this study. Your sample will have your 
code which is unique to yourself, a barcode and date of study. By using these 
numbers, we can trace which sample belongs to you. The analysis of samples 
will take place within the Respiratory Biomedical Research Unit at Nottingham 
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City Hospital. Please note; your sample will not be sold for profit or used in 
any animal research.  
 
Your tissue/blood sample will be retained for 7 years in accordance with the 
8QLYHUVLW\¶V&RGHRI5HVHDUFK&RQGXFWDQGWKHQGHVWUR\HGVKRXOG\RXZLVK
to do so. However, with your permission we would like to retain any remaining 
tissue/blood in a link-anonymised form for future laboratory research into 
respiratory disease (as yet unspecified). If you agree, the remaining 
tissue/blood will be stored on University premises under our Human Tissue 
Authority License.  
Involvement of the General Practitioner/Family Doctor (GP) 
With your permission we will write to your GP to notify them that you are going 
to take part in this study, and also inform them of any abnormal test results (if 
any) for appropriate action.  
Who is organising and funding this study? 
The research has been organised and funded by the University of 
Nottingham. Please be aware that the research team involved in this study are 
not being paid for including you in this study. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called 
a Research Ethics Committee, to protect your interests. This study has been 
reviewed and given a favourable ethical opinion for conduct in the NHS by the 
Leicestershire, Northamptonshire & Rutland Research Ethics Committee 1 
and will be subject to the Data Protection Act.   
What will happen to the results of this study? 
We intend to publish the results of this study in a medical respiratory journal. A 
summary of these results will also be made available on the Nottingham 
5HVSLUDWRU\ %LRPHGLFDO 5HVHDUFK 8QLW¶V ZHEsite (www.nrbru.org.uk). If you 
wish, you will be informed of the study results in clinic by the research nurse 
or doctor. Furthermore, a copy of any published material regarding the study 
will be made freely available to you. 
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What if there is a problem? 
If you wish to complain or have any concerns about the way in which you have 
been treated, please get in touch with the research team (see below), who will 
do their best to answer any problems you might have. In addition, the normal 
NHS complaints procedures are also available to you (e.g. Patient Advice and 
Liaison Service ± PALS). Details can be obtained from the hospital. 
 
 
 
 
 
Contact for Further Information 
Research Officers  
Mr Maath Alhaddad 
Tel: 0115 823 1678 
E-Mail: msxma7@nottingham.ac.uk 
Dr Charlotte Bolton, Principal Investigator  
Tel: 0115 8231317 
E-Mail: charlotte.bolton@nottingham.ac.uk 
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Appendix 2: Study Consent Form 
 
CONSENT FORM 
Title: The association of lung function and cardiovascular risk REC 
Ref: 10/H0406/65 
Chief Investigator: Dr Charlotte Bolton 
Name of Participant: 
1. I confirm that I have read and understand the information 
sheet (Version 1.4 dated 20/11/2011) for the above study and 
have had the opportunity to ask any questions. 
2. I understand that my participation in this study is entirely voluntary and that 
I am free to withdraw at any time, without giving any reason, and without 
my medical care or legal rights being affected. I understand that should I 
withdraw then the information collected so far cannot be erased and that 
this information may still be used for analysis. 
3. I understand that relevant sections of my medical notes and data 
collected in the study may be looked at by authorised individuals from the 
University of Nottingham, the research group and regulatory 
authorities where it is relevant to my taking part in the study. I give 
permission for these individuals to have access to these records and to 
collect, store, analyse and publish information obtained from my 
participation in this study. I understand that my personal details will be 
kept confidential. 
4. I understand and agree that samples of urine and blood will be taken for 
analysis of specific markers. 
5. I agree to my GP being informed of my participation in the study. I also 
agree for any abnormal results to be passed onto my GP for 
appropriate action. 
Please initial the box 
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Title: The association of lung function and 
cardiovascular risk REC Ref: 10/H0406/65 
Chief Investigator: Dr Charlotte Bolton 
Name of Participant:     Please 
initial the box  
 
6. Consent for Follow-Up (Optional) 
I agree to be contacted in the future and followed up in 
order to create a longitudinal study (a study over a longer 
period of time) of cardiovascular risk in patients with and 
without lung disease, dependent on funding. 
 
 
7. Consent for genetic research (Optional)  
I understand and agree that the samples I give may be 
used for genetic research in this the study and in future 
research aimed at understanding the relationship between 
lung function and the blood vessels. 
 
8. Consent for storage and use in possible future research 
(Optional) 
  I agree that the samples I have given and the information 
gathered about me can be stored by Dr Charlotte Bolton at 
the Respiratory Biomedical Research Unit at Nottingham 
City Hospital, for possible use in future studies (as yet 
unspecified). I understand that some of these studies may 
be carried out by researchers other than current team of Dr 
Charlotte Bolton, who ran the first study, including 
researchers working for commercial companies. Please 
note; these samples will not be sold for profit or used in any 
animal research. 
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9. Consent for 24 hour BP recording (Optional) 
I agree to have recorded my blood pressure (BP) over a 24 
hour period. The cuff will inflate time-to-time over a 24 hour 
period and record my BP. 
 
10. I agree to take part in the above study. 
 
 
 
   
   
3 copies: 1 for participant, 1 for the trial master file, 1 
for medical notes Version 1.4 (20/11/2011) 
g 
date signature Name of Participant 
 
signature date signature 
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Appendix 3: St. George ?Ɛ Respiratory Questionnaire 
 
67*(25*(¶65(63,5$725<48(67,211$,5( 
ORIGINAL ENGLISH VERSION 
 
 
 
 
67*(25*(¶65(63,5$725<48(67,211$,5(6*54 
 
 
 
 
 
This questionnaire is designed to help us learn much more about how your 
breathing is troubling you and how it affects your life. We are using it to find out 
which aspects of your illness cause you most problems, rather than what the 
doctors and nurses think your problems are. 
 
Please read the instructions carefully and ask if you do not understand anything. Do 
not spend too long deciding about your answers. 
 
 
 
 
 
 
Before completing the rest of the questionnaire: 
 
Please tick in one box to show how you describe 
your current health: 
 
 
 
 
Very 
good 
 
 
 
Good 
 
 
 
Fair 
 
 
 
Poor 
 
 
 
Very poor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright reserved 
P.W. Jones,  PhD  FRCP  
Professor of Respiratory Medicine,  
6W*HRUJH¶V8QLYHUVLW\RI/RQGRQ 
Jenner Wing, 
Cranmer Terrace,                                                                    Tel.  +44 (0) 20 8725 5371 
London SW17 ORE, UK.                                                         Fax  +44 (0) 20 8725 5955 
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6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH 
PART 1 
 
Questions about how much chest trouble you have had over the past 4 weeks. 
 
Please tick (9) one box for each 
question: 
 
 most 
days  
a week 
several 
days  
a week 
a few 
days  
a month 
only with 
chest 
infections 
not  
at  
all 
1. Over the past 4 weeks, I have coughed:         
 
2. Over the past 4 weeks, I have brought up  
phlegm (sputum):         
 
3. Over the past 4 weeks, I have had shortness  
of breath:          
 
4. Over the past 4 weeks, I have had attacks  
of wheezing:          
 
5. During the past 4 weeks, how many severe or very  
unpleasant attacks of chest trouble have you had? 
Please tick (9) one: 
 more than 3 attacks  
 3 attacks  
 2 attacks  
 1 attack  
 no attacks  
 
6. How long did the worst attack of chest trouble last? 
(Go to question 7 if you had no severe attacks) 
Please tick (9) one: 
 a week or more  
 3 or more days  
 1 or 2 days  
 less than a day  
 
7. Over the past 4 weeks, in an average week, how many good days 
(with little chest trouble) have you had? 
Please tick (9) one: 
 No good days  
 1 or 2 good days  
 3 or 4 good days  
 nearly every day is good  
 every day is good  
 
8. If you have a wheeze, is it worse in the morning? 
Please tick (9) one: 
 No  
 Yes 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6W*HRUJH¶V5HVSLUDWRU\Questionnaire 
PART 2 
 
Section 1 
 
How would you describe your chest condition? 
Please tick (9) one: 
 The most important problem I have  
 Causes me quite a lot of problems  
 Causes me a few problems  
 Causes no problem  
 
If you have ever had paid employment. 
Please tick (9) one: 
 My chest trouble made me stop work altogether  
 My chest trouble interferes with my work or made me change my work  
 My chest trouble does not affect my work  
Section 2 
 
Questions about what activities usually make you feel breathless these days. 
 
Please tick (9) in each box 
that 
applies to you these days: 
 True False 
 Sitting or lying still   
 Getting washed or dressed   
 Walking around the home   
 Walking outside on the level   
 Walking up a flight of stairs   
 Walking up hills   
 Playing sports or games 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6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH 
PART 2 
 
Section 3 
Some more questions about your cough and breathlessness these days. 
Please tick (9) in each box 
that 
applies to you these days: 
 True False 
 My cough hurts   
 My cough makes me tired   
 I am breathless when I talk   
 I am breathless when I bend over   
 My cough or breathing disturbs my sleep   
 I get exhausted easily   
 
Section 4 
Questions about other effects that your chest trouble may have on you these days. 
 
Please tick (9) in each box 
that 
applies to you these days: 
 True False 
 My cough or breathing is embarrassing in public   
 My chest trouble is a nuisance to my family, friends or neighbours   
 I get afraid or panic when I cannot get my breath   
 I feel that I am not in control of my chest problem   
 I do not expect my chest to get any better   
 I have become frail or an invalid because of my chest   
 Exercise is not safe for me   
 Everything seems too much of an effort   
 
Section 5 
Questions about your medication, if you are receiving no medication go straight to section 
6. 
 
Please tick (9) in each box 
that 
applies to you these days: 
 True False 
 My medication does not help me very much   
 I get embarrassed using my medication in public   
 I have unpleasant side effects from my medication   
 My medication interferes with my life a lot 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6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH 
PART 2 
 
Section 6 
 
These are questions about how your activities might be affected by your breathing. 
 
Please tick (9) in each box that applies to 
you because of your breathing: 
 True False 
 I take a long time to get washed or dressed   
 I cannot take a bath or shower, or I take a long time   
 I walk slower than other people, or I stop for rests   
 Jobs such as housework take a long time, or I have to stop for rests   
 If I walk up one flight of stairs, I have to go slowly or stop   
 If I hurry or walk fast, I have to stop or slow down   
 My breathing makes it difficult to do things such as walk up hills, carrying things 
 up stairs, light gardening such as weeding, dance, play bowls or play golf   
 My breathing makes it difficult to do things such as carry heavy loads, dig the 
 garden or shovel snow, jog or walk at 5 miles per hour, play tennis or swim   
 My breathing makes it difficult to do things such as very heavy manual work, 
 run, cycle, swim fast or play competitive sports   
 
 
Section 7 
 
We would like to know how your chest usually affects your daily life. 
 
Please tick (9) in each box that applies 
to 
you because of your chest trouble: 
 True False 
 I cannot play sports or games   
 I cannot go out for entertainment or recreation   
 I cannot go out of the house to do the shopping   
 I cannot do housework   
 I cannot move far from my bed or chair 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6W*HRUJH¶V5HVSLUDWRU\4XHVWLRQQDLUH 
 
 
Here is a list of other activities that your chest trouble may prevent you doing. (You do not 
have to tick these, they are just to remind you of ways in which your breathlessness may 
affect you): 
 
Going for walks or walking the dog 
Doing things at home or in the garden 
Sexual intercourse 
Going out to church, pub, club or place of entertainment 
Going out in bad weather or into smoky rooms 
Visiting family or friends or playing with children 
 
 
Please write in any other important activities that your chest trouble may stop you doing: 
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
Now would you tick in the box (one only) which you think best describes how your chest 
affects you: 
 
 It does not stop me doing anything I would like to do  
 It stops me doing one or two things I would like to do  
 It stops me doing most of the things I would like to do  
 It stops me doing everything I would like to do  
 
Thank you for filling in this questionnaire. Before you finish would you please check to see that you 
have answered all the questions. 
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Appendix 4: Medical Research Council (MRC) Dyspnoea Scale
(Fletcher, 1960) 
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Appendix 5: Body Composition - Bioelectrical Impedance (BIA) 
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Appendix 6: Carotid-Femoral Pulse Wave Velocity using the Vicorder 
 
Neck-pad  W carotid* 
Femoral cuff* 
*Whole cuff inflates over the femoral artery whilst the neck-pad is just a small 
section  W balloon only. 
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Appendix 7: Carotid-Femoral Pulse Wave Velocity - Screen Shot 
 
 
 
This is a screen shot of simultaneous carotid and femoral pulse wave forms 
obtained when performing pulse wave velocity measurements using the foot 
to foot method on the Vicorder machine. 
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Appendix 8: Borg Breathlessness Scale  
(Burdon et al., 1982) 
 
0 Nothing at all 
0.5 Very, very slight 
1 Very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very Severe 
8  
9 Very, very severe (almost maximal) 
10 Maximal 
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Appendix 9: Ambulatory Blood Pressure Device Mobil-o-graph 
 
 
ON/OF
EVENT 
DAY/NIGHT 
BRACHIAL 
CUFF 
START 
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Appendix 10: Ambulatory Blood Pressure  ? Summary Report 
Example of ambulatory BP summary report obtained from the Mobil-O-Graph device 
software 
Haemodynamic 
measurements 
Nocturnal dip 
   
 
 
242 
Appendix 11: BODE Index - Body Mass Index, Airway Obstruction, Dyspnoea 
and Exercise Capacity 
(Adopted from (Celli et al., 2004)) 
 
Abbreviations: Forced expiratory volume in one second (FEV1), six minute 
walk distance (6MWD), medical research council (MRC), body mass index 
(BMI)  
 0 1 2 3 
FEV1% predicted A? ? ? 50-64 36-49 A? ? ? 
6MWD (m) A? ? ? ? 250-349 150-249 A? ? ? ? 
MRC  1-2 3 4 5 
BMI (kg/m2) >21 A? ? ?  Q  Q 
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Appendix 12: ADO Index - Age, Dyspnoea and Airway Obstruction 
(Adopted from (Puhan et al., 2009)) 
 
 
0 points 1 point 2 points 3 points 4 points 5 points 
FEV1 (% predicted) A? ? ?A? A? ? ? W64% A? ? ?A?  Q ... ... 
Dyspnoea (MRC scale) 0 W1 2 3 4 ... ... 
Age (years) 40 W49 50 W59 60 W69 70 W79 80 W89 A? ? ? 
Abbreviations: Forced expiratory volume in one second (FEV1) and medical 
research council (MRC) 
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Chapter 10  
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